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Abstract
Nutrition and Genes Associated with Orofacial Cleft Birth Defects in Utah
by
Huong Dieu Meeks, Doctor of Philosophy
Utah State University, 2014
Major Professor: Dr. Ronald G. Munger
Department: Nutrition, Dietetics, and Food Sciences
Orofacial clefts (OFCs) are facial malformations that happen during early pregnancy
and have a complex and heterogeneous etiology, involving both genetic and environmental
risk factors. This project examined the association between maternal nutrition, folaterelated biomarkers, candidate genes involved in one-carbon metabolism (OCM), and OFCs
in order to achieve more comprehensive knowledge of how nutrition and genetics influence
OFC risk.
First, the association between maternal periconceptional multivitamin (PCMV) use,
maternal dietary patterns during the periconceptional period, and OFC risk was examined.
This study showed that neither PCMV use nor healthy dietary pattern score alone was
individually associated with OFC risk. However, the combination of PCMV use and a
higher score reflecting the ideal Dietary Approach to Stop Hypertension diet was associated
with 55% reduction in the risk of isolated OFCs, evidence that the prevention of OFCs may
require attention to both PCMV use and improving maternal diets.
Second, the association between maternal multivitamin use, folic acid supplemental intake, and measured blood folate levels in case mothers of OFC children and control mothers
was examined. Mothers who had an OFC-affected pregnancy compared with control mothers had lower mean levels of plasma folate in both multivitamin users and non-users. At

iv
levels of folic acid intake >400µg/day, the difference in plasma folate between case mothers
and control mothers narrowed, evidence that higher folate intake levels may be required for
mothers with a history of OFC-affected pregnancy. The ability to utilize supplement folic
acid might be modified by MTHFR C677T genotype. In mothers with 677CC genotype,
both case and control mothers’ plasma folate concentrations responded to increased levels
of folic acid supplemental intake, although case mothers’ plasma folate concentrations were
always significantly lower than control mothers’ until folate supplemental intake reached
400µg. In mothers with 677CT genotype, control but not case mothers’ plasma folate concentrations responded to increased levels of folic acid supplemental intake. In mothers with
677TT genotype, case but not control mothers’ plasma folate concentrations responded to
increased levels of folic acid supplemental intake.
Lastly, variations in folate-related OCM genes were examined in association with risk of
OFCs using GWAS data and the case-parent trio approach. Several genes in the OCM pathway were associated with isolated, non-syndromic OFCs with some through genetic effects
alone but most through gene-environment interaction effects with maternal multivitamin
supplementation during periconceptional period and maternal biomarker concentrations for
OCM-related nutrients. These results emphasize the need to consider gene-environment
interactions when searching for genes influencing isolated OFCs.
Reduction in the prevalence of OFCs could have tremendous importance. The results
of this dissertation may help identify factors important to OFCs etiology and in turn,
provide valuable targets for preventive intervention. Children born with an OFC require
medical care from birth until adulthood and encounter a higher mortality rate. The costs
incurred from caring for children born with OFCs not only include the clinical care of many
disciplines but also involve the emotional disturbance and social and employment exclusion
for affected individuals. Reducing the risk of OFCs would lessen considerable financial and
emotional burdens to families and societies.
(212 pages)
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Public Abstract
Nutrition and Genes Associated with Orofacial Cleft Birth Defects in Utah
by
Huong Dieu Meeks, Doctor of Philosophy
Utah State University, 2014

Major Professor: Dr. Ronald G. Munger
Department: Nutrition, Dietetics, and Food Sciences
Orofacial clefts (OFCs) are facial malformations that happen during early pregnancy
and have a complex and heterogeneous etiology, involving both genetic and environmental
risk factors. This project examined the association between maternal nutrition, folaterelated biomarkers, candidate genes involved in one-carbon metabolism (OCM), and OFCs
in order to achieve more comprehensive knowledge of how nutrition and genetics influence
OFC risk. All studies performed in this project used the data collected in the Utah Child
and Family Health Study (UCFHS) and the Johns Hopkins International Cleft Consortium.
Neither maternal periconceptional multivitamin use nor healthy dietary pattern score
alone was individually associated with OFC risk. However, the combination of PCMV use
and a higher score reflecting the ideal Dietary Approach to Stop Hypertension (DASH) diet
was associated with 55% reduction in risk of isolated OFCs, evidence that the prevention
of OFCs may require attention to both prenatal vitamin use and improving maternal diets.
Mothers who had an OFC-affected pregnancy were observed to have a lower blood folate
reduced levels, in both multivitamin users and non-users, evidence that they have a reduced
ability compared with control mothers to utilize supplemental folic acid. Higher folic acid
intake levels may be required for mothers with a history of an OFC-affected pregnancy.
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The ability to utilize supplement folic acid might be modified by MTHFR C677T genotype. Several genes in the OCM pathway were found to influence risk for OFCs with some
through genetic effects and most through gene-environment interaction effects with maternal multivitamin supplementation during periconceptional period and maternal biomarker
concentrations for OCM-related nutrients. These results emphasize the need to consider
gene-environment interactions when searching for genes influencing OFCs.
Reduction in the prevalence of OFCs could have tremendous importance. The results
of this dissertation may help identify factors important to OFCs etiology and in turn,
provide valuable targets for preventive intervention. Children born with an OFC require
medical care from birth until adulthood and encounter a higher mortality rate. The costs
incurred from caring for children born with OFCs not only include the clinical care of many
disciplines but also involve the emotional disturbance and social and employment exclusion
for affected individuals. Reducing the risk of OFCs would lessen considerable financial and
emotional burdens to families and societies.
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Chapter 1
Introduction
1.1

Background
Orofacial clefts (OFCs) are facial malformations that happen during early pregnancy,

affecting about one of every 700 live births worldwide. OFC frequency varies substantially
between regions, being highest in Asian or Amerindian populations, at about 2.0 per 1000
live births or higher, medium in Caucasian populations, about 1.0 per 1000 live births, and
lowest in African populations, about 0.4 per 1000 live births [1]. Just in the United States,
the Centers for Disease Control and Prevention (CDC) estimated that from 2004-2006, over
2600 babies were born with a cleft palate only (CPO) and over 4400 babies were born with
a cleft lip with or without cleft palate (CL/P) [2]. Mossey et al. [3] reported that there are
about 220,000 new cases per year worldwide. Thus, OFCs are considered some of the most
common birth defects.
Children born with an OFC often face a wide range of problems, including but not
limited to feeding and language difficulties, hearing loss, dental needs, and impaired cognitive development. Because these problems can have long lasting consequences in health
and social integration, children born with an OFC not only have higher mortality rates
but also have increased needs for medical care from birth until adulthood. Surgical repair
is recommended within the first 12 months of life for children with CL/P and 18 months
for children with CPO [4]. Additional surgeries and therapies are also needed to improve
language difficulties, the appearance of the child’s face, dental abnormalities, and cognitive
development [5]. The costs incurred from caring for children born with an OFC not only
include the clinical care of many disciplines such as nursing, plastic surgery, speech therapy,
audiology, genetics counseling, and dentistry but also involve the emotional disturbance and
social and employment exclusion for affected individuals. Families with children born with
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an OFC are affected financially and psychologically. Thus, OFCs pose considerable financial
and emotional burdens in both developing countries and developed countries [3, 6, 7].
Because of their commonality and the problems they cause to the affected individuals
and their families, OFCs have acquired much attention from researchers interested in birth
defects. However, up until now, the major causes and means for prevention of OFCs still
remain unknown.

1.2

Objectives
The overall goal of this dissertation is to examine the association between maternal

nutrition, folate-related biomarkers, and candidate genes involved in one-carbon metabolism
and the risk of OFCs in order to achieve more comprehensive knowledge of how nutrition
and genetics influence OFC risk.
The aims and hypothesis of this dissertation are:
• To determine whether there is an association between maternal multivitamin use and
dietary patterns (including the Mediterranean Diet (MD), the Diet Quality Index for
Pregnancy (DQI-P), and the Dietary Approach to Stop Hypertension (DASH) diet)
during the periconceptional period and risk of OFCs.
Hypothesis: Healthy maternal dietary patterns and multivitamin use during the periconceptional period can lower mothers’ risk of having a child with an OFC either
individually or in combination.
• To determine whether there is an association between maternal multivitamin use, supplemental folic acid intake, and measured blood folate concentrations in case-mothers
of OFC children and control-mothers.
Hypothesis: Mothers who had a child with an OFC have evidence of impaired utilization of folic acid compared to control-mothers.
• To determine whether variations in genes involved in one-carbon metabolism (OCM)
are associated with the risk of OFCs using genome-wide association (GWA) data and
the case-parent trio approach.
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Hypothesis: Genes associated with one-carbon metabolism or related nutrients are
associated with risk of OFCs, either individually or through gene-environment interactions.

1.3

Structure of the Dissertation
This dissertation is composed of six chapters. This first chapter introduces the problems

that OFC research currently face and how this dissertation can contribute to solving these
problems. The second chapter provides an overview of etiology and epidemiology of OFCs
and OCM and a review of literature including important studies and findings regarding the
association between maternal nutrition, genes involved in OCM pathway and the risk of
OFCs. The third chapter examines the first aim of this dissertation, which is to determine
whether there is an association between maternal multivitamin use and dietary patterns
during the periconceptional period and the risk of having a child with an OFC. The fourth
chapter examines the second aim of this dissertation, which is to determine whether there
is an association between maternal multivitamin use, supplemental folic acid intake, and
measured blood folate concentrations in case-mothers of OFC children and control-mothers.
The fifth chapter examines the third and last aim of this dissertation, which is to determine whether variations of genes involved in OCM are associated with the risk of OFCs
using GWA data and the case-parent trio approach. The sixth chapter summarizes the
findings and provides the public health significance of this dissertation and suggestions for
future research. The references for each chapter were listed at the end of each to facilitate
publication of chapter three to five separately in peer reviewed journals.

1.4

Study Design
All studies described in this dissertation used the data collected in the Utah Child and

Family Health Study (UCFHS) and the Johns Hopkins International Cleft Consortium.
The UCFHS is a population-based case-control study of OFCs conducted in Utah
during 2000-2005 in collaboration with the Utah Birth Defects Network (UBDN), a birth
defects registry operated by the Utah Department of Health (UDOH) and funded by the
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U.S. Centers for Disease Control and Prevention (CDC) and the State of Utah. This study
was operated using a grant given to Dr. Ronald G. Munger by the U.S. National Institute
of Child Health and Human Development (NICHD), the US National Institute of Dental
and Craniofacial Research (NIDCR) (Grant 5-RO1-HD39061) and funding from the Office
of the Vice President for Research and the Agricultural Experiment Station of Utah State
University (USU). Case- and control-mothers were recruited using the limited use of UBDN
data authorized by UBDN (for case-mothers) and the use of birth certificate data files of
the Utah Office of Vital Statistics authorized by UDOH (for control-mothers). Eligible
case-mothers included Utah residents with an OFC child live-born or still-born between
January 1st , 1995 and June 30th , 2004. The classification of the OFCs and associated birth
defects of the cases were made after review of all available medical recorded by UBDN and
a medical geneticist (Dr. John Carey). Eligible control-mothers included Utah residents
with a non-malformed child whose birth date and gender matched with cases. Cases and
controls were selected at a 1:1 ratio. Maternal interviews were conducted in April 2002
and included questions on demographic characteristics of the biological parents, a full reproductive health and pregnancy history, supplement use, medications, medical conditions,
smoking and alcohol use, occupational history, and a food frequency questionnaire covered
food intakes during the period of three months before mothers become pregnant and the
first three months of their pregnancies. Maternal non-fasting blood samples were obtained.
In total, 643 control-mothers and 550 case-mothers, in which 468 control-mothers and 415
case-mothers had complete laboratory results, were used for analysis in this dissertation.
The Johns Hopkins International Cleft Consortium was formed by several research
groups from Europe, the U.S., China, Taiwan, Singapore, Korea, and the Philippines, with
the intent to conduct a genome-wide search for genes influencing risk of OFCs using a caseparent trio design. The study was supported by U01-DE-018993 (Dr. Terri Beaty, PI, Johns
Hopkins University). Cases with an isolated OFC were recruited over a period of several
years by different members of the consortium, typically ascertained through a treatment
center. Most cases were given a physical exam to identify other congenital anomalies that

5
could reflect a recognized malformation syndrome. Informed consent was obtained from
parents of minor children and all affected individuals able to give informed consent directly.
Research protocols for recruiting human subjects were reviewed and approved by Institutional Review Boards of each participating institution or by US institutions for foreign
collaborators. Parents were interviewed about family history of OFCs and other malformations, pregnancy history, parental medical histories, plus maternal exposures to putative
risk factors such as maternal environmental tobacco smoke and multivitamin supplementation from 3 months before pregnancy through the first trimester. DNA was obtained from
both the cases and parents from whole blood, saliva, or mouthwash sample. In total, 717
trios of European ancestry and 1098 trios of Asian ancestry were used in the analysis.
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Chapter 2
Literature Review
2.1

Orofacial Clefts

2.1.1

Anatomy and Development of Orofacial Clefts

There are different ways to classify OFCs. If based on anatomy, OFCs can be divided
into cleft palate only (CPO) or cleft lip with or without cleft palate (CL/P). CPO describes OFCs that include the secondary palate only. CL/P describes OFCs that include
the primary palate involving the lip with or without a cleft of the secondary palate. The
manifestation of OFCs is even more diverse, ranging from unilateral cleft lip and isolated
cleft palate to complete bilateral clefts of the lip and palate (Figure 2.1). OFCs can also
be divided into isolated OFCs, in which the patient has no other related health problems,
and non-isolated OFCs, in which the patients also have other physical or developmental
anomalies. Non-isolated OFCs can be subdivided into multiple OFCs, in which clefts occurred with other major defects, and syndromic and chromosomal clefts, in which clefts
occurred with a known genetic syndrome or chromosomal disorder. It should be noted that
syndromic and chromosomal OFCs are also considered as multiple birth defects.

Formation of Cleft Lip Only
The primary palate forms the basis of the upper lip and the anterior portion of the
palate and is fundamental to mid-face development. The formation of the primary palate
begins with the orofacial development in the embryo, which starts at the 14th day postconception. Ectomesenchymal cells arise from ectodermal-mesodermal cellular interaction
and migration into the subjacent tissue of the designated neural crest cells at the tips of the
neural folds prior to neural tube formation. These ectomesenchymal cells form five facial
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Fig. 2.1: Illustrative drawings of types of cleft lip with or without cleft palate. a and e
show unilateral and bilateral clefts of the soft palate; b, c, and d show degrees of unilateral
cleft lip and palate; f, g, and h show degrees of bilateral cleft lip and palate. Clefts are
indicated in purple [1].
primordia, which are the frontonasal prominence, the paired maxillary processes, and the
paired mandibular processes. By the 24th day post-conception, the frontonasal prominences
are bounded by the maxillary prominences and can be recognized distinctively. At the 28th
day post-conception, the surface ectodermal cells thicken, develop into the olfactory region
of the nasal cavity, and form the nasal placodes, which in turn form inverted horseshoeshaped ridges on both sides of the frontonasal prominence. These ridges bulge up, form the
medial and lateral nasal prominences, and cause the nasal placodes to sink and form the
nasal pits. The maxillary prominences grow medially, push the medial nasal prominences
toward the midline, merge together and eliminate the frontonasal prominence. The merging
of the medial nasal and maxillary prominences forms the upper lip and the primary palate.
This process occurs between the 40th and 48th day post-conception [2].
The fusion of medial nasal prominences and the maxillary prominences requires critically precise timed correlation in the growth and locations of these two prominences and
the degeneration of the frontonasal prominence. Failures in any of the above requirements
result in cleft lip in different levels of severity [2–4]. In the mildest cases, the clefts are only
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Fig. 2.2: Schematic diagrams outline the development of the lip and palate in human. ac depict the development of the primary palate. a shows the embryonic development at
the fourth week; the developing frontonasal prominence, paired maxillary processes, and
paired mandibular processes surround the primitive oral cavity. b shows the embryonic
development at the fifth week; the nasal pits have formed, which leads to the formation of
the paired medial and lateral nasal processes. c shows the embryonic development at the
sixth week; the medial nasal processes have merged with the maxillary processes to form
the upper lip and primary palate by the end of the sixth week. The lateral nasal processes
form the nasal alae. Similarly, the mandibular processes fuse to form the lower jaw. d-f
depict the development of the secondary palate. d shows the development of the secondary
palate as bilateral outgrowths from the maxillary processes, which grow vertically down
the side of the tongue. e shows the elevation of the palatal shelves to a horizontal position
above the tongue. f shows the fusion of the palatal shelves, which ultimately divides the
oronasal space into separate oral and nasal cavities [1].
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limited to the lip’s vermillion border. In the more severe cases, the clefts develop through
the tissue of the lip (unilateral or bilateral cleft lip). In the most severe cases, the clefts
also involve the side of the nose (oblique clefts) [2].

Formation of Cleft Palate Only
The secondary palate includes the anterior and posterior palate and is part of the
floor of the nasal cavities and the roof of the mouth. The formation of the secondary
palate begins at the sixth week post-conception and is made up of three elements: the two
secondary palatal shelves and the primary palate. Initially, these three elements are widely
separated. However, within hours during the eighth week post-conception, the two palatal
shelves elevate into a horizontal position and grow medially toward each other. At the
same time, the epithelium of the palatal shelves is transformed into its different phenotypes
which are nasal, medial, and oral, and into mesenchyme. Only the medial epithelium can
undergo cytodifferentiation into peridermal and basal cells. Peridermal cells then undergo
apoptosis, while basal cells remain healthy. The epithelial-mesenchymal transformation of
the medial epithelium is essential to mesenchymal merging of the shelves. The merging of
the shelves begins during the ninth week and is completed by the 12th week post-conception.
The cells in the edges of the palatal shelves adopt a fibroblastic form, leading to the fusion
of the palatal shelves upon contact. The palatal shelves will also fuse anteriorly with the
nasal septum in the hard palate region, and subsequently merge with the soft palate region,
forming palatal closure [2].
Delay in elevation of the secondary palatal shelves from the vertical to the horizontal position results in a widening gap between the shelves and prevents the shelves from
contacting each other and subsequently, fusing with each other. When the shelves become
horizontal, the palatal closure cannot be completed, thus, leading to a cleft palate. Defective shelf fusion, failure of medial edge epithelial apoptosis or epithelium-mesenchymal
transformation, and post-fusion ruptures can also lead to a cleft palate [2, 4].
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2.1.2

Etiology of Orofacial Clefts

The risk of OFCs is associated with poor socioeconomic status, gender of the child,
mothers’ lifestyle and genetic variations [1, 5–9]. The association between parental socioeconomic status and OFCs is not well studied. In a study in Greater Glasgow, Scotland, the
OFC prevalence at birth in 1974-1985 was highest in areas with high proportions of unemployment, unskilled workers, and lowest in areas with high proportions of professional and
non-manual workers [10]. However, in another study conducted in California, after adjusting for ethnicity, maternal multivitamin use, smoking and drinking status, no association
between low socioeconomic status and increased OFC risk was found [11]. Because there
are no common criteria for socioeconomic status, it is difficult to form valid comparisons
between studies examining the association of OFCs and parental socioeconomic status; thus
making the investigation of the role of parental socioeconomic status in OFCs difficult [12].
Gender of the child can influence the risk of OFCs. The risk of CL/P is known to be
higher in males while the risk of CPO is higher in females [13,14]. Children born with other
birth defects are also at a higher risk of having CL/P [12].
Lifestyle of mothers during or prior to pregnancy is also associated with the risk of
OFCs. Exposure to various drugs, including vasoactive drugs used to support patients
with cardiovascular failure, aspirin, ibuprofen and cocaine, during pregnancy is linked to
higher OFC risk [15]. Maternal smoking and alcohol use during pregnancy may also lead
to increased OFC risk [7, 15].
Maternal smoking is the best understood risk factor for OFCs. Two meta-analyses
of the association between maternal cigarette smoking and nonsyndromic OFCs were conducted in 1994 and 2004, and both reported statistically significant increased OFC risk
among mothers who smoked [9, 16].

The National Birth Defects Prevention Study, a

population-based case-control study of major birth defects in the United States, assessed
the association between maternal smoking, maternal exposure to environmental tobacco
smoke, and the occurrence of OFCs and confirmed the association between smoking and
OFCs [17].
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Of all suggested causes for increased OFC risk, maternal periconceptional diets and
nutritional status are of particular interest because they are potentially modifiable. Maternal nutrition has been recognized as one of the most important factors influencing the
development of the fetus, and was suggested to be associated with the formation of OFCs as
early as 1914 [18]. Because pregnancy is a continuum consisting of different stages, the timing of a change in mothers’ nutritional status will have different impacts on the pregnancy
outcome. Regarding OFCs, because the formation of an OFC happens between the fourth
and 12th week, maternal nutritional status is especially important at the time of conception
and during the first trimester [2]. There has been extensive research on the association
between maternal nutrition and the risk of OFCs. However, most studies have been focused
on the periconceptional intake of single nutrient or food. Although these findings are important and have significant contributions to our knowledge of nutritional effects on birth
defects, they do not represent all nutritional effects on the risk of OFCs, and should only
be considered as “a starting point” [19]. Literature on the association between maternal
dietary pattern and the risk of OFCs is still very limited.
One-carbon metabolism (OCM) is a network of biochemical reactions involved in the
transfer of one-carbon groups necessary for deoxyribonucleic acid (DNA) synthesis, methylation, and homocysteine metabolism. Folate plays important roles in OCM and has been
an important focus in OFC research [20, 21]. In Utah, low maternal blood folate concentration was associated with an increased risk of OFCs, and the mean differences in case- and
control-mothers widened over time, suggesting a progressive disorder of folate metabolism
in case-mothers [22, 23]. Up until now, the mechanism of how folate associated with the
risk of OFCs remain to be defined.
Similar to nutrition, genetic effects on the risk of OFCs have gathered increasing attention from genetics and nutrition researchers. Despite the lack of clear Mendelian patterns of inheritance, family and twin studies have suggested a strong genetic component
for OFC etiology [24, 25]. Candidate gene studies have identified many genes associated
with OFCs, either as individual gene polymorphisms, such as interferon regulatory factor 6
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(IRF6), methylene tetrahydrofolate reductase (MTHFR), transforming growth factor alpha
(TGF-α), transforming growth factor beta 3 (TGF-β3, msh homeobox1 (MSX1), poliovirus
receptor-related 1 (PVRL1), and cysteine-rich secretory protein LCCL domain containing
2 (CRISPLD2), or through gene-gene and gene-environmental interactions, such as nitric
oxide synthase 3 (NOS3) and maternal smoking [1, 26]. Genome-wide association studies
(GWAS) have identified several new susceptibility loci for OFCs such as 8q24 and 10q25
based on analyses of hundreds of thousands of single nucleotide polymorphisms (SNPs)
across the genome in large population samples [1, 26]. However, GWAS have not been
able to confirm the effects of most candidate genes previously associated with the risk of
OFCs. This lack of association may be caused by insufficient SNP coverage or imputation
power in GWAS or by the lack of strong genetic determination by common genetic variants [1]. Hypothesis-driven studies using GWA data have been suggested to overcome the
limitations of current GWAS approach and confirm if candidate gene studies provide false
negative results.
Despite the increasing popularity of dietary pattern and GWAS approaches, reports on
these areas focusing on OFCs in nutritional epidemiology are scarce. Literature on the association between maternal dietary patterns and concentration of folate-related biomarkers
and the risk of OFCs is surprisingly limited and there have been few reports of hypothesisdriven studies using GWAS database in investigating OFC candidate genes.

2.2

One Carbon Metabolism-Related Nutrients and Orofacial Clefts
One carbon metabolism (OCM) is a series of biochemical reactions that involve the

transfer of methyl groups essential for DNA synthesis, DNA methylation, detoxification
and protection against oxidation. In this pathway, the water-soluble B vitamins, namely
B6 , folate (B9 ), and B12 , play key roles as enzyme cofactors or substrates [27, 28].
Studies of the association between maternal nutrition during pregnancy and risk of
OFCs started in the early 1900s by several groups of investigators using dietary deficiency
or specific nutrient antagonists in animal studies. These studies independently showed
that the use of folate antagonists and/or the lack of nutrients such as vitamin A, vitamin
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B6 , and riboflavin in diet can cause OFCs and other craniofacial anomalies and hence,
suggested the important role of nutrition in fetal viability and normal development of the
craniofacial region and other structures. However, the investigators were not able to explain
the mechanisms by which nutrient deficiencies or folate antagonists cause OFCs [29].
Human studies have not yet provided strong evidences that adequate maternal nutrition
during pregnancy can reduce the birth prevalence of OFCs. In this literature review, I will
focus on human studies analyzing the association between folate and related nutrients and
risks of OFCs.

2.2.1

Dietary Deficiency in Folate and Folate-Related Nutrients and Orofacial
Clefts

Folic Acid Fortification and Orofacial Clefts
The fortification of cereal grain products with folic acid in North America since 1998
has not resulted in the significant changes in OFC birth prevalence that many have hoped
for. Epidemiological studies have been carried out in the U.S., Canada, and three countries
in South America, namely Chile, Brazil, and Argentina. The results are inconsistent. It is
important to know that all these studies are observational analysis, and can only provide
a suggestion of a presence or a lack of an association between folic acid fortification and a
trend in OFC prevalence [30].
Folic acid fortification in the U.S. became mandatory on January 1st , 1998. A descriptive study examining the rates of offspring with OFCs conceived in Texas before and
after the mandatory folic acid fortification in the U.S reported no changes in the OFC birth
prevalence post-fortification, suggesting that folic acid fortification had little or no impact
on the prevalence of OFCs [30]. Because the study only used data on infants born between
1995 and 1999 in Texas, one could argue that the study was unintentionally focusing on the
transition and not the post-fortification period and therefore, the conclusion is imprecise.
In 2002, another study was performed to determine if folic acid fortification has reduced
the prevalence of OFCs and other birth defects in Arkansas. The study used data for live
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births to Arkansas residents in 1993-2000 from the Arkansas Reproductive Health Monitoring System and categorized the birth years into three different periods: pre-fortification
(1993-1995), transition (1996-1998) and post-fortification (1999-2000). No significant decrease in prevalence for either CL/P or CPO in any period was reported. The most recent studies were two multi-state population-based studies conducted in 2005 and 2007,
and both reported positive association between folic acid fortification and the reduction in
OFC prevalence [31, 32]. The first multi-state study used data reported by 23 states to
the National Birth Defects Prevention Network to compare OFC birth prevalence for two
time periods: pre-fortification (1995-1996) and post-fortification (1999-2000). The study
reported a 12% reduction in the birth prevalence of CPO in all states combined and 13%
reduction in the birth prevalence of CL/P in eight states with perinatal surveillance [31].
The second multi-state study used the U.S. birth certificate data for 45 states and the District of Columbia to evaluate the impact of folic acid fortification on OFC prevalence in two
time periods: pre-fortification (1/1990-12/1996) and post-fortification (10/1998-12/2002).
The study reported a 6% reduction in the birth prevalence of OFCs [32]. Both multi-state
studies mentioned above did not discern between isolated and non-isolated or syndromic
cases, which is important when conducting studies of potential risk factors for OFCs [33].
Also, both studies lacked data on formulation of supplements and thus, were unable to
separate the quantity and source of folic acid (vitamin supplements or fortified foods) consumed. It should be noted that along with the mandatory folic acid fortification, national
and state organizations also held frequent educational and media campaigns to promote the
consumption of folic acid through supplementation. According to the reports by the CDC,
the percentage of women who consumed supplements containing folic acid daily increased
from 28% in 1995 to 32% in 1997 and 1998 (SD ± 2) [34]. Hence, folic acid fortification
cannot be considered the sole contributor (or even be considered at all) to the observed
decreasing trend of OFC prevalence in these two studies.
In other countries that enforced folic acid fortification, no significant decrease in the
prevalence of OFCs was observed. By January 1998, most of Canada’s cereal grain products
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were fortified with folic acid. However, the rate of OFCs have not declined despite the
additional 0.2mg per day of dietary folate to nearly all women of reproductive age because
of the mandatory food fortification program [35]. In South America, three in ten countries,
starting with Chile in 2000 and followed by Argentina in 2003 and Brazil in 2004, have
implemented mandatory folic acid food fortification, with the doses ranging from 264µg
in Brazil to 500µg in Chile and Argentina [36–39]. An ECLAMC (Spanish acronym for
Latin American Collaborative Study of Congenital Malformations) study compared preand post-fortification rates of 52 selected types of congenital anomalies including NTDs
and OFCs within 77 hospitals of these three countries. Statistically significant reduction in
birth prevalence estimates after fortification was observed for NTDs but not for OFCs [40].
This observation is consistent with previous result from preliminary data of ECLAMC [41].
As in any hospital-based study, limitations of the investigation include the non-random and
non-representative nature of the investigated births.
A meta-analysis of folic acid fortification studies in Australia, Canada and the U.S.
published in 2008 showed a small decrease in prevalence of CL/P but not CPO [42]. More
specifically, the combined prevalence ratios (PRs) of CL/P and CPO in countries where there
is optional fortification remained the same or increased (PR = 1.02 (95% CI, 0.93-1.12) and
1.19 (95% CI, 1.03-1.38) for CL/P and CPO, respectively); the combined prevalence ratios
of CLP and CPO in countries where there is mandatory fortification decreased (PR = 0.93
(95% CI, 0.90-0.98) and 0.92 (95% CI, 0.85-0.99) for CL/P and CPO, respectively). It is not
clear whether the observed changes in the prevalence of CL/P and CPO in North America
are due to the mandatory fortification or in other differences to Australia. A case-control
study using 15 registries located in Europe, Australia, Canada, and the U.S. published
in 2006 reported major changes in trend for both CL/P and CPO. Significant decreases
by small margins were observed in Atlanta for CL/P and in Western Australia, Finland,
Germany, and Central and East France for CPO [43].
The lack of decreasing rates for OFCs can have different explanations. First, all the
studies evaluating the changes in prevalence of OFCs between the pre- and post-fortification
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periods neither account for the simultaneously changing factors that may affect the risk of
OFCs nor used adequate matching of case and control groups [44]. Second, OFCs could
be sensitive only to folic acid intake greater than commonly attained through fortification
[45–47]. Third, folic acid might not play a role in OFCs etiology.

Dietary Folate and Orofacial Clefts
There have been six studies examining the role of dietary folate intake during pregnancy
on OFC risk [46,48–52]. Five studies were population-based case-control analysis conducted
in different countries: the Netherlands, Norway, Australia, the U.K., and the U.S., and all
reported little or no significant association between the dietary intake of folate during periconception period and risk of OFCs [48–52]. However, three studies described a suggestive
effect of dietary folate intake [46, 48, 52]. Shaw et al. [48] reported an insignificant association between high dietary intake of folate and a decreased risk of CPO among women who
did not use vitamin supplements. van Rooij et al. [52] reported a significant dose-dependent
effect of maternal food folate intake on OFC risk. High maternal dietary folate intake was
associated with reduced risk of CL/P; this risk reduction was even greater when combined
with folic acid supplement use [52]. The study supported the importance of a folate-rich
diet and folic acid containing supplements use during periconception period [52]. Wilcox
et al. [46] also suggested a dose-response gradient association between dietary folate intake
and the crude risk of CL/P. This association was weakened and no longer significant after
adjustment for covariates. Groups with the lowest risk of CL/P were those who took more
than 400µg of supplemental folic acid in combination with multivitamin use and high dietary folate intake. However, no adjustment for other confounding factors such as maternal
smoking, drinking and educational status was reported in this analysis.
The first multi-site hospital-based case-control study investigating the association between maternal dietary folate intake and risk of nonsyndromic OFCs was conducted in
France in 2007. This study reported a beneficial effect of maternal dietary folate intake
on OFC risk. However, significant reduction in risk of OFCs was only found in mothers
whose level of dietary folate intake has 230-314µg but not in mothers whose level of dietary
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folate intake is higher than 314µg [49]. The study did not make any adjustment to account
for the statistically significant differences in dietary folate intake between different regions
in France, which might explain the curious result. The second multisite hospital-based
case-control study was conducted in Thailand in 2013 to examine the relationship between
micronutrients, supplements, and environmental risk factors and CL/P. Mothers who took a
vitamin or ate liver, which contains high level of folate, zinc, and B vitamins, were reported
to less likely have a CL/P- affected child than mothers who did not [53]. Because the study
classified mothers as having any vitamin use if they reported periconceptional intake of a
multivitamin, folic acid, calcium, iron, iron-B vitamin complex, or other type of vitamin,
it is unclear as to what specific nutrients, or combinations of nutrients contributed to the
significant reduction in risk of CL/P.

Dietary Nutrient Intake, other than Folate, and Orofacial Clefts
The number of studies focusing on the association of dietary nutrient intake other than
folate and the risk of OFCs is relatively small.
Using data provided by the Netherlands case-control study conducted by van Rooij
et al. [54], Krapels et al. [55] investigated the association of maternal periconceptional
dietary intake of thiamine, riboflavin, niacin, pyridoxine (B6 ), and cobalamin (B12 ) and the
occurrence of OFCs. Significantly lower periconceptional intakes of thiamine, niacin, and
pyridoxine were observed in mothers with an OFC-affected child. A decreasing trend of
OFC risk was also observed for increasing dietary intake of thiamine and pyridoxine (p =
0.04 and 0.03, respectively) [55]. In a separate study but with the same dataset, Krapels et
al. [56] investigated the periconceptional dietary intakes of macronutrients, vitamins, and
minerals in mothers with an OFC-affected child and control-mothers. The periconceptional
dietary intakes of zinc, along with other macronutrients (protein, fat, carbohydrate, fiber,
and cholesterol), vitamins (vitamin A, retinol, beta-carotene, ascorbic acid, and alphatocopherol), and other minerals (calcium, phosphorus, iron, and magnesium) were higher in
control-mothers than in case-mothers. However, after energy adjustment, only the dietary
intakes of vegetable protein, fiber, beta-carotene, ascorbic acid, alpha-tocopherol, iron and
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magnesium remained significantly higher in control-mothers.
The most recent study conducted by Wallenstein et al. [57] investigated the association of maternal periconceptional intake of vitamin supplements and dietary nutrients with
risk of developing CPO and CL/P in California. Among women who did not use vitamin supplements, dietary intakes of several micronutrients were associated with the risk of
OFCs. Low dietary intakes of riboflavin, magnesium, calcium, vitamin B12 , and zinc were
significantly associated with at least a two-fold elevated risk of CPO; low dietary intakes of
niacin, riboflavin, vitamin B12 , and calcium and high intakes of folate and cryptoxanthin
were significantly associated with a two-fold elevated risk of CL/P [57].

2.2.2

Supplementation Containing Folate or Folate-Related Nutrients and Orofacial Clefts

Observational Studies
Similar to folic acid fortification and dietary nutrient intake, the evidence for a preventive effect of supplements containing folate-related on OFCs is mixed, which is likely
caused by sample selection biases, differences in sample sizes, analytic models and nutrient
measures.
A population-based case-control study using the California Birth Defects Monitoring
Program provided compelling evidence that maternal multivitamin use in the periconception
period is associated with a reduced risk of OFCs [58]. Shaw et al. [58] reported a 50%
decrease in CL/P but not in CPO in mothers who used folic acid-containing multivitamins.
This result should be interpreted with caution because the author failed to address the
effect of other vitamins and minerals besides folate, which constitute a major part of most
multivitamins. The study also reported a small but significant association of fortified cereals
and reduced risk of isolated CL/P. However, the small sample size (22 case- and 32 controlmothers) limited the power of the analysis. Despite being one of the most exhaustive
observational studies regarding OFCs and maternal multivitamin use to date, this study
still could not provide an answer to the specific role of folic acid in the risk of OFCs [29].
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Other observational studies also provided equally confusing results, with some found
suggestive yet statistically insignificant effects of folic acid on OFCs and others found no
effects. van Rooij et al. [52] reported a significant reduction in CL/P risk with the use of
supplements containing folic acid only when combined with high folate diet in the Netherlands. Similar result was also reported by Wilcox et al. [46]. Little et al. [51] however found
no preventive effects of supplement and dietary folate on OFCs in Scotland and England,
although the lack of positive association could be due to a smaller sample size compared
to previous studies. Hayes et al. [59] reported an increased but statistically insignificant
risk for CL/P with folic acid-containing supplements; the control group of the study is not
optimal because it included children with other birth defects.
Two meta-analyses have been conducted to estimate the average effect of folic acid
from supplements on the risk of OFCs across several studies and samples. Badovinac et
al. [60] reported a significant reduction in birth prevalence of CL/P, CPO, and all OFCs
associated with the use of folic acid-containing supplement during pregnancy. Johnson
and Little (2008) reported a significant reduction in the risk of CL/P but not CPO with
the use of folic acid or folic acid-containing supplement. Significant associations between
the use of multivitamins, regardless of folic acid content, preconceptionally and decreasing
risks of CL/P and CPO were also observed [42]. In both studies, isolating the effect of
folic acid from the effect of multivitamin use was impossible because specific information
about the other nutrients included in the supplements taken by the participants were not
reported. Differences in measurements, doses and definitions of folic acid supplements,
sample selection bias, and the lack of confounding reports also prevent both studies from
generating an adjusted summary effect estimate, making the results difficult to interpret [44].

Interventional Studies
Few interventional studies have been conducted to study the effect of folic acid supplementation on the recurrence or occurrence of OFCs. Because of the preventive effect
of folate on the risk of NTDs reported in 1991, it is considered unethical to conduct interventional studies in which folate is withdrawn from women of reproductive age. Thus,
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most interventional studies analyzing the effect of folic acid supplementation on the risk of
OFCs were conducted before 1991 with substantial lack in methodological and statistical
validation. Conway (1959) provided daily vitamin supplements including 2mg of vitamin
B6 , 4µg of vitamin B12 , and 0.5mg of folic acid, and every other day intramuscular injection of vitamins including 5mg of vitamin B6 and 2.5µg of vitamin B12 for mothers with
an OFC-affected child during the periconception period of their subsequent pregnancies.
No recurrent OFC cases among 59 treated pregnancies were observed compared to four
recurrent OFC cases among 78 control pregnancies [61]. No details were provided on the
statistical analysis or how the mothers were assigned to different treatment groups; thus, it
is impossible to determine selection and other biases involved. Difference between groups
was calculated using Fisher’s exact test and revealed to be statistically insignificant (p =
0.13) [29]. Peer et al. [62] provided daily 5mg of folic acid and 10mg of vitamin B6 in
addition to vitamin supplements which included 2mg of vitamin B6 and 4µg of vitamin
B12 during the first trimester to 176 mothers with a previous OFC-affected pregnancy and
reported a 53% reduction in the recurrence of OFCs compared to 418 control mothers.
Briggs [63] extended the study with an additional of 52 supplemented women and reported
a 35% reduction in the recurrence of OFCs (p = 0.2) and a 65% reduction in the recurrence
of CL/P (p = 0.08).The addition of treated mothers without untreated mothers may introduce confounding related to environmental differences between the two groups. In both
studies, no details of the sample population or statistical support for their claim of folic
acid’s preventive effect on the recurrence of OFCs were provided [29].
The Hungarian Case-Control Surveillance of Congenital Abnormalities (HCCSCA)
study was a randomized, double-blind, controlled trial conducted to investigate the association between folic acid supplement and risk of OFCs. The first publication of the
study did not report any preventive effect on the first occurrence of isolated OFCs [64].
However, high doses of folic acid (3-6mg) consumed at any time during pregnancy were
reported to reduce the risk of CL/P and CPO in the following publication [65]. The next
publication showed that only the high pharmacological dose (e.g,, 6mg per day) and not the
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physiological dose (< 1mg) can reduce the birth prevalence of isolated clefts, suggesting a
dose-dependent effect of folic acid on the risk of OFCs [45]. The latest publication compared
the pooled data of the previously mentioned HCCSCA publications [45, 64, 65] only found
protective effect of high dose of folic acid in the first month post-conception on the risk of
CPO and not CL/P [66]. The Hungarian findings revealed association between the use of
supplements during periconception period and a reduced risk of OFCs, but did not specify
the independent role of folic acid. The use of other vitamins, minerals, and medicine in
addition to the use of folic acid alone were not reported, despite the fact that use of folic
acid alone was uncommon (14% of controls and 13% of cases). Also, the analysis did not
take into account the effect of confounders such as personal characteristics associated with
multivitamin use and risk of OFCs [29]. The Hungarian Birth Defects Prevention Trial was
another multi-center double-blind trial conducted to study the efficacy of periconceptional
multivitamin supplementation in the prevention of birth defects and other pregnancy complications. The multivitamin supplement contained 2.6mg of vitamin B6 , 4µg of vitamin
B12 , 15mg of folic acid and 7.5mg of zinc. A significant reduction in NTDs was revealed,
but no significant difference was observed in the occurrence of OFCs between treatment
groups [45, 67].
The Czech Cleft Prevention Trial included pedigrees of 8250 patients born with an
OFC between 1886 and 1982 in Bohemia. Supplementation including 10mg of folic acid
and additional multivitamin tablet containing 1mg of vitamin B6 was given to mothers
deemed at high risk of OFCs recurrence because they had either an OFC themselves or a
child with an OFC. The most recent results revealed that 3 of 211 supplemented pregnancies
and 77 of 1824 unsupplemented pregnancies were affected with OFCs [68]. Fisher exact p
value for an one-sided test was 0.03 and for a two-sided test was 0.06. The Czech study faced
a serious limitation, which was the lack of random assignment of mothers to treatment or
no treatment group. Mothers in the treatment group were those who accepted the offer of
supplementation and compliant, while the control group were those who did not. Mothers
in the treatment group also received additional interventions, such as recommendations for
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conceived time, which was not given to the control group. The exclusion of noncompliant
participants and the additional lifestyle interventions for treated mothers but not controlmothers may have resulted in confounding differences between two groups related to lifestyle
factors and risk of OFCs. Because of these limitations, the results are uninterpretable
regarding the role of nutrition in the prevention of OFCs [29].
The most recent interventional study was the Oral Cleft Prevention Program (OCPP),
a randomized double-blind clinical trial (RCT) in which the focus was to assess the doserespondent effect of folic acid supplementation on OFC recurrence among children of Brazilian women. The study randomized 2508 women at risk for OFC recurrence into two groups,
each group was supplemented with either 0.4 or 4mg of folic acid per day before pregnancy
and throughout the first trimester [69]. There were no significant differences in OFC recurrence rates between two groups (2.9% and 2.5% in the 0.4 and 4mg groups, respectively).
However, the OFC recurrence rates in the two groups both separately and combined were
significantly different from the post-fortification 6.3% historic OFC recurrence rate for this
population. Several limitations should be considered when evaluating the results. First,
the study introduced some changes in recruitment strategies and inclusion/exclusion criteria while the study was ongoing. Second, the participants were selected from craniofacial
clinics specialized in providing care to patients with OFCs, potentially overestimating the
population’s OFC recurrence risk [70].

2.2.3

Dietary Pattern Studies and Orofacial Clefts

Overview
A traditional approach in nutritional epidemiology, which analyzes the association
between diseases and a single or a few foods, have contributed valuable analysis to the
literature of nutritional science. However, this approach includes several conceptual and
methodological limitations. First, the traditional analysis fails to take into account that
meals are composed of several foods, which are combinations of interactive and synergistic
nutrients. Second, it is inadequate in examining the inter-correlation of individual nutri-
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ents. Third, it might not be able to detect some nutrients which effects are too small when
being analyzed separately. Fourth, statistically significant associations might be produced
by chance because of large number of nutrients or food items. Finally, single nutrient intakes are influenced by dietary patterns and thus, the effect supposedly observed in single
nutrient analysis may be confounded by the effect of dietary patterns [19].
Because of these limitations, dietary pattern studies have been proposed as a new
approach in nutritional epidemiology. Not only it addresses the limitations of traditional
analysis mentioned above, the dietary pattern approach also has major advantages. Dietary
pattern analysis resemblances diets in the real world more closely, and thus is the best
method to investigate the joint effects of nutrients and foods. Dietary pattern analysis also
has important public health implications. First, it helps people to approach their diets
more holistically. Narrow nutrient analysis gives the public the impressions of a “magic
bullet”, a single nutritional factor that can prevent diseases, and causes the public to focus
on taking supplements without regard to diet. Second, it provides a practical way to
evaluate the benefits of adherence to dietary guidelines based on its consistent conclusions
in relation to different disease outcomes. Third, it also provides an easy-to-understand
guide for nutritional intervention and education [19, 71].
Dietary pattern analysis relies on several statistical methods to characterize patterns
using collected dietary information. There are three different approaches that have been
used in literature to derive dietary patterns. The first approach is called a priori, or a
hypothesis-oriented approach, involves the use of diet-quality scores or indices. Dietary
indices may be based on dietary recommendations and then are used to examine the relationship between these indices with the disease outcomes. Some dietary recommendations
often used are the Healthy Eating Index (HEI), the Diet Quality Index (DQI), the Diet
Diversity Score (DDS), Recommended Food Score (RFS), the Mediterranean Diet (MD),
and the Dietary Approach to Stop Hypertension (DASH) diet [19]. The second approach
is exploratory, involving the use of factor analysis and cluster analysis. Factor analysis and
cluster analysis are multivariate methods that characterize dietary patterns based on food
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frequency questionnaire (FFQ) data or reported dietary records. Factor analysis, with principal component analysis (PCA) as the most frequently used method, aggregates foods or
food groups based on how the food items in the dataset are correlated with one another; thus
identifies common factors of food consumption. Cluster analysis aggregates individuals with
similar diets into relatively homogeneous clusters. After the patterns are defined, regression analysis can be used to examine the relationship between the different patterns and the
diseases outcomes. The third approach is called the hybrid approach. It uses information
from both sources: data from the study and prior information for defining responses. The
most commonly used method in the hybrid approach in dietary pattern analysis is Reduced
Rank Regression (RRR), or maximum redundancy analysis. If PCA determines dietary
patterns based on how similar the food items in the data set are, RRR identifies patterns
by aggregating the food items based on how similar their correlations are with the response
variables, such as disease outcomes and biomarkers. Decision tree analysis was recently
introduced to dietary pattern analysis, but still seldomly applied. Decision tree analysis,
involving classification and regression trees, identifies mutually exclusive subgroups in a
population containing common characteristics that are associated with the dependent variable of interest [72, 73]. Other data mining techniques, such as neural network approaches
and partial least squares are also new promising methods for dietary pattern analysis.
Dietary pattern approaches have been applied in many epidemiological studies, and
have provided positive results of associations with various diseases such as cardiovascular
disease, cancer, obesity, and birth defects [19,74–82]. A quick Pubmed search on April 2013
to identify all Dietary Pattern Studies (DPS) yielded a total amount 4079 articles, showing
the fast-paced growth of DPS literature. However, DPS focusing on the pregnancy period
and maternal and infant health outcomes are still very limited. Sanchez-Villegas et al. [83]
conducted a systemic search on Pubmed for literature published up to September 2009
exploring the associations between dietary patterns during pregnancy and the development
of health-related maternal and infant outcomes in the Framework of the Eurreca Network
of Excellence and only found seven studies satisfying the inclusion criteria. Further research
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to advance our understanding of the relationship between maternal dietary patterns and
birth defects in infants are necessary.
Dietary pattern analysis also has its own limitations. First, because diet varies between
geographic areas, cultures, and periods, replications of results in dietary patterns analysis
in diverse populations and different periods is necessary. Second, labeling dietary patterns
might be arbitrary and thus, confusing at times. Also, different statistical methods used to
determine the dietary patterns have different limitations. Third, dietary pattern analysis
does not provide understanding of the role of specific nutrients in the biological mechanism
of the diseases etiologies. In the case that the disease is caused by specific nutrient, it is
possible to miss this association while looking at the overall diet [19, 71]. Fourth, because
dietary pattern studies rely on diet measurement instruments such as the food frequency
questionnaire (FFQ), recalled, etc., they all face the same problem – biases in reporting.
In summary, dietary pattern analysis is a great approach to examine the relationship
between diet and disease risk. However, it should not be used as replacement of the traditional approach; instead, it should serve as a complementary method to the traditional
approach to help enhance our knowledge of nutritional science.

Maternal Dietary Patterns and the Risk of Orofacial Clefts
Despite the fact that dietary pattern analysis has become an increasingly popular
approach in nutritional epidemiology, literature on the association between maternal dietary
pattern and the risk of OFCs is still very limited. Only two studies in this research area
have been published, with both showing significant results.
The earliest study was published in 2007, comprised of 442 Dutch European mothers, of
which 225 were case-mothers of a child with CL/P and 217 were control-mothers of a child
without any birth defect. All mothers completed a validated food frequency questionnaire
used in the European Prospective Investigation into Cancer and Nutrition (EPIC) study at
14 months after the index pregnancy, based on the assumption that it is in the same season
as the preconception and that the nutritional habit of the mother is rather constant. Two
dietary patterns were then generated using PCA. The Western diet was characterized by
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high intakes of meat, pizza, legumes, potatoes, French fries, condiments, and mayonnaise,
and low intake of fruits. The Prudent diet was characterized by high intakes of fish, garlic,
nuts, and vegetables. High adherence to the Western diet was shown to be significantly
associated with an increased CL/P risk (odds ratio = 1.7, 95%CI: 1.0-3.0), even after
adjustment for maternal education, multivitamin intake, smoking, and alcohol use [84].
The second study, the National Birth Defects Prevention Study (NBDPS) was published in 2011, comprised of 2475 case-mothers of a child with CL/P and 6147 controlmothers of non-malformed children. This was a multi-center, population-based study with
a priori (hypothesis-oriented) assessments of the dietary patterns. Maternal diets before
pregnancy were self-reported between six weeks to 24 months after the infants’ estimated
date of delivery using a validated food frequency questionnaire developed for The Nurses’
Health Study (NHS). The data then were used to calculate the MD score and Diet Quality
Index for Pregnancy (DQI-P). The association between CL/P and CPO and DQI-P were
notable (odds ratios = 0.66, 95%CI: 0.54-0.81 and = 0.74, 95%CI: 0.56-0.96 for CL/P and
CPO, respectively) after adjustments for ethnicity, maternal energy intake, body mass index
(BMI), education, study center, and any drinking, smoking and multivitamin use [85].
One of the main problems these two studies faced is that although the used FFQs are
validated, they are not specifically validated for collecting data from diet during pregnancy.
The two case-control studies used the questionnaire developed for the EPIC and the NHS
studies with no modifying for maternal dietary patterns during pregnancy, thus lacking
in assessment of any changes in appetite and food habits that can accompany pregnancy.
Another problem is that none of the studies adjusted for the mothers’ physical activity,
use of vitamins and minerals supplements, and weight gain during pregnancy, considering
that having a healthier dietary pattern is also associated with having a healthier lifestyle.
Also, the selection of the period covered by FFQ is somewhat arbitrary. Vujkovic et al. [84]
assessed diet at 14 months after the pregnancy and covered maternal diet in the periconception period, which is defined as three months before until three months after conception of
the index child; Carmichael et al. [85] assessed diet between six weeks to 24 months after the
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infants’ estimated due date and covered maternal diet between three to six months before
pregnancy. These periods did not reflect the mothers’ changes in diet during pregnancy,
which can be caused by the pregnancy itself or the detection of the presence of the diseases
in the babies. OFCs are formed between the fourth and the ninth week of pregnancy, making the maternal diet in the periconception period very important. However, maternal diet
at this time is subjected to possible changes due to nausea caused by the pregnancy. In the
case of severe nausea or vomiting starting after the first week of pregnancy, a significant
change in food intake might happen. Other than these studies, I am unaware of any other
studies investigating the relationship between maternal dietary patterns and the risk of
OFCs in children.

Maternal Dietary Patterns and the Risk of Neural Tube Defects
Neural tube defects (NTDs) are very common birth defects that have some similarities
with OFCs, with frequency of about one per 1000 pregnancies in the United States. A
NTD is an opening in the spinal cord or brain that occurs very early in the pregnancy.
Neural tube formation is completed during the 28th day after conception; when the neural
tube does not close, a NTD develops. The two most common NTDs are spina bifida
and anencephaly. Anencephaly is when the neural tube fails to close, often resulting in
infant death. Spina bifida is when the neural tube closes incompletely, resulting in many
physical and neurological complications [86]. During the past decades, NTDs have been
shown to associate with maternal dietary intakes of many nutrients, particularly folate. The
discovery that the risk of NTDs could be decreased significantly by maintaining sufficient
folic acid intake before conception and during early pregnancy has led to the folic acid
fortification program in several countries [31, 43, 87, 88]. Similar to OFCs, although there
are many studies of the association between specific nutrients and NTDs, literature about
the association between maternal dietary patterns and the risk of NTDs is very limited.
Influence of mothers’ diet on NTD risk was first recognized through studies examining
mothers’ diet behaviors during early pregnancy. Poor maternal nutrition resulted from
food insecurity and special diet behaviors such as diets to lose weight, fasting diets, and
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eating disorders during the first trimester of pregnancy were reported to be associated with
increased NTD risk [89–92]. Lower diet quality among women who did not use multivitamin
supplements before pregnancy, were not regular consumers of cereals, and consumed high
intakes of fats and sweets, was repeatedly reported to associate with higher risk of NTDs
[93, 94].
Vujkovic et al. [95] published a paper in 2009 that was similar to their paper on OFCs
in 2007 but analyzed the effect of maternal dietary patterns on the risk of NTDs. This
case-control study consisted of 50 case-mothers of children with spina bifida and 81 controlmothers of children with no malformations and tested the hypothesis whether maternal
dietary patterns were associated with the risk of spina bifida in the offspring. All mothers
were Dutch Caucasian, and had to complete the FFQs used in the EPIC study at 14
months after the index pregnancy. The Mediterranean dietary pattern was identified by
both PCA and RRR, and low adherence to this diet was found to be highly correlated
with an increased risk of NTDs after the adjustment for maternal age, periconceptional
folic acid/multivitamin supplement and BMI (in PCA, odds ratio = 2.3, 95% CI: 0.9-5.6;
in RRR, odds ratio = 3.5, 95% CI: 1.5-8.2). This study is of significant importance because
it is the first study that used statistical methods to identify maternal dietary patterns,
independent of periconception folic acid supplementation, and their association with the
risk of having spina bifida-affected offspring. However, because of the small sample size,
this association needs to be interpreted cautiously [95].
The NBDPS, besides analyzing mothers of children with OFCs, also analyzed 936 cases
of children with NTDs. After covariates adjustment, the authors found reduced risks for
NTDs are associated with increasing diet quality based on both DQI and MD scores with
the strongest association was found between anencephaly and DQI (odds ratio = 0.49, 95%
CI: 0.31-0.75) [85].
The data in NBDPS were used in the most recent study published in 2013 investigating the association of maternal dietary pattern and the risk of NTDs [96]. Unlike the
study led by Carmichael [85], this study used latent class analysis (LCA) to derive dietary
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patterns from control-mothers’ dietary data with adjustment for energy intake (kcal/day).
Similar to cluster analysis, LCA can be used to classify individuals into mutually exclusive
dietary patterns so that diet variation is maximized across different dietary patterns and
individuals’ diets are similar within a dietary pattern. An unique feature of LCA is that
it allows adjustment for covariates, quantification of the uncertainty of class membership,
and assessment of goodness of fit. Four dietary patterns were identified: prudent, Western, low-calorie Western, and Mexican. After adjusting for folic acid intake, maternal age,
ethnicity, education, smoking status and BMI, logistic regression was used to measure the
association between maternal dietary patterns and the risk of NTDs. Among mothers who
did not use supplements, those in the Mexican, Western, and low-calorie Western classes
were significantly more likely to have NTD-affected offspring than those in the prudent class
(odds ratio = 1.6, 1.5, and 1.4, respectively) [96].
Similar to OFCs, dietary pattern studies involving NTDs also faced multiple biases
resulting from not using validated FFQs specifically designed for use in pregnancy, not
adjusting the results for maternal physical activity and the subjectivity in selecting the
time period to collect dietary data.

Maternal Dietary Patterns and Concentrations of Folate-Related Biomarkers
As the interest of nutritional epidemiologists in the application of dietary patterns
grows, so does their interest in the relationship between dietary patterns and concentrations
of biomarkers related to health outcomes. However, most dietary pattern analyses examining diet and its association with biomarker concentrations have focused on diet quality and
chronic diseases such as cardiovascular diseases and diabetes [97–99].
In 2003, Neuhouser et al. [100] published a paper supporting the use of biomarker
concentrations as a tool to measure diet quality [100]. The authors examined the plasma
concentrations of nine phospholipid fatty acids, vitamin C, α-tocopherol, γ-tocopherol, vitamin B12 , folate, and six carotenoids of 102 postmenopausal women in Seattle, Washington,
U.S. The obtained results showed that biomarkers of healthy food choices were associated
with better DQI scores, while biomarkers of less healthy food choices were associated with
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lower DQI scores. This study is one of the first dietary pattern studies that suggests the
use of biomarkers of nutrient intake to predict diet quality [100].
To my knowledge, there is only one published study that specifically reported on the
relationship between dietary patterns and the risk of OFCs and OFC-related biomarkers.
In this study, Western dietary pattern, i.e. high in meat, pizza, legumes, and potatoes,
and low in fruits, was related with lower concentrations of erythrocytel folate, vitamin B6 ,
vitamin B12 , and higher concentration of homocysteine. This pattern was also found to
have a positive association with higher risk of a CL/P [84].
Positive results regarding the association between dietary patterns and biomarkers
have opened doors to the possibilities of using biological indicators of dietary intake, i.e.
biomarkers, as an objective measure of diet. Most nutritional studies rely on self-reported
dietary assessment instruments such as recalls, records, FFQs, and etc.; thus, biases coming
from these self-reported measures of diet are possible. Measured concentrations of nutritional biomarkers are independent of participants’ memory; thus, using biomarkers as a
measure of diet would help avoiding the limitations and lessen the complications caused
by the reporting errors in self-reported dietary assessments. It is important to note that
although most nutritional biomarkers such as vitamin C, folate and the carotenoids, are
concentration-based and responsive to dietary intake, they are also associated with personal
characteristics, such as the metabolic characteristics which may be acquired or genetically
inherited [100].
Two intervention trials have been conducted to examine the association between MTHFR
C677T and folate utilization in healthy populations. A population-based, double-blind trial
of folic acid supplementation was conducted in Northern China to examine whether the
MTHFR C677T genotype modifies the response to folic acid supplementation and found
significant association between MTHFR genotype and plasma and erythrocyte folate during six months of folic acid supplementation and three months after discontinuation of
supplementation. More specifically, MTHFR 677TT but not 677CT or 677CC genotype
was associated with lower plasma and erythrocyte folate concentrations [101]. Another re-

32
cent folic acid intervention study using a crossover design assessed response of plasma and
erythrocyte folate to folic acid supplementation with the genetic polymorphism C677T of
the MTHFR gene. Plasma folate concentration was responsive to modest increases in folic
acid intake. Erythrocyte folate concentrations increased only with high doses (400µg) of
folic acid supplementation, and this response was applied for all MTHFR C677T genotypes.
The increase in erythrocyte folate concentration was larger with individuals with MTHFR
677 TT genotype than those with 677CC or CT genotypes [102]. Thus, biomarker analyses
are necessary in broadening knowledge of the association between nutrient intake and personal metabolic characteristics and should be used as important additions to self-reported
dietary assessments [100].

2.2.4

Biomarkers of Folate-Related Nutrients and Orofacial Clefts

Findings from studies associating folate-related biomarkers involved in OCM have also
been inconsistent. A Netherlands study published in 1999 reported lower plasma and erythrocyte folate concentrations and plasma pyridoxal-5’-phosphate (PLP) and higher total
homocysteine (tHcy) in mothers of infants with OFCs compared with mothers of infants
without malformations [103]. The subsequent Netherlands study in 2003 reported lower
vitamin B6 and B12 concentrations in case-mothers, but found no significant different in
folate concentrations between case- and control-mothers [54]. In the U.K., higher plasma
and erythrocyte folate concentrations were associated with a decreased risk of CL/P but
an increased risk of CPO [104]. In the Philippines, lower concentrations of vitamin B6 and
zinc were associated with increased OFC risks [105–107]. The analysis of the association
between folate and OFC risks gave confusing results in the Philippines study. Plasma folate
was marginally associated with an increased risk of OFCs. Erythrocyte folate was also associated with OFC risks, but in different directions in two different sites. High concentration
of erythrocyte folate was associated with a decreased risk of CL/P in Negros Occidental
and an increased risk of CL/P in Davao. The author explained the inconsistent association
between erythrocyte folate status and CL/P risk as a result of different effect of interaction
between folate and case-control status between areas of higher (Negros Occidental) and
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lower (Davao) prevalence of vitamin B-6 deficiency [105]. In Utah, there was no difference
in mean plasma zinc, PLP, and homocysteine concentrations, but low blood folate concentration was associated with an increased risk of OFCs, and the mean differences in case- and
control-mothers widened over time, suggesting a progressive disorder of folate metabolism
in case-mothers [22, 23].

2.3

One-Carbon Metabolism
Despite these inconsistent results, studies of maternal biomarkers of folate-dependent

OCM provide evidence of the involvement of this metabolic pathway in the risk of OFCs.
A solid knowledge of OCM will increase our understanding of how possible mechanisms in
this pathway may play a role in the etiology of OFCs.

2.3.1

Roles of Folate-Related Nutrients in One-Carbon Metabolism

There are many vitamins and micronutrients involved in OCM. However, in this dissertation, I will only focus on the role of water soluble B-vitamins in OCM. The metabolic
interrelations of these vitamins were shown in Figure 2.3.

Folate
The reduced forms of vitamin B9 found naturally in foods and in biological tissues are
generally referred to as folate. The oxidized forms of vitamin B9 found in fortified foods and
in supplements are referred to as folic acid. Other forms of vitamin B9 include pteroyl-Lglutamate and pteroyyl-L-glutamic acid. These forms of vitamin B9 , also called the folates,
are similar in that they are all made up of a pterdine ring attached to a p-aminobenzoic acid
and a glutamic acid (Figure 2.4). All three parts must be present for vitamin activity and
can be synthesized by the human bodies. However, humans do not have the enzyme required
for the coupling of the pteridine ring to p-aminobenzoic acid to form pteroic acid [108]. The
most biologically active form of folate in the body is tetrahydrofolates (THF), which can
have methyl C1 units enzymatically attached and thus serve as one-carbon carrier in the
folate-dependent OCM pathways [27].
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Fig. 2.3: Schematic of the metabolic interrelations of folate, vitamin B6 , and vitamin B12 in
OCM. SAH, S-adenosylhomocysteine; SAM, S-adenosylmethionine; MTHFR; Methylenetetrahydrofolate reductase; 5-methyl-THF, 5-methyl-tetrahydrofolate; THF, Tetrahydrofolate; dUMP, deoxyuridine monophosphate; dTMP, deoxythymidine.

Fig. 2.4: Structure of folic acid [108].
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Folate is often found in mushrooms, green vegetables, peanuts, legumes, lentils, fruits
and liver. Folate concentration is typically higher in raw foods than in cooked foods because
of folate losses incurred with cooking. Nowadays, because of the folic acid fortification of
flours, grains and cereals in 1998 (140µg folic acid per 100g of product), the major sources
of folate is fortified cereals, breads, and grain products [108].
The recommended dietary allowance (RDA) for folate is 400µg dietary folate equivalents (DFE) per day for adults and 600µg and 500µg for women who are pregnant and
lactating, respectively. One DFE is equal to 1µg of food folate, which is equal to 0.6µg of
folic acid from supplements or fortified foods consumed with a meal or 0.5µg from supplements consumed without food [108].
One role of folates in OCM is to act as coenzymes for the reversible reactions involving
the transfer of one-carbon units at various oxidation levels in OCM [27]. The oxidation
levels of one-carbon units in OCM are shown in Table 2.1. Folate is also a key participant
in the biosynthesis of DNA and ribonucleic acid (RNA) and the methylation of DNA, RNA,
and certain amino acids including histidine, serine, glycine, and homocysteine. A deficiency
of folate can impair OCM and lead to an increase in DNA strand breaks and imbalances in
DNA bases and thus, interferes with normal cell division [108].
Folate has a synergistic relationship with vitamin B12 and can create the “methyl-folate
trap” if lacking vitamin B12 . The methionine synthesis from homocysteine requires the presence of 5-methyl-THF. A methyl group is transferred from 5-methyl-THF to vitamin B12 ,
or cobalamin, by enzyme methionine synthase and formed methylcobalamin (Figure 2.3).
Methylcobalamin then serves as the methyl donor for converting homocysteine to methionine. Without adequate vitamin B12 to accept the methyl group from 5-methyl-THF, the
5-methyl-THF accumulates and is trapped, and THF is not generated. The “methyl-folate
trap” is dangerous in that it interferes with the regeneration of THF, which is needed for
OCM to perform its roles in DNA and RNA synthesis etc. [108].
Folate status is most often assessed by measuring folate concentrations in the plasma,
serum or red blood cells. Serum or plasma folate concentrations reflect recent dietary intake
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while erythrocyte folate concentration reflects vitamin status at the time the red blood
cells are synthesized and is more reflective of folate status. Serum folate concentration of
less than 6.8ng/mL or erythrocyte folate concentration of less than 363 nmol/L typically
suggest folate deficiency. However, erythrocyte folate concentration is lower with a vitamin
B12 deficiency [108].

Vitamin B6

Fig. 2.5: Structures of different forms of vitamin B6 [108].
Vitamin B6 exists as six different vitamers that are interchangeable and comparably
active: pyridoxine, pyridoxal, pyridoxamine, and their phosphate derivatives, pyridoxine5’-phosphate, pyridoxal-5’-phosphate (PLP), and pyridoxamine-5’-phosphate (Figure 2.5).
PLP is the coenzyme form of vitamin B6 .
All B6 vitamins are found in food. Pyridoxine and its phosphate derivative are found
almost exclusively in plant foods while pyridoxal and pyridoxamine and their phosphate
derivatives are found primarily in animal products. Rich sources of vitamin B6 include
meats, whole grain products, vegetables, some fruits (i.e., bananas), nuts, and fortified
cereals [108].
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The RDA for vitamin B6 for adult men and women age 19 to 50 years is 1.3mg per
day. The RDA for vitamin B6 for age group 51 years and older is 1.7mg per day for men
and 1.5mg per day for female. Vitamin B6 status is most often measured by plasma PLP,
with concentration of less than 20 nmol/L suggesting vitamin deficiency [108].
The role of vitamin B6 in OCM is to act as a coenzyme for several reactions in the
methyl cycle. First, homocysteine reacts with serine, forming cystathionine through the
action of cystathionine synthase. Second, cystathione is cleaved by cystathionine lyase to
form cysteine. Both cystathionine synthase and cystathionine lyase require the presence of
PLP. PLP is also the coenzyme responsible for the transfer of hydroxymethyl group from
serine to THF to form glycine [27, 108].

Vitamin B12

Fig. 2.6: General structure of vitamin B12 [108].
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Vitamin B12 , also known as cobalamin, is actually a generic term for corrinoids, which
belong to a family of compounds composed of corrin nucleus. The corrin is a tetrapyrrole
ring surrounding a central cobalt atom with 5,6-dimethylbenzimidazole and one of the following groups attached to the cobalt: cyanide, methyl, hydroxyl, water, 5’-deoxyadenosine
and nitride (Figure 2.6). Only two cobalamins, 5’-deoxyadenosylcobalamin and methylcobalamin, are active as coenzymes. The human body can convert most of the other cobalamins into an active coenzyme form of the vitamin [108].
Because the human body is incapable of synthesizing the corrin ring structure, humans
are completely dependent upon dietary sources of vitamin B12 . The only dietary sources
of vitamin B12 are animal products, which have derived their cobalamins from microorganisms. The best sources are meat and meat products, poultry, fish, shellfish, and eggs; the
cobalamins in these products are 5’-deoxyadenosine- and hydroxyl-cobalamins. Milk and
milk products such as cheese and yogurt contain less vitamin B12 , and mainly as methyland hydroxyl-cobalamins [108].
Vitamin B12 status can be measured by serum vitamin B12 , methylmalonyl COA,
methylmalonic acid, and of homocysteine. Serum vitamin B12 concentration of < 100
pg/mL suggests deficiency [108].
The role of vitamin B12 in OCM is to act as a cofactor in the form of methylcobalamin
in the remethylation of homocysteine to methionine, which connects the nucleotide synthesis and methylation cycle in OCM. Similar to folate, deficiency in vitamin B12 results in
megaloblastic macrocytic anemia and elevated plasma homocysteine concentration [108].

2.3.2

Compartmentation of One-Carbon Metabolism

OCM is an intercompartmental metabolism, meaning that OCM is compartmented
between different parts of cells. However, studies have only been able to show a clear interdependence of cytoplasmic and mitochondrial OCM in the liver by demonstrating the
participation of one-carbon donors, folate coenzymes and folate-dependent enzymes in these
compartments. Mitochondrial OCM is vital as the site of oxidation of one-carbon donors
such as serine, glycine, sarcosine, and dimethylglycine. Across the mitochondrial membrane,
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Fig. 2.7: Compartmentation of one-carbon metabolism. End products of one-carbon
metabolism are in red. One-carbon donors are in blue. Activated one-carbon units carried by tetrahydrofolate (THF) are in green. Reactions 1-4 are in both the cytoplasmic
and mitochondrial (m) compartments. Reactions 4 and 10 are also present in the nucleus (n). Reactions 1, 2, and 3: 10-formyl-THF synthetase, 5,10-methenyl-THF (CH+ THF) cyclohydrolase, and 5,10-methylene-THF (CH2 -THF) dehydrogenase, respectively,
are catalyzed by trifunctional C1 -THF synthase in the cytoplasm (MTHFD1). Reaction
1m is catalyzed by monofunctional MTHFD1L and reactions 2m and 3m by bifunctional
MTHFD2 or MTHFD2L. The other reactions are catalyzed by the following: 4, 4n, and
4m, serine hydroxymethyltransferase; 5, glycine cleavage system; 6,5,10-methylene-THF reductase; 7, methionine synthase; 8, dimethylglycine (DMG) dehydrogenase; 9, sarcosine
dehydrogenase; 10 and 10n, thymidylate synthase; 11, 10-formyl-THF dehydrogenase (only
the mitochondrial activity of this enzyme is shown, but it has been reported in both compartments); 12, methionyl-tRNA formyltransferase; 13, dihydrofolate (DHF) reductase; 14,
betaine-homocysteine methyltransferase. AdoHcy, S-adenosylhomocysteine; AdoMet, Sadenosylmethionine; Hcy, homocysteine
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the movement of reduced folates is slow but serine, glycine, and formate are rapidly equilibrated. Cytoplasmic OCM is vital as the site for the synthesis of purine and thymidylate,
the remethylation of homocysteine, and the synthesis of S-adenosylhomocysteine [27, 28].
OCM consists of two major pathways: a remethylation pathway and a transsulfuration
pathway. We will discuss each pathway in details. The compartmentation and details of
OCM are shown in Figure 2.7.

2.3.3

Remethylation Pathway

Cells contain a mixture of folate monoglutamates and polyglutamates. Folate monoglutamates consist of only one glutamate peptide and are found in the serum compartment.
Folate polyglutamates consist of five to eight glutamate peptides linked by γ-linked peptide bonds and are found in intracellular compartments. Because only monoglutamates
can be transported across membranes, folate polyglutamates, the main form found in dietary folates, must be deconjugated to folate monoglutamates, normally by 5-methyl-THF
monoglutamate, in the intestine through the action of the enzyme folylpoly-γ-glutamate
carboxypeptidase II prior to absorption and transport. Folate monoglutamates are then
absorbed into the bloodstream via the reduced folate carrier (RFC) and undergo a cellular
uptake process mediated by folate receptor α (FOLRα) [27]. Once taken into the cells, folate monoglutamates receive a polyglutamate tail and become folate polyglutamates; thus
folate is sequestered inside the cells. The process of adding polyglutamates tails to folate
monoglutamates is catalyzed by the enzyme folylpoly-γ-glutamate synthetase. These folate
derivatives then have to be enzymatically reduced to tetrahydrofolates in order to carry
one carbon units. This process of folate absorption and accumulation is a little different
between folic acid and other forms of folates. Because folic acid is a monoglutamate, it does
not have to undergo the deconjugation process but can be transported directly into the cells
and converted to THF; this conversion reaction is catalyzed by the enzyme dihydrofolate
reductase (DHFR) [27].
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The remethylation pathway will be explained step-by-step based on the following “backbone”: THF → 10-formyl-THF → 5,10-methenyl-THF → 5,10-methylene-THF → 5-methylTHF → Methionine → S-adenosylmethionine.

Reactions Starting with Tetrahydrofolate
The most important reaction concerning THF is the condensation of THF with formate to form 10-formyl-THF. This reversible reaction is catalyzed by the enzyme C1 -THF
synthase. The energetically favorable direction is the synthesis of 10-formyl-THF, which
is adenosine triphosphate (ATP)-dependent. The purpose of this direction is to remove
formate generated metabolically and to prepare for purine synthesis. The other direction
is the synthesis of formate, which is adenosine diphosphate (ADP)-dependent, and is thus
favored when there is sufficient ADP and inorganic phosphate [27, 28].
THF is also involved in the formation of 5,10-methenyl-THF and 5,10-methylene THF.
The formation of 5,10-methenyl-THF from THF is an irreversible two-step process with
5-formimino-THF as an intermediate compound. The conversion of THF to 5-formiminoTHF is catalyzed by formiminoglutamic acid, which comes from the breakdown of histidine,
and produces glutamic acid. The conversion of 5-formimino-THF to 5,10-methenyl-THF is
catalyzed by formimino-THF-cyclodeaminase [109]. The formation of 5,10-methylene-THF
from THF can be established through 5 different pathways. First, THF can condense with
formaldehyde to form 5,10-methylene-THF by nonenzymatic fashion. Second, THF can
condense with serine to form glycine and 5,10-methylene-THF via serine hydroxymethyltransferase. Third, THF can condense with sarcosine to form glycine and 5,10-methyleneTHF via sarcosine dehydrogenase [27, 28]. Last, THF can condense with glycine to form
CO2 , NH3 , and 5,10-methylene-THF via glycine cleavage enzyme system, which consists
of four different proteins called the P-protein, H-protein, L-protein, and T-protein, in a
nicotinamide adenine dinucleotide (NAD)-dependent reaction [110]. Except for the first
two reactions found in cytoplasm, all other three reactions are found exclusively in the
mitochondria [28].
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Reactions Starting with 10-formyl-tetrahydrofolate
10-formyl-THF has two main functions in folate-dependent OCM. The first main function is to synthesize purines; 10-formyl-THF supplies the C 2 and C 8 to the purine ring by
donating one-carbon unit to glycinamide ribotide (GAR) and aminoimidazole carboxomide
ribotide (AICAR) during the de novo biosynthesis of purines. These two reactions are catalyzed by GAR transformylase and AICAR transformylase, respectively, and both result
in the synthesis of THF. The second main function is to synthesize 5,10-methylene-THF
through a two-step process consisting of two reduction reactions with 5,10-methenyl-THF
as an intermediate compound. Both reactions are reversible, nicotinamide adenine dinucleotide phosphate (NADPH)-dependent and catalyzed by C1 -THF synthase [27, 28].
10-formyl-THF also has another function that is mentioned less frequently- as another
source of THF. This function can be performed in two other different ways. First, 10-formylTHF can be hydrolyzed to THF and CO2 via 10-formyl-THF dehydrogenase. The purpose
of this reaction is to prevent the accumulation of 10-formyl-THF by converting any 10formyl-THF not needed for the synthesis of purine to THF. Second, 10-formyl-THF can be
converted to THF via methionyl transfer RNA (tRNA) formyltransferase (fMET), forming
tRNA-N-Formylmethionine (fMET) during the process. This irreversible reaction has an
important role in initiating protein synthesis and is restricted to mitochondria only [28].

Reactions Starting with 5,10-methenyl-tetrahydrofolate
Besides being synthesized from 10-formyl-THF and 5-formimino-THF, 5,10-methenylTHF can also be formed from 5-formyl-THF, also known as folinic acid or leucovorin. This
reaction is catalyzed by 5,10-methenyl-THF synthetase and is not reversible [28]. 5,10methenyl-THF has only one function which is to be converted to 5,10-methylene-THF in a
NADPH-dependent reaction via C1 -THF synthase.

Reactions Starting with 5,10-methylene-tetrahydrofolate
5,10-methylene-THF is one of the most important folate derivatives in OCM because
of its role in thymidylate biosynthesis and its role in 5-methyl-THF formation. The biosyn-
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thesis of thymidylate occurs in both the cytoplasm and the nucleus and consists of three
steps. First, 5,10-methylene-THF is catalyzed by thymidylate synthase to form DHF. During this irreversible reaction, deoxyuridine monophosphate (dUMP) is also utilized to form
thymidine monophosphate, or thymidylate. Second, DHF is catalyzed by DHFR to form
THF in a reversible NADPH-dependent reaction. Third, THF is catalyzed by cytoplasmic
serine hydroxymethyltransferase to form 5,10-methylene-THF. During this reversible reaction, serine is also utilized to form glycine in the same reversible manner. The thymidylate
biosynthesis cycle is thus repeated continually to regenerate thymidylate, which is necessary
for DNA synthesis [27, 28, 109].
The formation of 5-methyl-THF from 5,10-methylene-THF is an extremely important conversion. The reduction reaction of 5,10-methylene-THF to form 5-methyl-THF
via methylene-THF is irreversible because of the tight bond between the electron donor
of the reaction and the reduced form of flavin adenine dinucleotide (FADH2 ) and thus,
commits 5-methyl-THF to the methionine/homocysteine remethylation cycle. Because of
its important role in the initiation of methyl cycle, this reaction is closely regulated by
S-adenosylmethionine (SAM) acting as an inhibitor. When SAM level is high, SAM inhibits MTHFR activity allosterically; thus, reduces the level of 5-methyl-THF and consequently, reduces the level of methionine and SAM. Disruptions in the methyl cycle, such
as vitamin B12 deficiency and mutations of genes mediating enzymes in methionine cycle,
would lead to an excess of 5-methyl-THF at the expense of all other folate derivatives and
ultimately impair the nucleotide biosynthesis due to folate substrate depletion. This phenomenon is referred to as “methyl trap.” Conversely, disruptions in the reduction reaction
of 5,10-methylene-THF to form 5-methyl-THF, such as mutation of MTHFR mediating
methylene-THF, would lead to an excess of 5,10-methylene-THF at the expense of the methionine cycle and ultimately an excess of thymidylate and other substrates formed during
the thymidylate biosynthesis cycle [27, 28].

Reactions Starting with 5-methyl-tetrahydrofolate
5-methyl-THF is involved in the synthesis of methionine and S-adenosylhomocysteine
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(SAH). In the synthesis of methionine, 5-methyl-THF acts as a methyl donor and donates
a methyl group to homocysteine, converting homocysteine to methionine and 5-methylTHF to THF. This methylation reaction is comprised of two parts. During the first part
of the reaction, which requires the catalysis of vitamin B12 dependent enzyme methionine synthase, a methyl group is transferred from 5-methyl-THF to cyanocobalamin to
form methylcyanocobalamin. Methylcyanocobalamin inactivates the methionine synthasecobalamin complex, thus, commits the reaction to the next step. During the second part of
the reaction, which requires the catalysis of the enzyme methionine synthase reductase, the
methyl group is transferred from methylcyanocobalamin to homocysteine to form methionine. The release of methyl group from methylcyanocobalamin reactivates the methionine
synthase-cobalamin complex, thus, restores this complex activity [27].
In the synthesis of SAH, 5-methyl-THF acts as an inhibitor. When 5-methyl-THF
level is high, 5-methyl-THF inhibits glycine N-methyltransferase activity; thus, reduces the
synthesis of SAH and sarcosine, and consequently, reduces the synthesis of homocysteine
and methionine [28, 111].

2.3.4

Transsulfuration Pathway

The transsulfuration pathway, also called the methyl/methylation cycle, is initiated
by the formation of methionine. Methionine is adenylated to form SAM via methionine
adenosyltransferase. SAM is then converted to SAH. This reaction is coupled with the
synthesis of sarcosine from glycine as well as other methylation reactions. SAH is then
utilized to form adenosine and homocysteine via SAH hydrolase. The ratio of SAM:SAH is
suggested to be an indicator of cellular methylation potential because it governs most methyl
transferase reactions. Homocysteine can be used either for the synthesis of methionine
or cystathione. To synthesize cystathione, homocysteine condenses with serine through
an irreversible transulfuration pathway catalyzed by the vitamin B6 - dependent enzyme
cystathionine β-synthase. Cystathione then undergoes a series of metabolic reactions to
form cysteine and glucose. To synthesize methionine, homocysteine is remethylated in a
reaction catalyzed by B12 -dependent enzyme methionine synthase. The methyl donor in
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this reaction is 5-methyl-THF, which is derived from 5,10-methylene-THF via an irreversible
reduction reaction explained above. Thus, homocysteine levels increase when the supplies
of vitamin B6 , B12 , and folate are insufficient, and vice versa [27, 28].

2.4

Genome-wide Association Studies
Genetic effects on the risk of OFCs have gathered increasing attention from geneticists

and epidemiologists in OFC research. Genetic mutations in OCM-related genes may cause
OFCs via altering the mechanisms of folate transport, nucleotide biosynthesis or the methionine/homocysteine cycle, making genes in OCM pathways important targets for studying
OFCs. Most notable OCM-related genes of interest as candidate genes for influencing OFC
risk are RFC/SLC19A1, FOLR1, MTHFR, MTRR, MTR, MTHFD1, and DHFR. Among
these genes, MTHFR was the first gene to be investigated in relation to OFCs, and remains
the most studied. Because multiple risk factors contribute to OFC etiology, the effect of
each gene on OFC etiology may be small individually but increase in combination with each
other. It is also possible that genetics may not have a strong effect on susceptibility with
OFCs but may have a significant effect when combined with environmental factors through
gene-environment interactions. Large-scale studies such as genome-wide association studies on gene-environment interactions are required to identify alleles and their mechanisms
associated with OFCs [1].

2.4.1

Overview

The Human Genome Project sponsored by National Institutes of Health’s (NIH) National Human Genome Research Institute (NHGRI) and the U.S. Department of Energy
was a ground breaking international research project with main purposes being identifying
and sequencing the human genome. Its completion in 2003 has led not only to a significant
increased pace in genomic research in finding the genetic basis of common and complex
diseases but also many novel research initiatives such as the International HapMap Project,
an international collaboration among scientists in Japan, U.K., Canada, China, Nigeria,
and U.S. [112]. The International HapMap Project identified genetic variants in the human
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genome across multiple ethnic populations and compared these genetic variants to determine the common patterns of human DNA sequence variation. The goal of this project is to
serve as a key resource for researchers to find genes affecting health, diseases, and responses
to environmental factors [112].
The above mentioned landmark projects have provided the initial foundation for new
approaches in genomic research such as GWAS that investigate genetic factors in addition
to environmental factors in order to explain complex human diseases and traits. According
to the NIH, a GWA study is defined as any study “that involves rapidly scanning markers
across the complete sets of DNA, or genomes, of many people to find genetic variations
associated with a particular disease” [113]. With the ability to assay more than a million
single-nucleotide polymorphism (SNP) from thousands of individuals, GWAS represent an
important advance compared to candidate genes studies and have rapidly become accepted
as a new and powerful tool to search for novel biological insights to explain susceptibility
for diseases. GWAS have successfully identified DNA variants associated with many human
diseases, such as cancer, autoimmune diseases, height, blood pressure, and BMI [114]. As of
11/16/13, 11,907 SNPs and 940 traits with 15,052 associations were reported by the GWAS
catalogue, which is maintained by the NHGRI [114].
Despite many accomplishments, there are still many challenges remaining in GWAS
design and analysis. Hardy and Singleton suggested four limitations of GWAS in their
paper published in 2009 [113]. First, because GWAS can rely only on statistical methods
to minimize the risk of reporting false positive results, sample sizes in GWAS must be
sufficiently large in order to effectively provide genetic information regarding the research
question. Second, GWAS can only detect common alleles with frequencies of larger than
5% in a population because of the limited SNP coverage and imputation. Third, GWAS
find loci but not necessarily functional mutations, which makes it challenging to identify
the pathogenic changes caused by the associated alleles. Fourth, GWAS require replication
in a similar large sample size [113, 115].
Many approaches have been taken to reduce the limitations in GWAS and have proven
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effective. To increase the sample size, most GWA publications now involve multiple data
sets resulting either from mega-analysis, the pooled analysis of raw data, or meta-analysis,
the pooled analysis of published results. Focusing on individuals with extreme phenotypes
is another approach used to increase statistical power in GWAS because of the enriched
genetic signals in such individuals. To better identify rare alleles, affordable and reliable
high-throughput genotyping and next-generation sequencing platforms were developed so
that polymorphic alleles can be inexpensively and efficiently genotyped and cover the whole
genome more adequately. Also, genotyping platforms have been customized to target certain
genomic regions with high density to fine map disease-associated variants. To address the
difficulty in interpreting the biological relevance of susceptible loci, GWA signals may be
prioritized by incorporating functional evidence, which allows for derivation of plausible
hypothesis for the prioritized genes or loci [116].
In conclusion, GWA is a great method to discover novel susceptibility loci for complex
diseases and has been applied successfully. In less than five years, GWAS has not only
facilitated new research in human genetics and genomics but also led to new discoveries
with direct clinical utility. Coupled with advances in technology and statistics and candidate
gene studies, GWA approach promises a wealth of new biological insights into many common
diseases and other complex traits.

2.4.2

Genome-Wide Association Studies in Relation to Folate-Related Biomarkers

Currently, there have been only three GWAS conducted to identify loci associated with
folate-related biomarkers. The first study was conducted by Pare et al. [117] to address the
common genetic determinants of homocysteine. The study tested 336,469 SNPs in 13,974
participants in the Women’s Genome Health Study (WGHS) and confirmed the association
with MTHFR and CBS and also found novel associations with CPS1, NOX4, and DPEP1.
The associations at MTHFR, DPEP1, and CBS were replicated in an independent sample
including both male and female participants from the Precocious Coronary Artery Disease
(PROCARDIS) study, but the association at CPS1 was only replicated among the female
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participants, suggesting that there might be a significant sex interaction for the CPS1 association [117]. The second study is conducted by Tanaka et al. [118] to determine SNPs associated with differential concentrations of B-vitamins and homocysteine in the Invecchiare
in Chianti (INCHIANTI) study from the Chianti region in Tuscany, Italy, the SardiNIA
study from Ogliastra province of Sardinia, Italy, and the Baltimore Longitudinal Study of
Aging based on the Baltimore-Washington DC area. The top loci were replicated in an
independent sample from the Progetto Nutrizione study based in Tuscany, Italy. The study
reported significant association between polymorphisms in the ALPL gene with vitamin B6
and FUT2 with vitamin B12 serum concentrations. The study also confirmed the association
of MTHFR with plasma homocysteine concentration [118]. The third study, modeling after
the study of Pare et al. [117], was conducted by Hazra et al. [119] using samples from the
National Cancer Institute’s NCI) Cancer Genetic Markers of Susceptibility (CGEMS) and
the Framingham SNP-Health Association Resource (SHARe) projects. The study confirmed
the associations of plasma vitamin B12 with FUT2 and plasma homocysteine with MTHFR.
Additionally, the study observed additional genome-wide significant loci for plasma vitamin
B12 in MUT, CUBN, and TCN1, for plasma homocysteine in GPR51/GABBR2, and for
plasma PLP in ALPL [119].
Grarup et al. [120] applied deeply sequenced large datasets including Icelandic whole
genome sequence data set combined with Danish exome sequence data set to gain insight
into the genetic architecture of vitamin B12 and folate concentrations. Even though the
study did not take the genome-wide association approach, it is an important study worth
mentioning because it is the first study aimed to identify and characterize associations of
single nucleotide variants (SNVs) with serum concentrations of vitamin B12 and folate using
next generation sequence data. An advantage of the sequencing approach is that it allowed
analysis of low frequency and rare variants in conjunction with common variants and thereby
improve the understanding of the underlying biology of human traits and diseases whereas
GWA approach mainly relies on common HapMap sequence variations. The study found six
novel loci associating with serum concentration of vitamin B12 (CD320, TCN2, ABCD4,
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MMAA, and MMACHC) and folate (FOLR3) and confirmed seven loci associating with
serum concentration of vitamin B12 in TCN1, FUT2, FUT6, CUBN, CLYBL, MUT, and
MTHFR [120].

2.4.3

Genome-Wide Association Studies in Relation to Orofacial Clefts

Data-Driven Genome-Wide Association Studies
To date, there have been four GWAS on OFCs [121–124]. The first GWAS for CL/P
was published by Birnbaum and colleagues, conducted on 224 cases and 383 controls of
Central European origin in Germany. In this study, a 640-kb region at chromosome 8q24.11
was identified for the first time, with SNP rs987525 as a key susceptibility locus for nonsyndromic CL/P (p-value = 3.34 × 10−24 ) [122]. The impact of 8q24.11 on the risk of
OFCs was also confirmed in the followed case-control design GWAS conducted on a pediatric U.S. cohort of European decent, consisting of 111 nonsyndromic CL/P cases and
5951 controls, by Grant and colleagues [123]. Birnbaum et al. [122] also confirmed the
role of IRF6 in the etiology of OFCs, which has been previously found in candidate gene
studies, but failed to find any evidence of interaction between IRF6 and 8q24, suggesting
that 8q24 and IRF6 confers the risk of OFCs through different pathway [122]. The third
GWAS, published in 2010, found two additional susceptibility loci for nonsyndromic CL/P
at chromosome 17q22 (with peak closest to NOG) and 10q25.3 (with peak values closest
to VAX1) using an additional set of 177 cases and 940 controls along with the German
sample in Birnbaum’s study [124]. The fourth GWAS is the only case-parent trio study
examining genetic effects in OFC etiology up until now, using an international consortium
that is part of the Gene-Environment Association Studies Consortium (GENEVA). This
study confirmed the IRF6 and 8q24 findings and identified risk variants near MAFB and
ABCA4 that are not previously found to be associated with CL/P. Interestingly, this study
revealed racial differences of genetic impact on CL/P after stratifying trios into European
and Asian ancestry. Stronger evidence for association with MAFB and ABCA4 were found
in Asian families, whereas families of European ancestry have stronger evidence for associa-
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tion with chromosome 8q24 [121]. Two reasons were suggested to explain this observation.
First, there are multiple genetic variants influencing the risk of CL/P. Second, while some
putative causal genes such as IRF6 have been identified through polymorphic markers in
most population, some of other genes like MAFB, ABCA4, and 8q24 may be differentially
tagged by polymorphic markers in a population-specific manner [1].
Recently, a meta-analysis combining data from the two previous largest GWAS [121,
124] not only confirmed associations with all previously identified loci but also identified six
additional susceptibility loci in PAX7, THADA, EPHA3, 8q21.3, SPRY2, and TPM1 [125].
These loci have been successfully confirmed in Chinese population [126], Mayan Mesoamerican population [127], and European and Filipino populations [125], indicating that these
loci are important determinants of CL/P in different ethnic groups. An important notion
is that some of these loci only attained genome-wide significance in specific populations,
confirming the influence of ethnic background of the affected individuals on the genetic
heterogeneity of CL/P.
Summary of the loci associated with OFCs in GWAS was reported in Table 2.2.

Hypothesis-Driven Genome-Wide Association Studies
Hypothesis-driven GWA approach has become a growing focus for epidemiologists interested in OFCs, partly because most data-driven GWAS had not been able to confirm the
role of genes previously found to be associated with OFCs in candidate gene studies.
RUNX2, which coded the Runt-related transcriptions factors 2, in chromosome 6p21
was analyzed in several studies because of its role as a key transcription factor associated
with osteoblast differentiation and tooth morphogenesis [128–130]. Mutations in RUNX2
gene in humans and mice are associated with dental anomalies and craniofacial abnormalities, including submucous cleft palate and cleft lip [128,131]. Sull et al. [132], in a case-parent
trio study of 146 Taiwanese families, 40 Korean families, 77 families from Maryland, and 35
Singaporean families, reported that RUNX2 appears to influence the risk of nonsyndromic
CL/P through a parent-of-origin effect with excess maternal transmission and paternal
transmission [132]. Wu et al. [133], in a case-parent trio study of 326 Chinese families, did
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not find any evidence for a parent-of-origin effect of these SNPs but reported significant
evidence of linkage and association with CL/P and possible interaction with environmental tobacco smoke. Jung et al. [134], in a case-parent trio study of 142 Korean families,
suggested possible involvement of SNP rs194328 in RUNX2, which was also found in Sull
et al. [132], in the etiology of CL/P without excess parental transmission. Different results
from the three studies may be contributed by differences in genetic susceptibility between
different ethnic groups and different sample sizes between these studies.
FGF, which coded the fibroblast growth factor, and FGFR, which coded the fibroblast growth factor receptor, genes have been considered excellent candidate genes for CL/P
because of their involvements during craniofacial developments [135–139]. Wang et al. [92]
tested the associations of CL/P risk with SNPs in 10 FGF/FGFR genes for genotypic effects,
interactions with one another and with common maternal environmental exposures (smoking and multivitamin use) in 221 Asian and 76 Maryland case-parent trios. Both FGFR1 and
FGF19 yielded evidence of association in the transmission disequilibrium test (TDT). Tests
of gene-gene interaction between SNPs in FGF9 and FGF18 and gene-environment interaction between markers in FGFR2 and maternal smoking or multivitamin supplementation
yielded significant evidence of gene-environment (GxE) and gene-gene (GxG) interaction.
However, except for the GxE interaction tests, no other test results remained significant
after Bonferroni correction [92].
Among genes identified as genetic risk factors for isolated, nonsyndromic CL/P, IRF6
is probably one of the best documented genetic risk factors. Wu et al. [140] tested for association between markers in IRF6 and CL/P in 326 Chinese case-parent trios for genotypic
effects, interactions with maternal smoking status and multivitamin use and parent-of origin effects. Fourteen SNPs, including rs642961 previously found in GWAS [122, 125], were
reported to significantly be associated with the risk of CL/P. Interaction through multivitamin supplementation and tobacco smoking were shown to influence CL/P risk. However,
after Bonferroni correction, the results were not significant [140].
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2.4.4

Selection of One Carbon Metabolism Candidate Genes

Given the importance of the B-vitamins in the regulation of OCM and the plausible
association of genes involved in the OCM with the pathogenesis of OFCs, I want to improve
my understanding of how common polymorphisms of folate-related OCM genes and folaterelated nutrients associate with the risks of clefts. A list of candidate genes was developed on
the basis of an extensive literature review of genetic association studies published through
December 2013 focusing on folate-related nutrients, specifically folate, vitamin B6 , vitamin
B12 , and homocysteine. Candidate genes were included if they were involved in OCM
pathway and satisfied one of the following criteria: 1) significant association with folaterelated nutrients in GWA studies, 2) significant association with folate-related nutrients
in whole genome sequence studies, 3) significant association with folate-related nutrients
in genetic association analysis of microRNA target sites in OCM genes. Summary of the
candidate genes and their OCM-related functions was recorded in Table 2.3.
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Table 2.1: Oxidation levels of the one-carbon substituents of the folate coenzymes [109].
Oxidation level

Corresponding folate coenzyme

(from most reduced to most oxidized)
Methane, CH4

None

Methanol, CH3-OH

5-Methyl-THF

Formaldehyde, CH2=O

5,10-Methylene-THF

Formic acid, HCOOH

5,10-Methynyl-THF
5,10-Formimino-THF
5-Formyl-THF
10-Formyl-THF

Carbon dioxide, CO2

None

Table 2.2: Loci associated with orofacial clefts in genome-wide association studies.
Locus

Nearby
gene

Most
significant
associated
SNP

Original studies and
associated populations

Replication studies and associated population

1p22

ABCA4

rs560426

European and Asian
descendants [121]

1p36

PAX7

rs742071

European and Asian
descendants [143]

1q32-q41

IRF6

rs642961

2p21

THADA

rs7590268

Central European
descendants (from
Germany) [122]
European and Asian
descendants [143]

Hispanic [141]; European descendants (from German
and Turkish) and Asian descendants (from Philippines)
[125]; Brazillians [142]
Mayan Mesoamerican [127]; European descendants
(from German and Turkish) and Asian descendants
(from Philippines) [125]
European descendants (from German and Turkish) and
Asian descendants (from Philippines) [125]

3p11.1

EPHA3

rs7632427

3q12.3

COL8A1

rs793464

8q21.3

DCAF4L2

rs12543318

European and Asian
descendants [143]
European and Asian
descendants [143]
European and Asian
descendants [143]

Han Chinese [126]; European descendants (from German and Turkish) and Asian descendants (from Philippines) [125]
Han Chinese [126]; Mayan Mesoamerican [127]*
European descendants (from German and Turkish) and
Asian descendants (from Philippines) [125]
Han Chinese [126]; Mayan Mesoamerican [127]; European descendants (from German and Turkish) and
Asian descendants (from Philippines) [125]

Continued on Next Page. . .
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Table 2.2 – Continued
Locus

Nearby
gene

Most
significant
associated
SNP

Original studies and
associated populations

Replication studies and associated population

8q24

Intergenic

rs987525

Estonian and Lithuanian [144]; Mayan Mesoamerican
[145]; European descendants (From German and Turkish) and Asian descendants (from Philippines) [125];
Brazilians [146]

9q22.1

GADD45G

rs1007966

9q22.3

FOXE1

rs6478391

10q25.3

VAX1

rs7078160

13q31

SPRY2

rs8001641

15q22

TPM1

rs1873147

17p13

NTN1

rs1880646

17q22

NOG

rs227731

17q25.3

RBFOX3

rs2612753

Central European
descendants
(from
Germany) [122]; European
descendant
(from Greater Philadelphia) [123]
European and Asian
descendants [143]
European and Asian
descendants [143]
Central European
descendants (from Germany) [124]
European and Asian
descendants [143]
European and Asian
descendants [143]
European and Asian
descendants [143]
Central European
descendants (from
Germany) [124]
European and Asian
descendants [143]

European descendants (from German and Turkish) and
Asian descendants (from Philippines) [125]
European descendants (from German and Turkish) and
Asian descendants (from Philippines) [125]
Estonian [147]; Mayan Mesoamerican [145]; Polish
[148]
Mayan Mesoamerican [127]
Han Chinese [126]; Mayan Mesoamerican [127]
European descendants (from German and Turkish) and
Asian descendants (from Philippines) [125]
Polish [148]

European descendants (from German and Turkish) and
Asian descendants (from Philippines) [125]*
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Table 2.2 – Continued
Locus

Nearby
gene

Most
significant
associated
SNP

Original studies and
associated populations

Replication studies and associated population

20q11.2

MAFB

rs13041247

European and Asian
descendants [121]

Hispanic [141]; Han Chinese [149]; Southern Han Chinese [150]; Mayan Mesoamerican [127]*; European descendants (from German and Turkish) and Asian descendants (from Philippines) [125]
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Table 2.3: Summary of functions of one-carbon metabolism related genes selected for the study; Johns Hopkins International Orofacial Cleft Genetics Consortium.

Gene ID

Folaterelated
nutrients

Chromosome1 Function related to folate-related nutrients

B6

1p36.12

Homocysteine

21q22.3

CD320

B12

19p13.3p13.2

CUBN

B12

10p12.31

DHFR

Folate

5q11.2-q13.2

FOLR1

Folate

11q13.3q14.1

FUT2

B12

19q13.3

FUT6

B12

19p13.3

ALPL

CBS

Study type

Mutations in the ALPL gene cause the accumulation of phosphor compounds including
vitamin B6 .
Catalyze the conversion of homocysteine to
cystathionine.

GWAS

Mediate the cellular uptake of
transcobalamin-bound vitamin B12 .

GWAS, whole genome
sequencing studies

Act as receptor for intrinsic factor, an important protein that helps the body to absorb
vitamin B12 .
Convert dihydrofolate into tetrahydrofolate.

GWAS, whole genome
sequencing studies

Candidate gene
studies

References2

[118, 119]
[151]

[120, 152]
[118–
120]

Candidate microRNA
sites studies

[152]

Transport 5-methyltetrahydrofolate into cells

Candidate microRNA
sites studies

[152]

Involve in the binding of intrinsic
B12 which is necessary to transport
intestine to blood.
Involve in the binding of intrinsic
B12 which is necessary to transport
intestine to blood.

factor to
B12 from

GWAS, whole genome
sequencing studies

factor to
B12 from

Whole genome
sequencing

[118–
120]
[120]
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Table 2.3 – Continued
Gene ID

Folaterelated
nutrients

Chromosome1 Function related to folate-related nutrients

Folate

21q22.11

GABBR2

B12

9q22.1-q22.3

MMAA

B12

4q31.21

MMACHC

B12

1p34.1

MTHFD1

Folate

14q24

MTHFD2L

Folate

4q13.3

MTHFR

Folate,
homocysteine

1p36.3

MTR

B12 , folate,
homocysteine

1q43

Folate

5p15.31

GART

MTRR

Catalyze the conversion of
10-formyltetrahydrofolate to tetrahydrofolate.
Regulate the activity of adenylylcyclase; impairment of adenylylcyclase cause vitamin B12
deficiency.
Involve in the translocation of vitamin B12
into the mitochondrion.
Involve in the binding and intracellular trafficking of vitamin B12 .
Catalyzes the interconversion of one-carbon
derivatives of tetrahydrofolate.
Catalyzes the interconversion of one-carbon
derivatives of tetrahydrofolate.

Study type

References2

Candidate microRNA
sites studies

[152]

GWAS

[119]

Whole genome
sequencing studies
Whole genome
sequencing studies
Candidate microRNA
sites studies
Candidate microRNA
sites studies

[120]

Catalyze the conversion of
5,10-methylenetetrahydrofolate to
5-methyltetrahydrofolate, a co-substrate
factor involved in the conversion of
homocysteine to methionine.

GWAS, whole genome
sequencing studies

Catalyze the conversion of homocysteine to
methionine.
Regenerate methionine synthase, an enzyme
involved in methionine synthesis, from
5-methyltetrahydrofolate.

Candidate microRNA
sites studies
Candidate microRNA
sites studies

[120]
[152]
[152]
[118–
120]

[152]
[152]
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Table 2.3 – Continued
Gene ID

Folaterelated
nutrients

Chromosome1 Function related to folate-related nutrients

B12

6p12.3

Folate

21q22.3

TCN1

B12

11q11-q12

TCN2

B12

22q12.2

MUT
SLC19A1

1
2

Study type

Encode the vitamin B12 -dependent enzyme
methylmalonyl coenzyme A mutase.
Act as a transporter of folate and is involved
in the regulation of intracellular concentrations of folate.

GWAS, whole genome
sequencing studies
Candidate microRNA
sites studies

Encode a member of the vitamin B12 -binding
protein family.
Encode a member of the vitamin B12 -binding
protein family.

GWAS, whole genome
sequencing studies
Whole genome
sequencing studies

References2
[118–
120]
[152]

[118–
120]
[120]

Gene information was taken from http://www.ncbi.nlm.nih.gov/gene.
References listed genes as associating with folate-related nutrients
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Chapter 3
Maternal Multivitamin Use, Dietary Patterns, and the Risk
of Orofacial Clefts in Utah
3.1

Abstract
Background and objective: The role of maternal nutrition in the prevention of

orofacial clefts (OFCs) is uncertain, as findings have been inconsistent across studies. We
conducted a population-based case-control study of maternal multivitamin use and dietary
patterns in relation to the risk of isolated OFCs in Utah.
Design: Data were available for 644 controls, 303 cases of isolated cleft lip with or
without cleft palate (CL/P) and 119 cases of cleft palate only (CPO). We examined associations between periconceptional multivitamin use (PCMV) and scores of three dietary
patterns, including the Mediterranean Diet (MD), Diet Quality Index for Pregnancy (DQIP), and the Dietary Approach to Stop Hypertension (DASH) diet and the risk of OFCs in
logistic regression models with adjustment for covariates.
Results: Neither PCMV use nor any of the dietary pattern scores were significantly
different between cases and controls. Among PCMV users only, the risk of isolated OFCs
declined with increasing tertile of the DASH score; for reference tertile 1, odd ratios (OR)
= 1.0 (reference tertile 1); for tertile 2, OR = 0.82 (95% CI: 0.50, 1.35); for tertile 3, OR
= 0.45 (95% CI: 0.26, 0.75), p-trend = 0.002. The results were similar for the subgroups
CL/P and CPO. Among PCMV non-users, there was no evidence of a protective effect of
DASH dietary pattern. The MD and DQI-P dietary scores were not significantly associated
with OFC risk among PCMV users.
Conclusion: Neither PCMV use nor healthy dietary pattern score alone were individually associated with risk of OFCs. However, the combination of PCMV use and a higher
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score reflecting the ideal DASH diet was associated with a 55% reduction in risk of isolated
OFCs, evidence that prevention of OFCs may require attention to both periconceptional
vitamin use and improving maternal diets.

3.2

Introduction
Orofacial clefts (OFCs) affect about one of every 700 live births worldwide each year

and pose considerable financial and emotional burdens to families and societies [1–3]. Thus,
it is important to expand our understanding of OFC etiology, in which protective maternal
periconceptional exposures are of particular interest because they could be promoted and
encouraged.
Maternal nutrition has been recognized as one of the most important factors influencing
the development of the fetus, and was suggested to be associated with the formation of OFCs
as early as 1914 by Pickerill [4]. Previous research on the association between maternal
nutrition and the risk of OFCs mainly focused on the maternal intake of single nutrients or
foods during pregnancy. These analyses failed to take into account the complexity of diet
and thus, failed to represent all nutrition effects on the risk of OFCs. Therefore, dietary
pattern analysis is necessary to help complementing our understanding of the association
between nutrition and the risk of OFCs.
Identification of dietary patterns through the use of dietary quality scores has increasingly gained interest [5, 6]. Three dietary quality scores of interest are the Mediterranean
Diet (MD), Diet Quality Index for Pregnancy (DQI-P), and the Dietary Approach to Stop
Hypertension (DASH) scores. The Mediterranean diet describes the eating habits traditionally followed by people in countries bordering the Mediterranean Sea, and is characterized
by high intake in vegetables, legumes, fruits, nuts, cereals, and olive oil, regular but moderate intake in fish and ethanol, primarily in the form of wine, low intake in saturated fat,
meat, and poultry, and low to moderate in dairy [7]. The DQI-P was originally developed
based on the 1992 Food Guide Pyramid to reflect how closely an individuals diet follows
the current recommendation [8]. Since then, it has been revised multiple times to serve
different purposes as well as to fit the constant changes of the Food Guide [9, 10]. The
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DASH diet describes a diet that is high in fruits and vegetables, moderate in low-fat dairy
products and low in animal protein but adequate in plant protein. This diet has been shown
to substantially reduce both systolic and diastolic blood pressure among individuals with
or without hypertension, as compared to a typical diet in the United States, as well as
lower low-density lipoprotein cholesterol levels [11, 12]. Two studies have shown significant
associations between dietary patterns and OFCs [13, 14]. Except for these studies, we are
unaware of studies investigating the relation between maternal dietary patterns and OFCs.
In the current study, we examined the associations between MD, DQI-P, and DASH
dietary adherence scores and the risk of nonsyndromic OFCs, using the data from the Utah
Child and Family Health Study (UCFHS).

3.3

Subjects and Methods

3.3.1

Subjects

The Utah Child and Family Health Study (UCFHS) is a case-control study of OFCs
conducted in Utah in collaboration with the Utah Birth Defects Network (UBDN), a
statewide birth defects registry operated by the Utah Department of Health (UDOH). All
study procedures were reviewed and approved by the institutional review boards (IRBs) of
Utah State University, the University of Utah, and the UDOH.
Case- and control-mothers were initially contacted by the UDOH and recruited using
the limited use of UBDN data authorized by UBDN (for case-mothers) and the use of
birth certificate data files of the Utah Office of Vital Statistics authorized by UDOH (for
control-mothers). Eligible case-mothers included Utah residents with an OFC-affected child
live-born or stillborn between January 1st , 1995 and June 30th , 2004. The classification of
OFCs and associated birth defects of the cases were made after reviewing all available
medical recorded by a UBDN medical geneticist. Eligible control-mothers included Utah
resident mothers of children without OFCs and control-children were frequently matched
to case-children by birth month and sex. The present analysis includes 658 control-mothers
and 562 case-mothers. Further details of participant recruitment and response rates are
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published [15].

3.3.2

Data Collection

Maternal interviews were conducted primarily by telephone, and included questions on
demographic characteristics, reproductive health, pregnancy history, supplement use, medications, medical conditions, and smoking and alcohol use. A food-frequency questionnaire
(FFQ) with 157 items based on that of the Nurses’ Health Study was also included in the
interview. The FFQ covered maternal average intake of foods during the period of three
months before conception and the first three months of pregnancies. A time-specific version
of the Food Processor (ESHA Research, Portland, Oregon) nutrient composition database
was used to obtain nutrient composition of food items. Both daily intake of nutrients and
servings of food groups were adjusted for total energy intake using the residual regression
method [16]. Because our focus is isolated OFCs, 132 cases with multiple birth defects
were excluded from the analysis. An additional 23 cases were excluded because their mothers provided implausible energy intake (≤ 500 or ≥ 5,000 kcalories per day), leaving 643
control-mothers and 422 case-mothers for analysis.
The composition of vitamin and mineral supplements was determined using details
reported by the mothers and composition data from the National Health and Nutrition
Examination Survey (NHANES) database and manufactures’ data [17].

3.3.3

Diet Quality Indices

Three dietary quality indices were used including the MD, DQI-P, and DASH scores.
The dietary adherence scores were computed using a ranking method to capture more
variability in intakes [18]. The ranking method was adapted from a previous study of
MD- and DASH-patterns [18]. For each component, mothers were ranked based on the
distribution of scores of food or nutrient component intakes. Positive scoring meant that
the mother who consumed the lowest amount in the food group received a rank score of one
and the mother who consumed the highest amount in the food group or nutrient component
received the highest rank score. Negative scoring meant that the mothers were ranked in
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reverse order. The rank scores of the relevant food and nutrient components were then
summed to obtain the individual diet adherence scores. Mothers were then categorized into
tertiles of each respective diet adherence score. All components are weighed equally because
of the lack of information on the relative impact that these nutrients have on pregnancy or
birth outcomes.
The MD and DQI-P used in this analysis were similar to those used by Carmichael [13],
but different in that rank scores were used rather than quartiles. The MD score reflects
the summary of nine dietary components selected to represent food groups targeted in the
Mediterranean diet, of which six (fruits and nuts, vegetables, legumes, grains, fish, and
the ratio of monounsaturated to saturated fatty acid intake) received positive scoring and
three (dairy, meats, and sweets and sweetened beverages) received negative scoring. The
DQI-P score reflects the summary of eight dietary components of which six (whole grains,
vegetables, fruits, folate, iron, calcium) are positively scored and two (solid fats, sweets
and sweetened beverages) are negatively scored. The DQI-P used in this analysis is also
different from the DQI-P used in Carmichael in that it followed the 2010 Dietary Guidelines
for Americans. More specifically, it includes components that reflect intake of whole grain,
low fat dairy, lean meat and fish rather than the total grains, dairy and meat food groups
and a component that capture the calories from solid fats.
The DASH score used in this analysis was based on the original DASH scoring provided
by Appel and Sacks [12, 19] but different in that it uses the ranking method rather than
the quartile method and it includes a component that reflects intake of whole grain (a
characteristic of the DASH-sodium trial rather than all cereal grains as defined in the original
DASH trial. The DASH score reflects the summary of ten dietary components selected to
represent food groups targeted in the DASH diet, of which six (fruits, vegetables, nuts
and legumes, whole grains, low-fat dairy, fish) received positive scoring and four (sodium,
red and processed meats, sweets and sweetened beverages, fats and oils) received negative
scoring.
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3.3.4

Covariates

The covariates of interest are maternal age, educational level, drinking and smoking
habits (yes vs. no), periconceptional multivitamin (PCMV) use (yes vs. no), and body
mass index. Periconceptional period is defined as one month before and one month after
conception. Educational level was defined by the highest completed education of the mother
and classified as 1) high school graduate, 2) some college, or 3) college graduate or more.
Body mass index (BMI) was calculated as weight in kilograms divided by height in meters
squared. BMI was included as a categorical variable, with 1) underweight (<18.5), 2)
normal weight (18.5-24.9), 3) overweight (25.0-29.9), or 4) obesity (≥ 30.0).

3.3.5

Statistical Analysis

One-way analysis of variance (ANOVA) and contingency table analysis with chi-square
tests were used to assess the associations between different types of OFCs and continuous
and categorical variables, respectively. Spearmans Rank-order correlation coefficients were
calculated to examine the relationship of the diet quality indices with each other, their
components, and selected nutrients. Multivariate linear regression analyses were used to
examine the association of the diet quality indices with selected covariates.
Data were stratified by maternal PCMV use. This stratification provides a means of
evaluating the effects of PCMV use modifying the association between dietary adherence
scores and OFC risk. The periconceptional period was defined as one month before and one
month after conception. Multivariate logistic regression analyses were conducted using the
whole dataset and stratified dataset to examine the association of levels of each diet quality
index with OFCs by estimating the odds ratios (ORs) and 95% confidence intervals (CI).
Walds F tests were used to test for linear trends of ORs across increasing levels of each diet
quality index using the median value within each tertile. In models using the whole dataset,
interactions between the diet adherence scores and PCMV use were tested by comparing
the likelihood ratio test statistics between models with and without the interaction terms.
Reported p-values are two-sided, and type I error rate for statistical significance was 0.05.
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3.4

Results
There was no significant difference between control- and case- mothers in maternal

age at birth of index child, BMI, alcohol use, ethnicity, and three dietary quality scores.
Compared to control-mothers, case-mothers had significantly higher smoking rate during
periconceptional period and were less likely to be college graduates (Table 3.1). Detailed
information regarding frequencies of maternal descriptive characteristics among controland case- mothers was given in Table 3.1.
Maternal multivitamin uses in three months before pregnancy and during pregnancy
were not significantly different between control- and case-mothers. The multivitamin use
percentage of pregnant mothers increased dramatically after periconceptional period. At
one month before conception, only 41.7% pregnant mothers used multivitamins. At two
months after conception, 74.1% pregnant mothers used multivitamins (Figure 3.1).
All three dietary quality scores were positively correlated. More specifically, among
control-mothers, the correlation of MD and DQI-P scores was 0.71 (p < 0. 0001), the
correlation of MD and DASH scores was 0.64 (p < 0. 0001), and the correlation of DQI-P
and DASH scores was 0.67 (p < 0.0001). The scores of MD and DQI-P but not DASH
were positively correlated with intakes of total sugar, and vitamin D; the scores of DQI-P
and DASH but not MD were positively correlated with polyunsaturated fats, vitamin D,
calcium, zinc and omega 6 fatty acids. In addition, all three diet indices were negatively
correlated with total calorie intake, although only the correlation coefficients of MD and
DASH scores and total calorie intake were significant. MD and DQI-P but not DASH
scores were positively correlated with intakes of carbohydrates. Vitamin B2 and calcium
were positively correlated with DQI-P and DASH scores and negatively correlated with MD
score. Vitamin B12, phosphorus, and sodium were positively correlated with DQI-P and
DASH scores but not with MD score (Table 3.8).
No significant associations between OFC risk and dietary quality scores were observed
in logistic regression models (Table 3.3). The odds ratio for the highest versus lowest tertile
of MD score was 0.85 (95% CI, 0.62-1.16), for DQI-P was 0.91 (95% CI, 0.66-1.25), and for
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DASH was 0.78 (95% CI, 0.56-1.06). Although not significant, these results are consistent
with the odds ratios from Carmichael et al. [13] which had a much larger sample size. After
stratifying the data based on periconceptional multivitamin use, among mothers who used
multivitamins during the periconceptional period, increasing tertiles of DASH score were
associated with reduced OFC risk. The odds ratio for the highest versus lowest tertile
was 0.38 (95% CI, 0.17-0.88) for risk of isolated CPO, 0.46 (95% CI, 0.26-0.83) for risk of
isolated CL/P, and 0.45 (95% CI, 0.26-0.75) for risk of isolated OFCs. Among mothers who
did not use multivitamins during the periconceptional period, increasing tertiles of DASH
score were not significantly associated with lower CPO, CLP, and OFC risk (p-trend = 0.42,
0.87, and 0.063, respectively) (Table 3.4). In multivariate logistic regression models with
maternal PCMV use and tertiles of DASH adherence score treated as product term, the
DASH-PCMV interaction was statistically significant for risk of all isolated OFCs (p-trend
= 0.01) and isolated CPO (p-trend = 0.03) and marginally significant for risk of isolated
cleft lip with or without cleft palate (p-trend = 0.09).
No similar interactions were observed between MD or DQI-P scores, PCMV use, and
risks of OFCs. That is, even after data stratifications and adjustments for covariates, MD
and DQI-P scores were not associated with reduced risk of cleft (Table 3.5 and 3.6).
We examined the association of maternal folate intake from food with OFCs in the
UCFHS using the whole dataset and stratifying the dataset based on periconceptional
multivitamin use. No significant association between OFC risk and maternal food folate
intake was found (Table 3.7). Among multivitamins reportedly used by mothers in our
study during periconceptional period, 98.1% included folic acid.

3.5

Discussion
Maternal nutrition and multivitamin use have been important topics in OFCs research,

especially at the time of conception and during the first trimester, because of the timing of
the formation of an oral cleft. We report a 55% reduction in risk of isolated OFCs among
mothers in the highest versus lowest DASH tertile who were multivitamin users during the
periconceptional period. This result is notable because PCMV use alone and DASH, MD,
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and DQI-P indices alone were not significantly associated with OFC risk. No significant
association between OFC risk and maternal food folate intake or supplemental folic acid
intake was found in our study.
Findings for maternal multivitamin supplement intake and OFCs have been inconsistent. A population-based case-control study in California reported a 25-50% reduction
in OFC risk among women who used multivitamins containing folic acid periconceptionally [20]. However, in a subsequent investigation in this same area but among a 1999-2003
cohort, Wallenstein et al. [21] found no association between vitamin supplement intake and
risk of OFCs. Another population-based case-control study using data from the National
Birth Defects Prevention Study (NBDPS) also did not reveal reduced risks for OFCs associated with maternal intake of vitamin supplements [22]. A significantly lower risk for
CPO was found in mothers in Boston, Philadelphia, and Toronto who used multivitamins
during periconceptional period [23] and differed from an earlier finding in the same area,
which reported no protective association between the periconceptional use of folic acid supplements and the risk of OFCs though the observed number of OFC-affected pregnancies
was small [24]. No preventive effect on the occurrence of OFCs was found in women who
used periconceptional supplements including 0.8mg of folic acid in a Hungarian randomized controlled trial [25]. In contrast, a 48% risk reduction for CL/P was found among
mothers who used multivitamins during the periconceptional period or who started multivitamin use during the first postconceptional month [26]. A hypothesis was suggested that
multivitamins have a protective effect against OFCs in a folic acid dose-response manner.
The Czech Cleft Prevention Trial led by Tolarova in 1982 found a significant association
between recurrence of CL/P and supplementation with multivitamins containing a very
high dose of folic acid (10mg) [27]. However, the obtained result from this study may have
been seriously biased by the lack of randomization in assigning mothers to treatment or no
treatment group [28]. Updated results in 1987 and 1995 revealed no significant association
between high intake of folic acid and decreased recurrence of OFCs [29, 30]. Another supportive study of the above mentioned hypothesis, the Hungarian Birth Defects Prevention
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Trial, reported a reduction in the birth prevalence of isolated OFCs among women given
high pharmacological doses (6mg per day) compared to women with no supplementation
during pregnancy but not periconceptional daily supplementation with multivitamins including physiological doses (< 1mg) of folic acid or folic acid alone [31]. Also, there was no
significant difference observed in the occurrence of clefts between treatment groups, namely
the vitamin-supplemented and the trace element-supplemented groups [31]. It is possible
that observed preventive effect presumed to be of folic acid could be from the interaction of
other vitamins/trace-element in the supplements. No similar study has been done regarding
first occurrence of isolated OFCs because of the possible rare side effects. Currently the
upper tolerable level of folic acid is 1 mg for the preventive program.
Two meta-analyses have been conducted to estimate the average effects of folic acid
across several studies and samples. Badovinac et al. [32] reported a significant reduction
in birth prevalence of CL/P, CPO, and all clefts associated with the use of folic acid containing supplement intake during pregnancy. Johnson and Little (2008) reported significant
reduction in the risk of CL/P but not CPO with the use of folic acid or folic acid-containing
supplement. Significant association between the use of multivitamins, regardless of folic acid
content, preconceptionally and decreasing risks of CL/P and CPO were also observed [33].
In both studies, isolating the effect of folic acid from the effect of multivitamin use was impossible because specific information about the other nutrients included in the supplements
taken by the participants were not reported. Differences in doses and definition of folic
acid supplements, measurement, sample selection bias, and the lack of confounding reports
also prevent both studies from generating an adjusted summary effect estimate, making the
results difficult to interpret [34].
Literatures on the association between OFCs and food nutrients have mostly focused
on dietary folate and also bring mixed results. Wilcox et al. [35] reported a modest association between dietary folate intake and crude risk of CL/P. However, this association was
weakened and no longer significant after covariate adjustment. A case-control study in the
Netherlands also investigated the association between maternal folate intake from food and
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the risk of CLP offspring and reported a small reduced risk for CL/P in higher maternal
food folate intake [36]. Notably, both studies demonstrated significant preventive effects
of using folic acid supplements in addition to a high folate diet. Wilcox et al. [35] showed
a 54% reduction of cleft lip among women with folate rich diets who also took folic acid
supplements [35]. van Rooij et al. [36] showed a 74% reduction of cleft lip with or without
cleft palate on mothers who had a diet of more than 200 ug folate per day in combination
with a folic acid multivitamins. In contrast, a case-control study from Scotland and England found no association between OFCs and either energy adjusted total folate intake or
supplemental folic acid use, irrespective of dosage [37].
Studies of the association between OFCs and single nutrients fail to take into account
the complexity of human diets and the interaction of nutrients in foods. We cannot isolate
a folic acid effect because of many other associated nutrients, many of which are involved in
one-carbon metabolism. For example, inadequate vitamin B12 can interfere with the generation of tetrahydrofolate, which is the most biologically active form of folate in the body and
is needed for one-carbon metabolism to perform its roles in DNA and RNA synthesis [38].
Single nutrient analyses are also inadequate in detecting some nutrients in which effects
are too small when being analyzed separately; statistically significant associations might
be produced by chance because of large number of nutrients or food items tested. Single
nutrient intakes are directly influenced by dietary patterns and thus, the effect supposedly
observed in single nutrient analysis may be confounded by the effect of dietary patterns [5].
Because of these limitations, dietary pattern studies have been proposed as a more
useful approach than focus on single nutrients. However, literature on the association
between maternal dietary pattern and the risk of OFC is still very limited. One study of
Dutch mothers observed that high adherence to a Western diet, which was characterized by
high intakes of meat, pizza, legumes, and potatoes, and low in fruits, was associated with
increased CL/P risk [14]. In the National Birth Defects Prevention Study (NBDPS), a 34%
reduction in CL/P risk and 26% reduction in CPO risk were observed among mothers in
the highest level of DQI score [13]. Our study also observed reductions in CL/P and CPO

87
risk among mothers in the highest level of DQI-P score, although the reductions are much
smaller and not significant (ORs = 0.93 (95% CI, 0.57-1.52) and 0.90 (95% CI, 0.63, 1.29)
for CPO and CL/P, respectively). This difference might be explained by the considerably
larger sample size of the NBDPS study. What is notable about our finding is the statistical
reduction (55%) in OFC risk with the combination of DASH and PCMV use; this effect
was not observed for MD and DQI-P. A significant reduction in risk of isolated OFCs
observed in the UCFHS only among periconceptional multivitamin users with a DASH-like
diet suggested that neither healthy maternal diet nor supplement use alone is enough to
substantially reduce risk of OFCs.
The fact that DASH but not MD and DQI-P had a protective effect for isolated OFCs
among PCMV supplements users may provide mechanistic clues to the causes of OFCs. The
DASH diet, now recommended in the current Dietary Guidelines for Americans, includes
high intakes of fruits, vegetables, whole grains, low-fat dairy foods and reduced intake of red
and processed meats, sweet desserts and sweetened beverages (Table 3.9) and is associated
with a reduced risk of developing hypertension and stroke in several prospective studies
[39–41], as well as lower low-density lipoprotein cholesterol levels [11,12]. High adherence to
DASH diet also has been shown to potentially prevent type 2 diabetes [42] and link to obesity
via lowering blood pressure and lipid-induced oxidative stress [43]. Interestingly, maternal
diabetes and obesity have been observed to be associated with OFCs and the protective
effect of a DASH diet and PCMV use may be related to these mechanisms. In a populationbased case-control study using the 1996 National Center for Health Statistics United States
Nationality database, after adjusting for potential confounding variables, diabetic mothers
were found to be 1.35 times (95% CI, 1.00-1.82) more likely than nondiabetic mothers to
have a newborn with CL/P [44]. Isolated CPO was also observed to associate with familial
diabetes in a case-only study consisted of 126 cleft patients in Southern Italy [45]. Similarly,
obese (BMI > 29) mothers were shown to have an overall increased risk for having an infant
with OFCs, with odds ratio of 1.30 (95% CI, 1.11-1.53) [46]. A meta-analysis conducted
in 2009 also confirmed that compared with mothers of recommended BMI, obese mothers
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were at increased odds of pregnancies affected by OFCs [47]. It is possible that a DASH
diet may reduce the risk of OFCs due to mechanisms related to blood pressure and diabetes
in addition to having a high intake of folate and folate-related nutrients important in one
carbon metabolism.
Our study has several key strengths: recruitment of case-mothers from a populationbased birth defects registry, randomly sampled population controls that were matched by
birth-month and sex to cases, and detailed and structured interview questionnaire by trained
interviewers. Recall bias is a concern for all case-control studies but is not thought to be
a major source of bias in studies of birth defects [23, 48, 49]. Dietary quality indices have
a potential limitation in that all dietary components are weighed equally, however, this is
a reasonable approach because of the lack of knowledge regarding which components may
deserve greater or lesser weight [13]. Healthy dietary patterns are associated with healthy
lifestyle factors including education, smoking, and alcohol use. Although we did control for
these and other characteristics that were related to both diet and clefts, there may be other
unmeasured characteristics or residual confounding that may have biased our results.
In conclusion, higher adherence to DASH-like diets and the use of multivitamins simultaneously during the periconceptional period, which is defined as one month before
conception and the first month of pregnancy, were associated with a substantially lower
risk of isolated OFCs among Utah mothers. Similar analysis with MD and DQI-P do not
yield the same result. Our finding supports the proposition that neither healthy diet nor
multivitamin use alone, but the combination of both has a preventive effect in oral cleft.
Thus, appropriate public health messages promoting both PCMV supplement usage and
adherence to DASH-like diets may provide a preventive strategy for reducing risks of OFCs
and need to be studied and developed.
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Table 3.1: Characteristics of mothers of orofacial clefts cases and controls, Utah Child and
Family Health Study.
Participants
Characteristics

Age at birth of index child2
Body Mass Index2
Smokinga, 1
Alcohol Usea, 1
Multivitamin Usea, 1
Education1
High school graduate or less
Some college
College graduate or more
Race/Ethnicity1
Caucasians
Asians
Hispanics
Others
Mediterranean Diet Score2
Diet Quality Index for Pregnancy
Score2
Dietary Approach to Stop
Hypertension Score2

1
2
a

*

Controls

Isolated
CPO

Isolated
CL/P

(n = 643)

(n = 119)

(n = 303)

All
Isolated
OFCs
(n = 422)

27.3 (5.2)
26.1 (6.4)
10.0
22.6
26.3

27.7 (5.5)
26.7 (6.7)
15.1
21.8
28.6

27.4 (5.6)
25.9 (5.4)
15.8*
26.7
22.9

27.5 (5.6)
26.1 (5.8)
15.6*
25.4
24.5

24.7
44.2
31.1

28.6
38.7
32.8

33.7*
42.6*
23.8*

32.2*
41.5*
26.3*

89.6
0.6
5.6
4.2
5449.1
(1309.0)
4228.7
(1441.4)
6054.9
(1410.7)

90.8
3.4
2.5
3.4
5247.6
(1377.5)
4209.9
(1465.8)
5911.9
(1354.7)

86.8
0.7
7.9
4.6
5378.6
(1294.1)
4120.5
(1419.2)
5891.9
(1420.1)

87.9
1.4
6.4
4.3
5341.7
(1317.8)
4145.7
(1431.3)
5897.5
(1400.4)

Abbreviations: CPO, cleft palate only; CL/P, cleft lip with or without cleft palate; OFC, orofacial
cleft.
Percent.
Mean (standard deviation).
Use during periconceptional period defined as one month before pregnancy and first month of pregnancy.
Achieved significance in Pearson Chi-square tests (p-value < 0.05) when compared with control
group.

Table 3.2: Food groups and nutrient scoring criteria for Mediterranean Diet (MD) score, Diet Quality Index for Pregnancy
(DQI-P) score, and Dietary Approach to Stop Hypertension (DASH) score; Utah Child and Family Health Study (n =
1199).
Food Group

Food Items

Scoring
Criteria1

Median
(interquartile range)

MD
s.c.

DQI-P
s.c.

DASH
s.c.

All grains
(serv/d)2

Cold and cooked breakfast cereal, oatmeal,
dark and white bread or pita, bagels, muffins,
rolls or biscuits, rice, pasta, tortillas, other
grains, pancakes or waffles, popcorn, potatoes, french fries, and crackers
Potatoes, boiled, baked or mashed

Positive

1.69 (0.97, 2.74)

Yes

No

No

Positive

0.18 (0.11, 0.40)

Yes

Yes

Yes

Cooked breakfast cereal, oatmeal, dark bread
or pita, other grains, brown rice, oat bran,
bran, and wheat germ
Popcorn
Peanut butter, peanuts, other nuts

Positive

0.18 (-0.19, 0.74)

No

Yes

Yes

Positive
Positive

0.10 (0.05, 0.17)
-0.01 (-0.16, 0.20)

Yes
Yes

Yes
Yes

No
Yes

Soy products, all cooked beans and peas excluding green beans and green peas

Positive

0.36 (0.22, 0.61)

Yes

Yes

Yes

Beef, pork, lamb, chicken, turkey, liver,
salami, bologna, hotdogs, bacon, sausages,
and other processed meats (15 items)
Beef, pork, lamb, liver, salami, bologna, hotdogs, bacon, sausages, other processed meat,
and liver (12 items)
Chicken, lean hamburger, and eggs

Negative

1.48 (1.17, 1.83)

Yes

No

No

Negative

0.94 (0.70, 1.21)

No

No

Yes

Positive

0.69 (0.43, 0.98)

No

Yes

No

Potatoes
(serv/d)2, 3
Whole grains
(serv/d)
Popcorn (serv/d)6
Nuts
(serv/d)4, 5
Legumes and
soy products
(serv/d)4
All meat (serv/d)
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Red and
processed meats
(serv/d)
Lean meats
(serv/d)
Continued on Next Page. . .

Table 3.2 – Continued
Food Group

Food Items

Scoring
Criteria1

Median
(interquartile range)

MD
s.c.

DQI-P
s.c.

DASH
s.c.

Fish (serv/d)

Canned tuna fish, salmon/dark meat fish and
other fish
Canned tuna fish, salmon/dark meat fish,
shrimp, lobster, scallops or clams and other
fish
Whole, low-fat and skim milk, yogurt, ice
cream, sherbet, cheese, cream, sour cream and
cream cheese (20 items)
Skim and low-fat milk, low-fat or non-fat yogurt, cottage or ricotta cheese, low-fat or nonfat cheese
All fruits and 100% fruit juices (16 items)

Positive

0.13 (0.06, 0.22)

Yes

No

No

Positive

0.14 (0.06, 0.26)

No

Yes

Yes

Negative

1.04 (-0.21, 3.51)

Yes

No

No

Positive

0.78 (-0.36, 3.65)

No

Yes

Yes

Positive

0.79 (0.11, 1.60)

Yes

Yes

Yes

All vegetables except potatoes and legumes
(25 items)
All sweets and sweetened beverages (21 items)

Positive

2.50 (1.60, 3.84)

Yes

Yes

Yes

Negative

0.40 (-0.45, 1.50)

Yes

Yes

Yes

Ratio of total monounsaturated
acids/total saturated fatty acids
Sum of sodium content of all foods

Positive

0.81 (0.73, 0.88)

Yes

No

No

Negative

3569.34
(3250.61, 3937.12)
11.90 (10.03, 13.65)

No

No

Yes

No

Yes

No

455.83
(358.13, 558.47)

No

Yes

No

Seafoods (serv/d)

All dairy (serv/d)

Low-fat dairy
(serv/d)
Fruits
(serv/d)
Vegetables
(serv/d)3
Sweets and
sweetened
beverages
(serv/d)
MUFA/SUFA
ratio
Sodium (mg/d)
SoFaS
(% calories)
Folate (mg/d)

fatty

Calories from solid fats and added sugars

Positive
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Folate dietary intake exclusive of vitamin/mineral supplements
Continued on Next Page. . .

Negative

Table 3.2 – Continued
Food Group

Food Items

Scoring
Criteria1

Median
(interquartile range)

MD
s.c.

DQI-P
s.c.

DASH
s.c.

Calcium (mg/d)

Calcium dietary intake exclusive of vitamin/mineral supplements
Iron dietary intake exclusive of vitamin/mineral supplements
Butter, margarine, mayonnaise, salad dressing

Positive

No

Yes

No

Positive

1389.90
(1113.28, 1670.70)
18.71 (16.73, 21.15)

No

Yes

No

Negative

0.60 (0.19, 1.04)

No

No

Yes

Iron (mg/d)
Fats (serv/d)
1

2
3
4
5
6

Positive scoring: participant consuming the lowest amount received a rank score of 1, participants with highest amount received rank score
of 1199; negative scoring: participant consuming the lowest amount received a rank score of 1199, participant with the highest amount
received rank score of 1.
Potatoes and grains combined for MDS adherence score.
Potatoes and vegetables combined for DQI and DASH adherence score.
Nuts and legumes combined for DASH adherence score.
Nuts and fruits combined for MDS adherence score.
Popcorn and whole grains combined for DQI adherence score.
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Table 3.3: Association of orofacial clefts with the Mediterranean Diet (MD) score, Diet Quality Index for Pregnancy (DQI-P) score,
and Dietary Approach to Stop Hypertension (DASH) score; Utah Child and Family Health Study.
Isolated CPO (n = 119)
Diet Indices1

N cases/
controls

ORs (95% CI)2

Mediterranean Diet score
200/50
1.0 [Reference]
Tertile 1 (1774-4799)
219/29
0.51 (0.31, 0.85)
Tertile 2 (4800-5978)
224/40
0.72 (0.44, 1.16)
Tertile 3 (5979-10016)
0.16
p-value for Trend3
Diet Quality Index for Pregnancy score
211/41
1.0 [Reference]
Tertile 1 (143-3526)
208/37
0.86 (0.52, 1.42)
Tertile 2 (3527-4864)
224/41
0.93 (0.57, 1.52)
Tertile 3 (4865-8073)
0.76
p-value for Trend3
Dietary Approach to Stop Hypertension diet score
202/41
1.0 [Reference]
Tertile 1 (1106-5390)
215/43
1.03 (0.63, 1.66)
Tertile 2 (5391-6598)
226/35
0.79 (0.47, 1.33)
Tertile 3 (6599-10399)
0.36
p-value for Trend3
1
2

3

Isolated CL/P (n = 303)

All isolated OFCs (n = 422)

N cases/
controls

ORs (95% CI)2

N cases/
controls

ORs (95% CI)2

200/98
219/110
224/95

1.0 [Reference]
1.06 (0.76, 1.49)
0.92 (0.65, 1.32)
0.66

200/148
219/139
224/135

1.0 [Reference]
0.87 (0.64, 1.18)
0.85 (0.62, 1.16)
0.30

211/105
208/108
224/90

1.0 [Reference]
1.15 (0.82, 1.62)
0.90 (0.63, 1.29)
0.60

211/146
208/145
224/131

1.0 [Reference]
1.06 (0.78, 1.45)
0.91 (0.66, 1.25)
0.58

202/113
215/97
226/93

1.0 [Reference]
0.83 (0.59, 1.17)
0.76 (0.54, 1.08)
0.13

202/154
215/140
226/128

1.0 [Reference]
0.88 (0.65, 1.19)
0.78 (0.56, 1.06)
0.11

Abbreviations: CPO, cleft palate only; CL/P, cleft lip with or without cleft palate; OFC, orofacial cleft.
Calculated based on energy adjusted foods.
Odds ratio (95% confidence interval) adjusted for maternal body mass index, education (high school graduate or less, some college,
college graduate or more), and any drinking and smoking during periconceptional period. Periconceptional period is defined as one
month before and one month after conception.
Statistical significance of the F value from the Type 3 Tests of Fixed Effects; the variable representing the median value of the tertile
scores was entered into the model as a continuous variable.

98

Table 3.4: Association of orofacial clefts with the three tertile levels of the Dietary Approach to Stop Hypertension (DASH) score.
Data were stratified by maternal multivitamin use during periconceptional period, defined as one month before and one month after
conception; Utah Child and Family Health Study.
Isolated CPO (n = 119)
Diet Indices1

N cases/
controls

ORs (95% CI)2

Isolated CL/P (n = 303)
N cases/
controls

Mothers who used multivitamins during periconceptional period
58/18
1.0 [Reference]
58/39
Tertile 1 (1106-5390)
82/25
1.03 (0.51, 2.10)
82/40
Tertile 2 (5391-6598)
105/12
0.38 (0.17, 0.88)
105/34
Tertile 3 (6599-10399)
0.02
p-value for trend3
Mothers who did not use multivitamins during periconceptional period
144/23
1.0 [Reference]
144/74
Tertile 1 (1106-5390)
133/18
0.95
(0.48,
1.88)
133/57
Tertile 2 (5391-6598)
121/23
1.32 (0.68, 2.54)
121/59
Tertile 3 (6599-10399)
0.42
p-value for trend3
1
2

3

All isolated OFCs (n = 422)

ORs (95% CI)2

N cases/
controls

ORs (95% CI)2

1.0 [Reference]
0.72 (0.41, 1.27)
0.46 (0.26, 0.83)
0.01

58/57
82/65
105/46

1.0 [Reference]
0.82 (0.50, 1.35)
0.45 (0.26, 0.75)
0.002

1.0 [Reference]
0.89 (0.58, 1.38)
1.05 (0.67, 1.62)
0.87

144/97
133/75
121/82

1.0 [Reference]
0.90 (0.60, 1.34)
1.11 (0.74, 1.65)
0.63

Abbreviations: CPO, cleft palate only; CL/P, cleft lip with or without cleft palate; OFC, orofacial cleft.
Calculated based on energy adjusted foods.
Odds ratio (95% confidence interval) adjusted for maternal body mass index, education (high school graduate or less, some college,
college graduate or more), and any drinking and smoking during periconceptional period. Periconceptional period is defined as one
month before and one month after conception.
Statistical significance of the F value from the Type 3 Tests of Fixed Effects; the variable representing the median value of the tertile
scores was entered into the model as a continuous variable.
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Table 3.5: Association of orofacial clefts with the three tertile levels of the Mediterranean Diet (MD) score. Data were stratified
by maternal multivitamin use during periconceptional period, defined as one month before and one month after conception; Utah
Child and Family Health Study.
Isolated CPO (n = 119)
Diet Indices1

N cases/
controls

ORs (95% CI)2

Isolated CL/P (n = 303)
N cases/
controls

Mothers who used multivitamins during periconceptional period
65/19
1.0 [Reference]
65/32
Tertile 1 (143-3526)
71/17
0.82 (0.38, 1.78)
71/38
Tertile 2 (3527-4864)
108/19
0.63 (0.30, 1.31)
108/43
Tertile 3 (4865-8073)
0.21
p-value for trend3
Mothers who did not use multivitamins during periconceptional period
146/26
1.0 [Reference]
146/73
Tertile 1 (143-3526)
137/31
1.46
(0.80,
2.66)
137/70
Tertile 2 (3527-4864)
115/20
1.22 (0.63, 2.39)
115/47
Tertile 3 (4865-8073)
0.51
p-value for trend3
1
2

3

All isolated OFCs (n = 422)

ORs (95% CI)2

N cases/
controls

ORs (95% CI)2

1.0 [Reference]
1.20 (0.65, 2.20)
0.87 (0.49, 1.53)
0.52

65/51
71/55
108/62

1.0 [Reference]
1.06 (0.62, 1.80)
0.77 (0.47, 1.28)
0.26

1.0 [Reference]
1.15 (0.75, 1.75)
0.95 (0.60, 1.52)
0.89

146/95
137/90
115/69

1.0 [Reference]
1.10 (0.75, 1.63)
1.07 (0.70, 1.62)
0.75

Abbreviations: CPO, cleft palate only; CL/P, cleft lip with or without cleft palate; OFC, orofacial cleft.
Calculated based on energy adjusted foods.
Odds ratio (95% confidence interval) adjusted for maternal body mass index, education (high school graduate or less, some college,
college graduate or more), and any drinking and smoking during periconceptional period. Periconceptional period is defined as one
month before and one month after conception.
Statistical significance of the F value from the Type 3 Tests of Fixed Effects; the variable representing the median value of the tertile
scores was entered into the model as a continuous variable.
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Table 3.6: Association of orofacial clefts with the three tertile levels of the Diet Quality Index for Pregnancy (DQI-P) score. Data
were stratified by maternal multivitamin use during periconceptional period, defined as one month before and one month after
conception; Utah Child and Family Health Study.
Isolated CPO (n = 119)
Diet Indices1

N cases/
controls

ORs (95% CI)2

Isolated CL/P (n = 303)
N cases/
controls

Mothers who used multivitamins during periconceptional period
65/24
1.0 [Reference]
65/33
Tertile 1 1774-4799)
85/11
0.35 (0.16, 0.79)
85/34
Tertile 2 (4800-5978)
95/20
0.61 (0.30, 1.22)
95/46
Tertile 3 (5979-10016)
0.17
p-value for trend3
Mothers who did not use multivitamins during periconceptional period
135/26
1.0 [Reference]
135/65
Tertile 1 1774-4799)
134/18
0.69
(0.35,
1.35)
134/76
Tertile 2 (4800-5978)
129/20
0.83 (0.42, 1.65)
129/49
Tertile 3 (5979-10016)
0.55
p-value for trend3
1
2

3

All isolated OFCs (n = 422)

ORs (95% CI)2

N cases/
controls

ORs (95% CI)2

1.0 [Reference]
0.81 (0.45, 1.45)
0.99 (0.56, 1.74)
0.97

65/57
85/45
95/66

1.0 [Reference]
0.62 (0.37, 1.04)
0.84 (0.52, 1.37)
0.55

1.0 [Reference]
1.21 (0.79, 1.85)
0.86 (0.54, 1.38)
0.59

135/91
134/94
129/69

1.0 [Reference]
1.06 (0.72, 1.56)
0.85 (0.56, 1.29)
0.47

Abbreviations: CPO, cleft palate only; CL/P, cleft lip with or without cleft palate; OFC, orofacial cleft.
Calculated based on energy adjusted foods.
Odds ratio (95% confidence interval) adjusted for maternal body mass index, education (high school graduate or less, some college,
college graduate or more), and any drinking and smoking during periconceptional period. Periconceptional period is defined as one
month before and one month after conception.
Statistical significance of the F value from the Type 3 Tests of Fixed Effects; the variable representing the median value of the tertile
scores was entered into the model as a continuous variable.
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Table 3.7: Association of orofacial clefts with the energy adjusted maternal food folate intake during periconceptional period; Utah
Child and Family Health Study.

Isolated CPO (n = 119)
Folate Intake1

N cases/
controls

ORs (95% CI)2

Isolated CL/P (n = 303)
N cases/
controls

All mothers
216/39
1.0 [Reference]
216/104
Tertile 1 (-23.6-395.7)
214/42
1.09 (0.67, 1.78)
214/103
Tertile 2 (395.8-513.8)
213/38
0.98 (0.59, 1.63)
213/96
Tertile 3 (513.9-1746.2)
0.92
p-value for Trend3
Mothers who used multivitamins during periconceptional period
54/17
1.0 [Reference]
54/26
Tertile 1 (-23.6-395.7)
83/20
0.73 (0.35, 1.55)
83/47
Tertile 2 (395.8-513.8)
108/18
0.57 (0.27, 1.22)
108/40
Tertile 3 (513.9-1746.2)
0.92
p-value for Trend3
Mothers who did not use multivitamins during periconceptional period
162/22
1.0 [Reference]
162/78
Tertile 1 (-23.6-395.7)
131/22
1.33 (0.69, 2.56)
131/56
Tertile 2 (395.8-513.8)
105/20
1.48 (0.75, 2.92)
105/56
Tertile 3 (513.9-1746.2)
0.25
p-value for Trend3
1
2

3

All isolated OFCs (n = 422)

ORs (95% CI)2

N cases/
controls

ORs (95% CI)2

1.0 [Reference]
1.09 (0.77, 1.53)
1.03 (0.73, 1.47)
0.87

216/143
214/145
213/134

1.0 [Reference]
1.09 (0.80, 1.48)
1.03 (0.75, 1.41)
0.89

1.0 [Reference]
1.21 (0.66, 2.20)
0.81 (0.44, 1.48)
0.87

54/43
83/67
108/58

1.0 [Reference]
1.02 (0.61, 1.73)
0.71 (0.42, 1.20)
0.89

1.0 [Reference]
0.95 (0.62, 1.45)
1.23 (0.79, 1.91)
0.39

162/100
131/78
105/76

1.0 [Reference]
1.05 (0.71, 1.54)
1.31 (0.88, 1.96)
0.19
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Abbreviations: CPO, cleft palate only; CL/P, cleft lip with or without cleft palate; OFC, orofacial cleft.
Calculated based on energy adjusted foods.
Odds ratio (95% confidence interval) adjusted for maternal body mass index, education (high school graduate or less, some college,
college graduate or more), and any drinking and smoking during periconceptional period. Periconceptional period is defined as one
month before and one month after conception.
Statistical significance of the F value from the Type 3 Tests of Fixed Effects; the variable representing the median value of the tertile
scores was entered into the model as a continuous variable.
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Table 3.8: Correlation coefficients of the Mediterranean Diet (MD), the Diet Quality Index
for Pregnancy (DQI-P), and the Dietary Approaches to Stop Hypertension (DASH) scores
with nutritional factors, among control mothers only; Utah Child and Family Health Study.
Nutrients
Total Calories Intake
Protein
Carbohydrates
Fiber 0.71**
Total sugar
Monosaccharide
Disaccharide
Other carbohydrates
Total fats
Saturated fats
Monounsaturated fats
Polyunsaturated fats
Trans fats
Cholesterol
Vitamin A (as retinol)
Vitamin A (as betacarotene)
Vitamin B1
Vitamin B2
Vitamin B3
Vitamin B6
Vitamin B12
Vitamin C
Vitamin D
Vitamin E
Folate
Pantothenic acid
Calcium
Copper
Iron
Magnesium
Manganese
Phosphorus
Potassium
Selenium
Sodium
Zinc
Continued on Next Page. . .

Correlation with
MD

Correlation with
DQI-P

Correlation with
DASH

-0.09*
0.11**
0.23**
0.72**
-0.07
0.17**
-0.07
0.28**
-0.30**
-0.42**
-0.10*
0.19**
-0.03
0.03
0.35**
0.50**

-0.07
0.30**
0.28**
0.62**
-0.08
0.02
-0.09*
0.32**
-0.48**
-0.47**
-0.40**
-0.16**
-0.31**
0.01
0.48**
0.59**

-0.12**
0.19**
0.25**

0.30**
-0.08*
0.21**
0.28**
-0.03**
0.50**
-0.19**
0.27**
0.28**

0.49**
0.25**
0.40**
0.57**
0.23**
0.55**
-0.10*
0.26**
0.66**
0.43**
0.11**
0.44**
0.52**
0.61**
0.65**
0.29**
0.54**
0.49**
0.16**
0.25*

0.21**
0.28**
0.06
0.32**
0.17**
0.53**
0.15**
0.15**
0.35**
0.42**
0.31**
0.41**
0.17**
0.72**
0.54**
0.40**
0.62**
0.27**
-0.24**
0.07

**

-0.11**
0.43**
0.25**
0.51**
0.58**
0.06
0.42**
0.32**
0.06
-0.05

0.16**
0.14**
0.18**
0.01
-0.36**
-0.20**
-0.19**
-0.13**
-0.08
0.00
0.45**
0.51**
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Table 3.8 – Continued
Nutrients
Omega 3
Omega 6
Alcohol
Caffeine
*

Correlation with
MD
0.38**
0.18**
-0.06
-0.07

Correlation with
DQI-P
0.10*
-0.11*
-0.05
-0.18**

Correlation with
DASH
0.25**
-0.12**
-0.05
-0.14**

Correlation is significant at the 0.05 level (2-tailed)
Correlation is significant at the 0.01 level (2-tailed)
Note: Nutrients in which correlations are different between DASH and the other diet scores (MD)
and DQI) were highlighted

**
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Table 3.9: Correlation coefficients of the Mediterranean Diet (MD), Diet Quality Index
for Pregnancy (DQI-P), and Dietary Approach to Stop Hypertension (DASH) scores with
their food and nutrient components among control mothers; Utah Child and Family Health
Study.
Food and nutrient
components

Correlation with
MD

MDS
DQI
DASH
Meat (servings/day)1, †
Fish (serving/day)1, 3
Dairy (serving/day)1
Fruits and Nuts
(serving/day)1
Vegetables (serving/day)1, 2, 3, †
Grains (serving/day)1
Legumes (serving/day)1
Sweets and Sweetened
Drinks (serving/day)1-0.29**
Fats ratio1, ‡
Fruits Only (servings/day)2, 3
Whole Grains
(serving/day)2, 3
Solid Fats and Added
Sugar2
Red Meat (serving/day)3
Low-fat Dairy
(serving/day)3
Nuts and Legumes
(servings/day)3
Fats and Oils
(servings/day)3
Sodium Intake3
Folate Intake2
Iron Intake2
Calcium Intake2
1

Correlation with
DQI-P

Correlation with
DASH

n.a.
0.71**
0.64**
-0.14*
0.39**
-0.41**

0.71**
n.a.
0.67**
-0.01
0.16**
-0.16**

0.64**
0.67**
n.a.
-0.35**
0.34**
0.22**

0.51**

0.55**

0.60**

0.50**
0.31**
0.49**

0.53**
0.21**
0.35**

0.46**
0.05
0.36**

-0.50**

-0.38**

0.30**
0.47**

0.04
0.56**

-0.04
0.56**

0.42**

0.47**

0.40**

-0.44**

-0.55**

-0.21**

-0.18**

-0.11**

-0.42**

-0.32**

-0.07

0.26**

0.47**

0.23**

0.39**

0.03

-0.06

-0.27**

0.06
0.28**
0.25**
-0.11**

0.16**
0.66**
0.52**
0.11**

-0.24**
0.35**
0.17**
0.31**

Component of MD score
Component of DQI-P score
3
Component of DASH score
†
The food items included in these food groups were slightly different for MD, DQI-P, and
DASH (see Methods section for details).
‡
Ratio of monounsaturated to saturated fatty acid intake
*
Correlation is significant at the 0.05 level (2-tailed)
**
Correlation is significant at the 0.01 level (2-tailed)
Note: Food groups in which correlations are different between DASH and the other diet
scores (MD and DQI-P) were highlighted.
2
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Fig. 3.1: Multivitamin use before and during pregnancy of Utah mothers of orofacial cleft
cases and controls.
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Chapter 4
Orofacial Clefts and Maternal Folate Levels in Utah
4.1

Abstract
Background and Objective: The evidence of a protective effect of folic acid intake

against orofacial clefts (OFCs) has been weak. The association between maternal multivitamin (MV) use in early pregnancy and OFC risk is uncertain and may be confounded by
other maternal lifestyle factors associated with multivitamin use.
Design: Maternal MV use, supplemental folic acid intake and maternal concentrations
of plasma and erythrocyte folate were measured at the same time point in a populationbased case-control study in Utah with 233 case-mothers of isolated cleft lip with or without
cleft palate, 94 case-mothers of cleft palate only, and 468 control-mothers. We compared
blood folate levels between cases and controls using general linear models with adjustment
for covariates.
Results: Plasma folate levels were significantly higher in controls than in cases in both
MV users and non-users. Among mothers whose folic acid intakes from supplements were
400µg or less, plasma folate levels were significantly higher in controls than in cases (73.4
nmol/L vs 57.3 nmol/L, p = 0.004). Among mothers with a folic acid intake larger than
400µg, the plasma folate levels of both groups increased, but the difference between controls
and cases lessened and was no longer significant (74.8 nmol/L vs 68.3 nmol/L, p = 0.25).
No significant difference in plasma folate levels between control and case mothers were
observed among mothers whose folate intakes from supplements were more than 400µg.
Results for erythrocyte folate levels were similar. The ability to utilize supplement folic
acid might be modified by MTHFR C677T genotype. In mothers with 677CC genotype,
both case and control mothers’ plasma folate concentrations responded to increased levels
of folic acid supplemental intake, although case mothers’ plasma folate concentrations were
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always significantly lower than control mothers’ until folate supplemental intake reached
400µg. In mothers with 677CT genotype, control but not case mothers’ plasma folate
concentrations responded to increased levels of folic acid supplemental intake. In mothers
with 677TT genotype, case but not control mothers’ plasma folate concentrations responded
to increased levels of folic acid supplemental intake.
Conclusion: Mothers who had an OFC-affected pregnancy had an impaired utilization
of folic acid, evidence that higher folate intake levels may be required for mothers with a
history of an OFC-affected pregnancy. The ability to utilize supplemental folic acid might
be modified by MTHFR C677T genotype.

4.2

Introduction
Folate plays important roles in one-carbon metabolism (OCM), which is a network

of biochemical reactions involved in the transfer of one-carbon groups necessary for DNA
synthesis, methylation, and homocysteine metabolism [1, 2]. Adequate status of folate is
important for growth and development early in life [3]. Folate deficiency is well recognized as
one of the causal factors of many health problems, especially neural tube defects (NTDs),
leading to the fortification of grain products starting in 1998 in the U.S. [4–7]. Because
the neural tube and the craniofacial regions both arise from the neural crest cells, this
discovery also led to the hypothesis that folate deficiency may also contribute to the risk
of nonsyndromic OFCs. However, population-based studies have shown mixed evidence
regarding the protective effect of folic acid against the development of OFCs since dietary
folate fortification [4, 8]. Some studies suggested that longer periods may be required to
achieve converging evidence for significant changes in birth prevalence for OFC post-folic
acid fortification [9–11].
Similar to folic acid fortification, the evidence for a preventive effect of folic acid containing supplements on OFCs in observational studies and interventional trials is mixed,
with some reporting statistically significant and others found no effects of folic acid on
OFCs [12–16]. Multiple studies suggested a dose-dependent effect of folic acid on the risk
of OFCs [17, 18]. However, the analysis did not report the use of other vitamins, minerals,
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and medicine in addition of the use of folic acid alone and failed to take into account the
effect of confounders such as personal characteristics associated with supplement use and
risk of OFCs [19]. Additional analyses are needed to confirm this analysis.
Findings from studies associating maternal blood folate levels and risk of OFCs have
been inconsistent. A Netherlands study published in 1999 reported higher plasma and
erythrocyte folate concentrations in mothers of infants with OFCs compared with mothers
of infants without malformations [20]. However, the subsequent Netherlands study in 2003
found no significant difference in folate concentrations between case and control mothers
[21]. In the Philippines, analysis of the association between blood folate levels and OFC
risks gave mixed results. Plasma folate was marginally associated with an increased risk of
OFCs. Erythrocyte folate was also associated with OFC risks, but in different directions
in two different sites. High levels of erythrocyte folate were associated with a decreased
risk of CL/P in Negros Occidental and increased risk in Davao. The author explained
the inconsistent associations between erythrocyte folate status and CL/P risk as a result
of different effects of interaction between folate and case-control status between areas of
higher (Negros Occidental) and lower (Davao) prevalence of vitamin B-6 deficiency [22].
In the U.K., higher plasma and erythrocyte folate concentrations were associated with a
decreased risk of CL/P but an increased risk of CPO [23]. In Utah, low maternal blood
folate concentration was associated with an increased risk of OFCs, and the mean differences
in case and control mothers widened over time, suggesting a progressive disorder of folate
metabolism in case mothers [24].
The enzyme 5,10-methylenetetrahydrofolate reductase (MTHFR) is an important enzyme in the OCM and catalyzes the conversion of 5,10-methylenetetrahydrofolate into 5methyltetrahydrofolate, the predominant circulating form of folate. A mutation in nucleotide position 677 (C to T) of this gene allows the generation of a thermolabile enzyme
with decreased activity [25]. MTHFR C677T genotypes have been linked to both OFCs
and blood folate levels. Studies examining the role of MTHFR C677T and risk of OFCs
provided mixed results with some suggesting MTHFR C677T genotypes as risk factors
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for OFCs [23, 26–28] while others reported no association between MTHFR C677T and
OFCs [29, 30]. Among studies reporting associations between MTHFR C677T and OFCs,
the presence of the T allele was found to cause the reduction in the MTHFR activity and
thus, leads to increased risk of OFCs [27, 28, 31, 32]. Patients with heterozygous variant
(CT) have 65% of the normal enzyme activity and 10% lower erythrocyte folate levels;
patients with homozygous variant (TT) have 30% of the normal enzyme activity and 18%
lower erythrocyte folate levels [33, 34]. Additional studies reported lower plasma folate and
vitamin B12 levels and increased homocysteine levels associating with the TT variant [35].
Up until now, the mechanisms of how folate may decrease the risk of OFC recurrence
remain to be defined [5,9]. The objective of this study was to evaluate blood levels of folate
in case and control mothers in relation to intake of multivitamins and supplemental folic
acid.

4.3

Materials and Methods

4.3.1

Subjects

This investigation was a part of a case-control study of OFCs conducted in Utah during
2000-2005 in collaboration with the Utah Birth Defects Network (UBDN). All procedures
were reviewed and approved by the Institutional Review Boards of Utah State University,
the University of Utah, and the Utah Department of Health (UDOH).
Cases and controls were selected at a 1-1 ratio using the UBDN data authorized by
UBDN (for case-mothers) and birth certificate data files of the Utah Office of Vital Statistics
authorized by UDOH (for control mothers). Eligible case-mothers included Utah residents
with an OFC child, live-born or still-born, between January 1st , 1995 and June 30th , 2004.
The classification of the OFCs was made after a review of all available medical records by
UBDN and a medical geneticist (Dr. John Carey). Eligible control-mothers included Utah
residents with a non-malformed child whose birth date and gender matched with cases.
Participants’ recruitment started in November 2001. Prior to recruitment, UBDN
updated mailing addresses for case and control mothers using online directories, websites,
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computerized UDOH immunization records, and Utah Drivers License Division records
maintained through the Utah Population Database. If no mailing address was available,
attempts were made to locate the mothers through in-person field tracking which includes
visits to the last known home address and inquiries with neighbors. Consent for name
release to USU investigators was then obtained from all found mothers via mail. The present
analysis included 468 control-mothers and 415 case-mothers with completed interviews and
laboratory results.
Mothers’ interviews began in April 2002 and were completed via telephone or in person
if telephone was unavailable. Interview materials were available in both English and Spanish,
and mothers speaking only Spanish were contacted by a bilingual interviewer. The interview
questionnaire was developed based on the Iowa Child Health Study, including questions
on demographic characteristics of the biological parents, a full reproductive health and
pregnancy history, supplement use, medications, medical conditions, smoking and alcohol
use, and occupational history. A FFQ based on the Nurses’ Health Study was also included
in the interview.
Blood samples from non-fasting subjects were obtained using heparin containing trace
mineral-free evacuated tubes and EDTA-containing evacuated tubes from mothers 12 months
after the end of their last pregnancy to avoid artifacts of the effects of pregnancy and lactation [36]. Blood samples were kept on ice and processed within two hours of collection.
Aliquots of whole blood for folate assays were mixed with a 1% ascorbic acid solution.
Plasma and whole blood samples were shipped on dry ice and were kept at −80o C until
analyses.
Plasma and erythrocyte folate concentrations were determined by microbiological assay
using Lactobacillus Rhamnosus as described previously [37]. Erythrocyte folate was assayed
after whole blood samples were incubated for 60 minutes at 37o C to hydrolyze polyglutamyl forms of folate present in erythrocytes using endogenous plasma folate conjugase.
The calculation of erythrocyte folate was done using the following formula: erythrocyte
folate concentration = [whole blood folate concentration - plasma folate concentration ×
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(1-hematocrit)]/hematocrit.

4.3.2

Genotyping

Mothers’ DNA samples were genotyped MTHFR C677T was genotyped either by kinetic PCR or by Tagman assays (Applied Biosystems) in Dr. Jeffrey C. Murray’s lab in
University of Iowa. For kinetic PCR, each DNA sample was amplified in two separate reactions, with allele-specific primers in each reaction. Each PCR procedure was repeated
twice. Primer sequences are available on request [38, 39].
For Tagman assays, either the Assay-on-Demand or the Assay-by-Design service from
Applied Biosystems was used. Each Tagman genotyping assay was also repeated twice,
with use of conditions set forth by the manufacturer. The sequences of primers and probes
from the Assay-by-Design service are available on request [39, 40].

4.3.3

Estimated folate from dietary supplements

During the interviews conducted as part of the blood draw process, mothers were
asked a series of questions about vitamin and mineral supplements currently used on a
regular basis, defined as more than once a week or longer, during the last three months.
If the mothers reported that supplements were consumed, they were asked to indicate the
number of supplements consumed. For each supplement reported, the interviewer recorded
the name of the product and the manufacturer. Mothers were also asked for the frequency
and duration of supplement use. After the survey was completed, if the supplements were
found in the NHANES database, information about the supplements was pulled; otherwise
we researched and added information about the supplements that were reported to the
database. The estimates of folate intakes were based on the content in one dose of the
product, the dosage reported, and the frequency reported (calculated as frequency per
day).
The composition of vitamin and mineral supplements was determined using details
reported by the mothers and composition data from the NHANES database and manufacturers’ data [41].
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Because the estimated folate from dietary supplements wasn’t uniformly distributed,
but clustered around the commonly intake levels provided by the manufacturer, it was
assessed as categorical variables. Folate supplemental intake level was classified as 1) none,
2) low (≤ 400µg), or 3) high (> 400µg).

4.3.4

Covariates

The possible covariates of interest are maternal age, educational level, ethnic origin,
smoking habits (yes vs. no), alcohol use (yes vs. no), multivitamin use at the time of blood
draw (yes vs. no), and body mass index (BMI). Educational level was assessed by the
highest completed education of the mother and classified as 1) high school graduate, 2) some
college, and 3) college graduate or more. Maternal ethnicity was classified as 1) Caucasians,
2) Hispanics, 3) Asians, and 4) others. Body mass index (BMI) is calculated as weight in
kilograms divided by heights in meters squared (kg/m2 ). BMI can be assessed as continuous
variable or categorical variable, with 1) underweight (< 18.5), 2) normal weight (18.5-24.9),
3) overweight (25.0-29.9), or 4) obesity (≥ 30.0). To be considered as confounders and
included in general linear models, the covariates must be significantly correlated with both
the response and main predictor variables. The association was determined by chi-square
tests and t-tests.

4.3.5

Statistical Analysis

Unadjusted cross-tabulation with chi-square tests and t-tests were used to assess the
associations between different phenotypes of OFCs and categorical and continuous variables,
respectively. Because of the skewed distributions of the folate biomarkers variables, log
transformations were used. The resulting residuals after log transformation were normally
distributed and homoscedastic; therefore, we used log transformation with the appropriate
retransformation to arrive at the adjusted results.
Data were stratified by maternal multivitamin use and supplemental folate intake. This
stratification provides a means of comparing plasma and erythrocyte folate between case
and control mothers thus making it possible to observe the differences, if any, in nutrient
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utilization between case and control mothers given a specific amount of supplemental intakes. General linear regression was used to test for differences in biomarker levels between
cases and controls, adjusting for confounders, which were determined as variables correlated
to the main predictor (case/control status) and outcome (maternal blood folate level).
Plasma and erythrocyte folate levels were also compared across categories of supplemental folate dosage, case and control status, and MTHFR C677T genotype using standard
ANOVA techniques. This multi-level stratification allowed us to compare case and control
mothers’ folate utilization between different genotypes of MTHFR C677T. Adjustment for
confounders was carried out using multiple linear regressions. Statistical analyses were
conducted using SPSS, version 21 [42].

4.4

Results
Most control-mothers were Caucasian and had at least some college education; 16%

smoked, 23.9% drank alcohol and 47.2% used multivitamins at the time of the blood draw
(Table 4.1). Frequencies of these characteristics among case-mothers are also given in
Table 1. Compared to case-mothers, control mothers had significantly higher smoking rates
and were more likely to be college graduates. Control-mothers also had significantly higher
plasma and erythrocyte folate concentrations than case-mothers. There were no significant
differences between case- and control-mothers in multivitamin use, folate supplemental intake at the time of blood draw, or in MTHFR C677T genotypes.
When stratified by maternal multivitamin use and adjusted for covariates, significantly
lower mean plasma folate concentrations were found in case mothers compared to control mothers regardless of maternal multivitamin use (multivitamin users: 61.0 nmol/L vs
73.8 nmol/L, p = 0.004; multivitamin non-users: 46.5 nmol/L vs 57.6 nmol/L, p < 0.001)
(Figure 4.1). Results for isolated CL/P were similar (Table 4.2). Mean plasma folate
concentrations in mothers who had a child with isolated CPO was marginally lower than
control mothers in groups that did not use multivitamins regularly but were significantly
lower than control mothers in groups that used multivitamins regularly at the time of the
blood draw (Table 4.4). Significantly lower mean erythrocyte folate concentrations were
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found in mothers who had a child with isolated OFCs compared to control mothers in groups
that did not use multivitamins but not in groups that used multivitamins regularly at the
time of blood draw (multivitamin users: 2145.1 nmol/L vs 2316.0 nmol/L, p = 0.10; multivitamin non-users: 1779.1 nmol/L vs 1996.1 nmol/L, p = 0.005) (Figure 4.2). Results
for isolated CL/P were similar (Table 4.3). In contrast, mean erythrocyte folate concentrations in mothers who had a child with isolated CPO was significantly lower compared to
control mothers in groups that used multivitamins but not within groups that did not use
multivitamins regularly at the time of their blood draw (Table 4.5).
When stratified by maternal folic acid supplement intake and adjusted for covariates,
significantly lower mean plasma folate concentrations were found in case mothers compared
to control mothers within none or low folic acid supplement intake levels but not in high
folic acid supplement intake levels (none: 46.2 nmol/L vs 58.5 nmol/L, p < 0.001 ; 0.01400µg: 57.3 nmol/L vs 73.4 nmol/L, p = 0.004; > 400µg: 68.3 nmol/L vs 74.8 nmol/L,
p = 0.25) (Figure 4.3). Results for isolated CL/P and CPO were similar (Table 4.2).
The ratio of mean plasma folate levels in mothers who had a child with isolated OFCs to
control mothers was 0.80 (95% CI, 0.73, 0.87) among mothers who did not use any folate
supplemental intake, 0.81 (95% CI, 0.72, 0.97) among mothers who used less than 400µg
of folate supplemental intake, and not significantly different (0.84 (95% CI, 0.68, 1.04))
among mothers who used 400µg or more of folate supplemental intake (Table 4.4). Similar
analysis for erythrocyte folate concentrations gave mixed results (Table 4.5).
Data on plasma folate levels in case and control mothers stratified by MTHFR C677T
genotypes are shown in Table 4.6. In mothers with the CC genotypes, both case and control mothers’ plasma folate levels increased significantly as maternal folic acid supplemental
intake level increased (p-values for plasma folate concentration’s trend = 0.001 for both control and case mothers). In mothers with the CT genotypes, only control mothers’ plasma
folate levels increased significantly as maternal folic acid supplemental increased (p-values
for plasma folate concentration’s trend = 0.001 and 0.359 for control and case mothers,
respectively). In mothers with the TT genotypes, only case mothers’ plasma folate levels
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increased significantly as maternal folic acid supplemental increased (p-values for plasma
folate concentration’s trend = 0.988 and 0.032 for control and case mothers, respectively).
Adjustment for confounders did not change the result (Table 4.7). Similar analysis for erythrocyte folate concentrations also showed differences in case and control mothers’ plasma
folate concentrations across folate supplemental intake levels between different MTHFR
C677T genotypes (Table 4.8). These differences became even more distinctive after adjustment for confounders (Table 4.9).

4.5

Discussion
Maternal multivitamin use and folate intake have been important focuses in oral cleft

research. We report a significantly lower plasma folate concentration among mothers who
had a child with isolated cleft whose folic acid supplemental levels were none or low (≤
400µg) compared to control mothers with the same folic acid supplement intake. No significant difference in plasma folate concentration was observed between case and control
mothers with higher folic acid supplemental levels (> 400µg). We also reported a significantly different response to folate supplemental intake in plasma folate concentration
among case and control mothers between MTHFR C677T genotypes. Mothers who had an
OFC-affected pregnancy had lower mean plasma folate levels than controls even when using
multivitamins or with a supplemental folic acid intake up to 400µg. At folic acid intakes
greater than 400µg, the plasma folate levels of both groups were higher and the difference
between cases and controls narrowed. MTHFR genotype was associated with plasma folate
with evidence that the CC genotype among controls was more responsive to folic acid intake
than cases, and this difference narrowed at the higher level of intake. In conclusion, mothers
of OFC children appear to be less responsive to folic acid intake than controls.
This is the first study to our knowledge that showed evidence of impaired utilization of
folic acid in mothers who had a child with cleft compared to controls and different responses
of cases and controls to folic acid supplementation by MTHFR C677T genotype.
Folate absorption and utilization has gathered increasing attention in neural tube defects (NTDs) research. By 1992, it was clear that NTDs could be substantially prevented
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by maternal periconceptional supplementation with folic acid, leading to the mandatory
folic acid fortification in multiple countries. The mechanism of how folate can prevent NTD
is still unknown. Similar to OFCs, lower maternal plasma and erythrocyte folate concentrations were found in NTD-affected pregnancies than in normal pregnancies [43]. Studies
examining whether folate absorption is impaired in women with NTD-affected pregnancies
gave mixed results. Bower et al. [44] found no differences in response to 4.5 mg of yeast
folate polyglutamates in test meals between women with a history of NTD-affected pregnancies and matched control subjects. Schorah et al. [45] found a significantly lower response
to food folates in orange juice in women with a history of a NTD-affected pregnancy. Neuhouser et al. [46] found a significant lower response to supplemental folic acid but not to
food folates in orange juice in women with a history of a NTD-affected pregnancy. All three
studies suffered from limitations caused by small sample sizes (less than 20 case mothers in
each study) and a lack of controlling for confounders. Boddie et al. [47] used a stable-isotope
technique to determine whether women who had a NTD-affected pregnancy (cases) had a
reduced ability, compared to control women, to absorb polyglutamyl folate, the primary
form of naturally occurring food folate relative to folic acid in supplements or fortified food.
Eleven healthy, non-pregnant cases and eleven controls were given an oral dose containing
two different stable isotopes of polyglutamyl folate after consuming 2 mg of folic acid daily
for 30 days to saturate the tissues. Participants were asked to abstain from all alcohol,
medications, and vitamin-mineral supplements during the entire study. No significant differences between cases and controls in plasma or erythrocyte folate concentrations before or
after the 30-day supplementation period were found. A trend for lower absorption of both
forms of folates in all cases was observed. A significantly lower recovery of both folate forms
in case mothers than in controls in the first 24 hours but not in the second 24 hours after the
oral dose was administered. The study had several strengths over previous studies including
the uses of 48-hour urinary excretion and the stable-isotope method, which allowed for a
higher degree of specificity in the type of folate administered [47].
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The failure of detecting significance in mean differences of erythrocyte folate concentration in case and control mothers among mothers who took less than 400µg of folate
supplemental intake can be attributed to the differences between erythrocyte and plasma
folate markers in response to folate status. Farrell et al. [48] assessed many different aspects
of the performance of plasma and erythrocyte folate assays and found no evidence for the
better performance of erythrocyte folate. In fact, regarding responsiveness to folic acid
supplementation, after reviewing thirteen studies reporting the response of plasma and erythrocyte folate to folic acid supplementation in different populations, the authors concluded
that plasma folate appeared to give the greater response at both short- and long-term follow
up. Of the thirteen studies mentioned in the review, two studies focused on healthy and
non-pregnant women specifically. Hao et al. [49] conducted a randomized trial including
1108 women assigned to different intervention groups for which daily intakes of folic acid
for six months were 100µg per day, 400µg per day, 4000µg per day, or 4000µg per week.
Plasma and erythrocyte folate concentrations were measured at baseline, at one, three, and
six months, and as well as three months after the discontinuation of folic acid intakes [49].
West et al. [50] conducted a controlled folate intake study including 21 non-pregnant women
for whom a folic acid containing prenatal supplement (750µg/day) plus natural food folate
(400µg/day) were given from ten to twelve weeks. Blood samples were collected at baseline,
study midpoint, and study end. In all situations, plasma folate levels responded faster and
more sensitively to the changes in supplemental or dietary folic acid intake. The specific
results of both studies are summarized in Table 4.10. A recent folic acid intervention
study using a crossover design assessed response of plasma and erythrocyte folate to folic
acid supplementation; significant responses in plasma folate concentrations were seen after
supplementation with 200µg and 400µg. Erythrocyte folate concentrations only increased
after supplementation with 400µg but not 200µg [51].
The observed differences in folate utilization between case and control mothers between
different genotypes of MTHFR C677T in this study seem to be contributed in part by genetic
factors. In mothers with 677CC genotype, even though both case and control mothers’
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plasma folate concentrations responded to increased level of folic acid supplemental intake,
case mothers’ plasma folate concentrations seemed to respond more slowly and were always
significantly lower than control mothers’ until folate supplemental intake reached larger
than 400µg. In mothers with 677CT genotype, control- but not cases-mothers’ plasma
folate concentration responded to an increased level of folic acid supplemental intake. In
mothers with 677TT genotype, only case mothers’ plasma folate concentrations responded
to increased level of folic acid supplemental intake. Among mothers with 677CT and 677TT
genotypes, plasma folate concentrations of case mothers were always significantly lower than
control mothers in group that did not take any folic acid supplement but not in group that
took folic acid supplement.
To our knowledge, no other study compared the genetic influence of MTHFR C677T
on folic acid utilization between mothers who had a history of an OFC-affected pregnancy
and mothers who did not. de Villarreal et al. [52] conducted a case-control study to analyze
the role of folate levels and MTHFR genotype in mothers who had a child died due to a
NTD. The authors reported that mothers who had a child with NTDs had lower blood
folate concentrations compared to control mothers, with a significant difference in mothers
with MTHFR 677TT and 677CT genotypes [52]. The authors also reported that mutation
in the MTHFR gene coupled with folate deficiency is associated with a greater risk of NTDs
via gene-nutrient interaction. This finding supported the results from a previous study [53].
Literature on the combination effects of MTHFR and folic acid supplement intakes on OFC
risk through gene-environment interaction is scarce. We only know of one case control
study that analyzed the association between OFC risk and gene-environment interaction of
maternal MTHFR genotypes with periconceptional folic acid supplementation and dietary
folate intakes; mothers with the MTHFR 677TT and low periconceptional folate intake
were reported to have higher risk of giving birth to a child with OFCs [21].
Two intervention trials have been conducted to examine the association between MTHFR
C677T and folic acid utilization in healthy populations. A population-based, double-blind
trial of folic acid supplementation conducted in northern China examined whether the
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MTHFR C677T genotype modifies the response to folic acid supplementation and found
significant association between MTHFR genotype and blood folate concentrations during
six months of folic acid supplementation and three months after discontinuation of supplementation. More specifically, MTHFR 677TT genotype was associated with lower plasma
and RBC folate concentrations than was the CT or CC genotype [54]. Another recent folic
acid intervention study using a crossover design assessed response of plasma and erythrocyte
folate to folic acid supplementation with the genetic polymorphism C677T of the MTHFR
gene. Erythrocyte folate concentrations increased after supplementation with 400µg but
not 200µg, and this response was depended on MTHFR C677T genotype, with 677TTs
having a larger response than 677CCs or 677CTs [51].
Our study has several key strengths: cases ascertained from a population-based birth
defect registry, randomly sampled population controls that were matched by birth-month
and sex to cases, high rates of participants, and the collection and rapid processing of
maternal blood specimens and assays of biomarkers. The collection of interview data allowed
us to calculate the amount of folic acid supplemental intake at the time of blood draw from
mothers and added an additional strength to the study. The results of our analysis must
be considered in light of its limitations. We were unable to collect maternal dietary data
at the time of the blood drawn, which might also influence the blood folate concentration.
The lack of randomized assignment of folic acid intake is another limitation of the study,
although this limitation is the nature of observational studies.
In conclusion, in the Utah Child and Family Health Study, we observed that among
mothers who took multivitamins containing 400µg or less of folic acid, case-mothers who had
a child with an OFC had significantly lower mean plasma folate concentrations compared
to controls, despite having taken the same amount of folate supplements. The difference
in plasma folate concentration lessened among mothers who took multivitamins containing
more than 400µg of folic acid. Analysis of erythrocyte folate levels yielded similar but less
significant results. Our finding supports the hypothesis that mothers who had a child with
an OFC have impaired utilization of folic acid compared to control mothers. Case and
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control mothers also appear to respond differently to folic acid supplementation according
to MTHFR genotype. Additional research is needed to confirm this hypothesis and to
explore the causal mechanisms.
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Table 4.1: Characteristics of mothers of orofacial clefts cases and controls, Utah Child and
Family Health Study (n = 883).

Participants
Characteristics

Age at time of blood draw2
Body Mass Index2
Smokinga, 1
Multivitamin Usea, 1
Education1
High school graduate or less
Some college
College graduate or more
Race/Ethnicity1
Caucasians
Asians
Hispanics
Others
Mediterranean Diet Score2
Diet Quality Index for Pregnancy
Score2
Dietary Approach to Stop
Hypertension Score2

1
2
a

*

Controls

Isolated
CPO

Isolated
CL/P

(n = 468)

(n = 94)

(n = 233)

All
Isolated
OFCs
(n = 327)

31.8 (5.9)
27.4 (6.8)
16.0
47.2

31.0 (5.8)
27.5 (6.6)
22.3*
51.2

31.4 (5.7)
27.1 (6.0)
22.3*
49.0

31.3 (5.7)
27.2 (6.1)
22.3*
49.6

26.3
44.2
31.1

27.7
38.7
32.8

33.7*
42.6*
23.8*

32.2*
41.5*
26.3*

89.6
0.6
5.6
4.2
5449.1
(1309.0)
4228.7
(1441.4)
6054.9
(1410.7)

90.8
3.4
2.5
3.4
5247.6
(1377.5)
4209.9
(1465.8)
5911.9
(1354.7)

86.8
0.7
7.9
4.6
5378.6
(1294.1)
4120.5
(1419.2)
5891.9
(1420.1)

87.9
1.4
6.4
4.3
5341.7
(1317.8)
4145.7
(1431.3)
5897.5
(1400.4)

Abbreviations: CPO, cleft palate only; CL/P, cleft lip with or without cleft palate; OFC, orofacial
cleft.
Percent.
Mean (standard deviation).
Use during periconceptional period defined as one month before pregnancy and first month of pregnancy.
Achieved significance in Pearson Chi-square tests (p-value < 0.05) when compared with control
group.

Table 4.2: Means plasma folate concentrations in Utah orofacial cleft case (n = 415) and control (n = 468) mothers according to
maternal multivitamin use and supplemental folic acid intake levels; Utah Child and Family Health Study.

Control
Subgroup

N

Mean (SD)1

Multivitamin use at the time of blood draw
226
57.6 (28.4)
No
202
73.8 (36.0)
Yes
Folic acid supplement intake at the time of blood draw
283
58.5 (30.2)
None
113
73.4 (38.7)
Low (0.01-400µg)
72
74.8 (31.0)
High (> 400µg)
1

Isolated CPO

Isolated CL/P

All Isolated OFCs

N

Mean (SD)1

N

Mean (SD)1

N

Mean (SD)1

40
42

50.3 (28.0)
61.9 (31.8)

102
97

45.0 (21.4)
60.7 (27.0)

142
139

46.5(23.5)
61.0 (28.4)

56
21
17

49.1 (25.3)
48.4 (23.4)
79.1 (36.2)

144
59
29

45.1 (21.6)
60.5 (26.4)
61.9 (30.6)

200
80
46

46.2 (22.7)
57.3 (26.0)
68.3 (33.5)

Abbreviations: CPO, cleft palate only; CL/P, cleft lip with or without cleft palate; OFC, orofacial cleft.
Mean (Standard deviation).
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Table 4.3: Means erythrocyte folate concentrations in Utah orofacial cleft case (n = 415) and control (n = 468) mothers according
to maternal multivitamin use and supplemental folic acid intake levels; Utah Child and Family Health Study.

Control
Subgroup

N

Mean (SD)1

Multivitamin use at the time of blood draw
226
1996.1 (829.4)
No
202
2316.0 (805.6)
Yes
Folic acid supplement intake at the time of blood draw
283
1996.2 (828.9)
None
113
2314.3 (846.5)
Low (0.01-400µg)
72
2323.6 (705.6)
High (> 400µg)
1

Isolated CPO

Isolated CL/P

All Isolated OFCs

N

Mean (SD)1

N

Mean (SD)1

N

Mean (SD)1

40
42

1815.6 (710.3)
2038.9 (924.4)

102
97

1764.7 (677.5)
2191.5 (829.7)

142
139

1779.1 (684.8)
2145.1 (901.9)

56
21
17

1838.7 (661.2)
1900.9 (1095.4)
2191.5 (765.2)

144
59
29

1839.4 (768.1)
2111.9 (684.6)
2260.9 (1219.1)

200
80
46

1839.2 (737.8)
2056.5 (810.3)
2234.7 (1061.2)

Abbreviations: CPO, cleft palate only; CL/P, cleft lip with or without cleft palate; OFC, orofacial cleft.
Mean (Standard deviation).
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Table 4.4: Ratios of mean plasma folate concentrations of Utah orofacial cleft case (n = 415) and control (n = 468) mothers
according to maternal multivitamin use and supplemental folic acid intake levels; Utah Child and Family Health Study.

Isolated CPO
Subgroup

Control

Unadjusted
ratio
(95% CI)1

Adjusted
ratio
P3
(95% CI)1, 2

Multivitamin use at the time of blood draw
1.0
0.85
0.86
No
(ref)
(0.73, 1.00) (0.73, 1.01)
1.0
0.82
0.83
Yes
(ref)
(0.70, 0.97) (0.71, 0.98)
Folic acid supplement intake at the time of blood draw
1.0
0.84
0.84
None
(ref)
(0.73, 0.97) (0.73, 0.96)
1.0
0.67
0.69
Low (0.01-400µg)
(ref)
(0.53, 0.84) (0.55, 0.87)
1.0
1.03
1.00
High (> 400µg)
(ref)
(0.80, 1.32) (0.79, 1.26)
1
2
3

Isolated CL/P
Unadjusted
ratio
(95% CI)1

All Isolated OFCs

Adjusted
ratio
P3
(95% CI)1, 2

Unadjusted
ratio
(95% CI)1

Adjusted
ratio
P3
(95% CI)1, 2

0.77
(0.69, 0.86)
0.82
(0.73, 0.93)

0.77
(0.69, 0.86)
0.86
(0.77, 0.97)

<
0.79
0.0001 (0.72, 0.88)
0.82
0.02
(0.74, 0.91)

0.79
(0.72, 0.87)
0.85
(0.77, 0.95)

<
0.0001

0.78
(0.71, 0.86)
0.83
0.002
(0.72, 0.97)
0.79
1.00
(0.64, 0.99)

0.78
(0.71, 0.86)
0.87
(0.72, 0.97)
0.84
(0.68, 1.04)

<
0.80
0.0001 (0.73, 0.87)
0.79
0.06
(0.69, 0.90)
0.87
0.10
(0.72, 1.06)

0.80
(0.73, 0.87)
0.79
(0.71, 0.93)
0.90
(0.75, 1.08)

<
0.0001

0.06
0.03

0.01

0.004

0.004
0.25

Abbreviations: CPO, cleft palate only; CL/P, cleft lip with or without cleft palate; OFC, orofacial cleft.
Ratio of mean plasma folate concentrations in case to control mothers (95% confidence interval).
Adjusted for the following covariates: maternal body mass index (BMI), education, and smoking status at the time of blood draw.
Statistical significance of the F value from the Type 3 Tests of Fixed Effects; the models include maternal BMI (continuous), education, and
smoking status at the time of blood draw as confounders and natural log transformed plasma folate as dependent variables.
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Table 4.5: Ratios of mean erythrocyte folate concentrations of Utah orofacial cleft case (n = 415) and control (n = 468) mothers
according to maternal multivitamin use and supplemental folic acid intake levels; Utah Child and Family Health Study.

Isolated CPO
Subgroup

Control

Unadjusted
ratio
(95% CI)1

Adjusted
ratio
P3
(95% CI)1, 2

Multivitamin use at the time of blood draw
1.0
0.92
0.91
No
(ref)
(0.81, 1.03) (0.80, 1.03)
1.0
0.86
0.87
Yes
(ref)
(0.76, 0.97) (0.77, 0.97)
Folic acid supplement intake at the time of blood draw
1.0
0.94
0.93
None
(ref)
(0.84, 1.04) (0.84, 1.04)
1.0
0.79
0.79
Low (0.01-400µg)
(ref)
(0.66, 0.94) (0.66, 0.95)
1.0
0.93
0.94
High (> 400µg)
(ref)
(0.78, 1.10) (0.79, 1.11)
1
2
3

Isolated CL/P

0.13
0.02

0.20
0.01
0.45

Unadjusted
ratio
(95% CI)1

All Isolated OFCs

Adjusted
ratio
P3
(95% CI)1, 2

0.88
(0.81, 0.96)
0.93
(0.85, 1.02)

0.89
(0.82, 0.97)
0.96
(0.88, 1.05)

0.92
(0.85, 1.00)
0.93
(0.83, 1.04)
0.91
(0.77, 1.07)

0.93
(0.86, 1.00)
0.95
(0.84, 1.06)
0.97
(0.83, 1.14)

0.01
0.39

0.05
0.36
0.72

Unadjusted
ratio
(95% CI)1

Adjusted
ratio
P3
(95% CI)1, 2

0.89
(0.83, 0.96)
0.91
(0.84, 0.99)

0.90
(0.83, 0.97)
0.93
(0.86, 1.01)

0.93
(0.86, 0.99)
0.89
(0.80, 0.99)
0.91
(0.80, 1.05)

0.93
(0.87, 0.99)
0.90
(0.81, 1.01)
0.96
(0.84, 1.10)

0.005
0.10

0.05
0.07
0.57

Abbreviations: CPO, cleft palate only; CL/P, cleft lip with or without cleft palate; OFC, orofacial cleft.
Ratio of mean erythrocyte folate concentrations in case to control mothers (95% confidence interval).
Adjusted for the following covariates: maternal body mass index (BMI), education, and smoking status at the time of blood draw.
Statistical significance of the F value from the Type 3 Tests of Fixed Effects; the models include maternal BMI (continuous), education, and
smoking status at the time of blood draw as confounders and natural log transformed erythrocyte folate as dependent variables.
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Table 4.6: Means plasma folate concentrations stratified by MTHFR C677T genotypes of Utah orofacial cleft case (n = 415) and
control (n = 468) mothers according to folic acid supplement intake levels; Utah Child and Family Health Study.

MTHFR
C677T
Genotype

CC

CT

TT
1

2

Case/Control
Status

Controls
Cases
p-value2
Controls
Cases
p-value2
Controls
Cases
p-value2

Folic acid supplement intake levels
None

Low (0.01-400µg)

High (> 400µg)

N

Mean ± SE

N

Mean ± SE

N

Mean ± SE

p-value1

115
61

59.4 ± 2.6
46.9 ± 2.6
0.003
54.2 ± 2.4
48.0 ± 2.8
0.02
64.9 ± 8.1
41.4 ± 4.8
0.007

48
31

81.6 ± 6.7
54.8 ± 4.4
0.003
66.7 ± 4.2
54.4 ± 5.5
0.07
57.7 ± 9.2
68.3 ± 9.5
0.53

20
19

80.3 ± 8.1
74.0 ± 7.2
0.70
71.5 ± 5.0
57.0 ± 6.5
0.08
59.9 ± 8.9
70.0 ± 25.6
0.93

0.001
0.001

97
80
28
22

35
20
15
10

35
15
7
5

0.001
0.36
0.99
0.03

Significance achieved from ANOVA compared means of maternal plasma folate concentrations across folic acid supplement intake levels in caseand control-mothers.
Significance achieved from ANOVA compared means of maternal plasma folate concentrations between case- and control-mothers within a folic
acid supplement intake level.
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Table 4.7: Means plasma folate concentrations stratified by MTHFR C677T genotypes of Utah orofacial cleft case (n = 415) and
control (n = 468) mothers according to folic acid supplement intake levels with adjustment for maternal body mass index (BMI),
education, and smoking status; Utah Child and Family Health Study.

MTHFR
C677T
Genotype

CC

CT

TT
1

2

Case/Control
Status

Controls
Cases
p-value2
Controls
Cases
p-value2
Controls
Cases
p-value2

Folic acid supplement intake levels
None

Low (0.01-400µg)

High (> 400µg)

N

Mean ± SE

N

Mean ± SE

N

Mean ± SE

p-value1

115
61

59.4 ± 2.6
46.9 ± 2.6
< 0.0001
54.2 ± 2.4
48.0 ± 2.8
0.04
64.9 ± 8.1
41.4 ± 4.8
0.06

48
31

81.6 ± 6.7
54.8 ± 4.4
0.02
66.7 ± 4.2
54.4 ± 5.5
0.04
57.7 ± 9.2
68.3 ± 9.5
0.09

20
19

80.3 ± 8.1
74.0 ± 7.2
0.69
71.5 ± 5.0
57.0 ± 6.5
0.21
59.9 ± 8.9
70.0 ± 25.6
0.60

0.008
0.001

97
80
28
22

35
20
15
10

35
15
7
5

0.003
0.21
0.91
0.01

Significance achieved from ANOVA compared means of maternal plasma folate concentrations across folic acid supplement intake levels in caseand control-mothers; the models include maternal BMI (continuous), education, and smoking status as confounders and natural-log transformed
plasma folate concentrations as dependent variables.
Significance achieved from ANOVA compared means of maternal plasma folate concentrations between case- and control-mothers within a folic
acid supplement intake level; the models include maternal BMI (continuous), education, and smoking status as confounders and natural-log
transformed plasma folate concentrations as dependent variables.
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Table 4.8: Means erythrocyte folate concentrations stratified by MTHFR C677T genotypes of Utah orofacial cleft case (n = 415)
and control (n = 468) mothers according to folic acid supplement intake levels; Utah Child and Family Health Study.
MTHFR
C677T
Genotype

CC

CT

TT
1

2

Case/Control
Status

Controls
Cases
p-value2
Controls
Cases
p-value2
Controls
Cases
p-value2

Folic acid supplement intake levels
None

Low (0.01-400µg)

High (> 400µg)

N

Mean ± SE

N

Mean ± SE

N

Mean ± SE

p-value1

115
61

2092.7 ± 88.2
1840.2 ± 91.0
0.05
1963.3 ± 76.8
1858.3 ± 83.1
0.30
1764.5 ± 110.9
1879.4 ± 184.8
0.94

48
31

2347.0 ± 131.2
1941.0 ± 131.1
0.06
2264.2 ± 145.4
2122.5 ± 248.2
0.34
2208.4 ± 208.7
2226.7 ± 248.8
0.92

20
19

2176.1 ± 164.4
2192.7 ± 179.8
0.97
2393.1 ± 129.8
2128.3 ± 217.1
0.17
2106.0 ± 196.6
2884.4 ± 1127.5
0.75

0.22
0.18

97
80
28
22

35
20
15
10

35
15
7
5

0.005
0.46
0.11
0.03

Significance achieved from ANOVA compared means of maternal erythrocyte folate concentrations across folic acid supplement intake levels in
case- and control-mothers.
Significance achieved from ANOVA compared means of maternal erythrocyte folate concentrations between case- and control-mothers within a
folic acid supplement intake level.
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Table 4.9: Means erythrocyte folate concentrations stratified by MTHFR C677T genotypes of Utah orofacial cleft case (n = 415)
and control (n = 468) mothers according to folic acid supplement intake levels with adjustment for maternal body mass index
(BMI), education, and smoking status.; Utah Child and Family Health Study.

MTHFR
C677T
Genotype

CC

CT

TT
1

2

Case/Control
Status

Controls
Cases
p-value2
Controls
Cases
p-value2
Controls
Cases
p-value2

Folic acid supplement intake levels
None

Low (0.01-400µg)

High (> 400µg)

N

Mean ± SE

N

Mean ± SE

N

Mean ± SE

p-value1

115
61

2092.7 ± 88.2
1840.2 ± 91.0
0.02
1963.3 ± 76.8
1858.3 ± 83.1
0.37
1764.5 ± 110.9
1879.4 ± 184.8
0.56

48
31

2347.0 ± 131.2
1941.0 ± 131.1
0.13
2264.2 ± 145.4
2122.5 ± 248.2
0.33
2208.4 ± 208.7
2226.7 ± 248.8
0.61

20
19

2176.1 ± 164.4
2192.7 ± 179.8
0.33
2393.1 ± 129.8
2128.3 ± 217.1
0.33
2106.0 ± 196.6
2884.4 ± 1127.5
0.64

0.24
0.11

97
80
28
22

35
20
15
10

35
15
7
5

0.004
0.22
0.11
0.06

Significance achieved from ANOVA compared means of maternal erythrocyte folate concentrations across folic acid supplement intake levels
in case- and control-mothers; the models include maternal BMI (continuous), education, and smoking status as confounders and natural-log
transformed plasma folate concentrations as dependent variables.
Significance achieved from ANOVA compared means of maternal erythrocyte folate concentrations between case- and control-mothers within a
folic acid supplement intake level; the models include maternal BMI (continuous), education, and smoking status as confounders and natural-log
transformed plasma folate concentrations as dependent variables.
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Table 4.10: Studies reporting the response of plasma and erythrocyte folate to folic acid supplementation regimes (Modified from
Table 2 reported in Farrell et al. [48]).

Study

[49]
[50]

Folic acid
dosage,
µg/day

100
400
571
4000
750

Follow-up
period

6 months
6 months
6 months
6 months
12 weeks

Baseline
plasma
folate,
nmol/L

9.7
9.6
9.8
9.7
44.9

Baseline
erythrocyte
folate,
nmol/L

595
603
611
599
1161

Response to supplementation

Plasma folate
response, %
increased

Erythrocyte
folate
response, %
increased

108
259
141
460
46

28
72
72
137
25

137

138

Fig. 4.1: Mean maternal plasma folate concentrations of Utah orofacial cleft case (n =
415) and control (n = 468) mothers by maternal multivitamin use at the time of blood
draw. P-values listed are statistical significance of the F value from the type 3 tests of fixed
effects; the models include maternal body mass index (continuous variable), education, and
smoking status as confounders, maternal multivitamin use as main predictor variable and
natural log transformed maternal plasma folate concentrations as independent variable.
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Fig. 4.2: Mean maternal erythrocyte folate concentrations of Utah orofacial cleft case (n
= 415) and control (n = 468) mothers by maternal multivitamin use at the time of blood
draw. P-values listed are statistical significance of the F value from the type 3 tests of fixed
effects; the models include maternal body mass index (continuous variable), education, and
smoking status as confounders, maternal multivitamin use as main predictor variable and
natural log transformed maternal erythrocyte folate concentrations as independent variable.

140

Fig. 4.3: Mean maternal plasma folate concentrations of Utah orofacial cleft case (n = 415)
and control (n = 468) mothers by maternal folic acid supplement intake use at the time of
blood draw. P-values listed are statistical significance of the F value from the type 3 tests of
fixed effects; the models include maternal body mass index (continuous variable), education,
and smoking status as confounders, maternal folic acid supplement intake levels as main
predictor variable and natural log transformed maternal plasma folate concentrations as
independent variable.
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Fig. 4.4: Mean maternal erythrocyte folate concentrations of Utah orofacial cleft case (n
= 415) and control (n = 468) mothers by maternal folic acid supplement intake use at
the time of blood draw. P-values listed are statistical significance of the F value from the
type 3 tests of fixed effects; the models include maternal body mass index (continuous
variable), education, and smoking status as confounders, maternal folic acid supplement
intake levels as main predictor variable and natural log transformed maternal erythrocyte
folate concentrations as independent variable.

Fig. 4.5: Mean maternal plasma folate concentrations of Utah orofacial cleft case (n = 415) and control (n = 468) mothers by
maternal multivitamin use at the time of blood draw stratified by maternal MTHFR C677T genotypes (CC, CT, and TT); Utah
Child and Family Health Study.
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Fig. 4.6: Mean maternal plasma folate concentrations of Utah orofacial cleft case (n = 415) and control (n = 468) mothers by
maternal maternal MTHFR C677T genotypes (CC, CT, and TT) stratified by maternal folic acid supplement intake levels (None,
0.01-400µg, and > 400µg); Utah Child and Family Health Study.

143

144

Chapter 5
Folate-Related Genes in One-Carbon Metabolism and the
Risk of Orofacial Clefts in a Case-Parent Trio Study using
Genome-Wide Association Data
5.1

Abstract
Background and objective: Polymorphisms in genes involved in folate-related one

carbon metabolism (OCM) pathway may cause orofacial clefts (OFCs) by altering the
mechanisms of folate transport, nucleotide biosynthesis or folate-dependent methylation
reactions. Candidate gene and genome-wide association studies have not yet been able to
consistently confirm OCM genes as a genetic risk factor for OFCs. Findings from studies
associating maternal biomarkers of OCM-related nutrients have also been inconsistent.
Methods: We tested for associations between 21 OCM-related candidate genes and
isolated OFCs for genotypic effects and interactions with maternal multivitamin use during
the periconceptional period and for maternal OCM-related biomarkers. Data include 717
case-parent trios of European ancestry and 1098 case-parent trios of Asian ancestry. Data
regarding maternal multivitamin use were available on the full sample and data regarding
maternal biomarkers were available for 208 case-parent trios from Utah. Genotypic transmission disequilibrium tests (gTDT) were used in two-degree of freedom tests including
genetic effect and gene-environment (GxE) interaction simultaneously and one-degree of
freedom tests including either genetic effect or GxE interaction alone. Genes were selected
because they were previously associated with OCM or related nutrients.
Results: FUT6 and TCN2, both known to be associated with vitamin B12 , were
associated with OFC risk showing marginal effects in the Asian samples. Gene by maternal
multivitamin use interaction revealed six OCM genes associated with OFCs: CBS and
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MTHFD2L in Asians; plus DHFR, MMAA, MTR, and TCN2 in Europeans. In the Utah
samples with measured maternal blood biomarkers, ALPL and GART were associated with
OFC risk through gene-biomarker interaction.
Conclusions: Our results suggest several genes in the OCM pathway may influence
risk for isolated OFCs either through direct genotypic effect or through gene-environment
interaction effect with maternal multivitamin supplementation during the periconceptional
period, and associated with maternal biomarker concentrations for OCM-related nutrients.
These results emphasize the need to consider gene-environment interactions when searching
for genes influencing OFCs.

5.2

Introduction
Orofacial clefts (OFCs) are common craniofacial malformations with origin during early

pregnancy, affecting about one of every 700 live births worldwide. OFCs have acquired much
attention from researchers interested in birth defects because of their high prevalence and
the problems they impose on affected children and their families. The major causes of OFCs
still remain unknown [1–3].
Genes affecting risk of OFCs have gathered increasing attention from geneticists and
epidemiologists interested in OFCs. Despite the lack of clear Mendelian inheritance, family and twin studies have suggested genes play a major role in determining risk in the
etiology of OFC [4, 5]. Candidate gene studies have identified many genes frequently reported to be associated with OFCs, either as individual markers or through gene-gene and
gene-environment (GxE) interactions [1,6]. Genome-wide association studies (GWAS) have
recently identified several new susceptibility loci for OFCs such as markers in 8q24 and
10q25 based on its ability to genotype hundreds of thousands of single nucleotide polymorphisms (SNPs) across the genome in large population sets [1, 6]. However, markers
achieving genome-wide significance in GWAS do not necessarily represent functional mutations and often occur between genes or well removed from any known gene, and can not
identify pathogenic changes. GWAS also have not been able to confirm many of the genes
previously determined to be associated with OFC risk in candidate gene studies due to
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limited SNP coverage even with imputation [7, 8]. Hypothesis-driven studies using GWAS
data may overcome these limitation of our current GWAS approach [9].
One carbon metabolism (OCM) is a series of biochemical reactions involving the transfer of the methyl groups essential for DNA synthesis, DNA methylation, detoxication and
protection against oxidation [10, 11]. Genes in the OCM pathway have been of interest as
candidate genes for influencing OFC risk, with the most notable genes being RFC/SLC19A1,
FOLR1, MTHFR, MTRR, MTR, MTHFD1, and DHFR. Among these genes, MTHFR was
the first gene to be investigated in relation to OFCs, and remains the most studied. Genetic mutations in OCM-related genes may cause OFCs by altering the mechanisms of folate
transport, nucleotide biosynthesis or the methionine/homocysteine cycle [1, 6]. Bhaskar et
al. [12] reviewed articles published up to October 2010 on polymorphic markers of genes
related to OCM and their associations with nonsyndromic cleft lip with or without cleft
palate (CL/P) and found no strong association between the risk of CL/P and any known
OCM gene. The etiology of nonsyndromic OFCs is complex and heterogeneous, meaning
both genetic and environmental risk factors contribute to the causes of OFCs [2, 13]. Because multiple risk factors contribute to OFC etiology, the effect of each factor may be
rather small and interaction is likely. It is also possible that although the child’s genotype
does not have a strong effect on susceptibility, maternal genotypes might exert significant
effects on the risk of OFCs in the embryo through gene-environment interactions. Thus,
large-scale association studies or studies on gene-environment interactions are required to
identify alleles and their mechanisms associated with OFCs.
In this study, we tested SNPs in 21 genes previously associated with OCM or related nutrients for their roles in controlling OFC risk either through genotypic effect or
GxE interaction with maternal periconceptional multivitamin (PCMV) use using an international consortium drawing affected individuals from Europe, United States, China,
Taiwan, Singapore, Korea, and the Philippines. We also tested GxE interaction with maternal OCM-related biomarker concentrations using the subset of mothers from Utah in this
consortium.
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5.3

Materials and Methods

5.3.1

Subjects

This investigation used data from the “International Genetic Epidemiology of Oral
Clefts”, a multi-center, international family-based study initiated in 2003 to investigate the
genetic etiology of oral clefts. Cases with an isolated, nonsyndromic OFCs were recruited
over a period of several years by different members of the consortium, typically ascertained
through a treatment center or a population-based study. Most cases had medical record
data based on physical exams to classify the type of OFC in the caseand to identify other
congenital anomalies that could reflect a recognized malformation syndrome. Informed
consent was obtained from parents of minor children and all affected individuals able to
give informed their own consent. Research protocols for recruiting human subjects were
reviewed and approved by Institutional Review Boards of each participating institution and
by the U.S. institutions for foreign collaborators. Parents were interviewed about family
history of OFCs and other malformations, pregnancy history, parental medical histories,
plus maternal exposures to putative risk factors such as maternal environmental tobacco
smoke and multivitamin supplementation during periconceptional period ( defined as three
months before pregnancy through the first trimester). DNA was obtained from both cases
and parents from whole blood, saliva, or mouthwash sample. In total, 717 trios of European
ancestry and 1098 trios of Asian ancestry were used in the analysis.

5.3.2

Gene Selection and Genotyping

We developed a list of candidate genes based on an extensive literature review of genetic
association studies published through December 2013 focusing on OCM-related nutrients,
specifically folate, vitamin B6 , vitamin B12 , and homocysteine. Candidate genes were included if one of the following criteria were met: 1) significant association with OCM-related
nutrients were reported in GWAS, 2) significant association with OCM-related nutrients
were reported in whole genome sequence studies, 3) significant association with OCMrelated nutrients were reported in genetic association analysis of microRNA target sites in
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OCM genes. Summaries of these candidate genes are listed in Table 5.2 and their functions were recorded in Table 5.6. Genomic coordinates of selected genes were obtained
from the current major human genome assembly released by the Genome Reference Consortium, GRCh37/hg19, via the website of the National Center for Biotechnology Information
(NCBI) and sent to Johns Hopkins University for identification of GWAS genotyping results. DNA samples were previously genotyped using the Illumina Human610 Quad v.1 B
BeadChip platform by the Center for Inherited Disease Research (CIDR) [14].

5.3.3

Laboratory Assays of Folate-Related Biomarkers

Non-fasting blood samples were obtained from Utah mothers using heparin containing
trace mineral-free evacuated tubes and EDTA-containing evacuated tubes from mothers ≥
12 months after the end of their last pregnancy to avoid artifacts of the effects of pregnancy
and lactation [15]. Blood samples were kept on ice and processed within 2 hours of collection.
Aliquots of whole blood for folate assays were mixed with a 1% ascorbic acid solution.
Plasma and whole blood samples were shipped on dry ice and were kept at −80o C until
analyses. Plasma folate, plasma total homocysteine, plasma pyridoxal-5’-phosphate (PLP),
and plasma vitamin B12 concentrations were determined as previously described [16, 17].
Vitamin B12 , holotranscobalamin (HoloTC), and methylmaloic acid (MMA) were determined by Dr. Anne Molloy, Trinity College, Dublin, and by Dr. Per Neland, University
of Bergen [18].

5.3.4

Statistical Analyses

Four quality control (QC) criteria were used to flag SNPs: (1) high rates of missing
genotype calls (>1%), (2) low minor allele frequency (MAF) (<10−4 ), and (3) deviation
from Hardy-Weinberg equilibrium (p >10−5 ). MAFs were computed using parents. Only
SNPs within 100kb upstream and downstream of the selected genes’ genomic coordinates
were selected and used in this analysis.
The genotypic transmission disequilibrium test (gTDT) was used to test for evidence
of association between the selected genes and OFCs. The gTDT is an alternative procedure
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to the allelic TDT (aTDT), originally proposed by Spielman et al. [19], which aimed to
detect alleles at a marker preferentially transmitted from the parents to the affected offspring reflecting linkage and association. The gTDT is different from the aTDT in that
it considered both the genotype of the offspring and the Mendelian genotype realizations
not transmitted by the parents to test for association, assuming a specific genetic mode
of inheritance (i.e., an additive, dominant, or recessive model). At each marker, one of
four possible pairs of parental alleles is transmitted to the affected offspring, and the other
three unobserved genotype realizations are used as artificial controls (usually referred to
as pseudo-controls). The gTDT can be formulated using logistic regression models which
within the ith trio can be written as:

ln P (ith case)/[(1 − P (ith case)] = βα + βG × Xi

(5.1)

Where Xi represents the corresponding risk genotype(s) under an additive, dominant, or
recessive model (for an additive model, heterozygotes for the risk allele are coded as 1 and
homozygotes for the risk allele are coded as 2; for a dominant model, both heterozygotes
and homozygotes for the risk allele are coded as 1; for a recessive model, only homozygotes
for the risk allele are coded as 1). P(ith case) is the probability of being the observed case
in the case and pseudo-controls set in the ith trio. βα and βG are the coefficients for the
slope of Xi . The odds ratio (OR) of having OFCs can be assessed as OR = exp(βG ) with
95% confidence interval (CI) calculated from estimated standard errors of βG [20,21]. When
testing for GxE interactions, an additive model of inheritance was assumed for all SNPs.
gTDT can be formulated using logistic regression models which can be written as:

ln P (ith case)/[(1 − P (ith case)] = βα + βG × Xi + βGE × (Xi × Ei )

(5.2)

Where Ei = 0 or 1 represents unexposed or exposed mothers to environmental factors,
respectively. The odds ratio of being a child with OFC with at least one copy of the risk
allele in the absence of maternal environment exposures can be assessed as OR(OFC | G
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no E) = exp(βG ) and the odds ratio of being a case with at least one copy of the risk
allele in the presence of maternal exposure can be assessed as OR(OFC | G and E) =
exp(βG + βGE ) [20, 21]. A 2 degree of freedom (df) likelihood ratio test (LRT) examining
the joint effects of G and GxE interaction and a 1 df LRT examining the effect of GxE
interaction alone were performed. The 2 df LRT examines the effect of SNP genotype after
taking into account the effect of GxE interaction, while the 1 df LRT examines the GxE
interaction’s exclusive effect.
The gTDT is considered more powerful than the aTDT because: 1) it considers individuals instead of alleles as units of the analysis and enables the direct assessment of
the relative risks. More specifically, the gTDT yields parameter estimates, standard errors,
and confidence intervals in addition to p-values; 2) it can be used to model specific risk
relationships (additive, recessive, or dominant), whereas the aTDT can only model additive
effects; 3) it allows testing for gene-environment interactions [22].
Statistical analyses were performed using the TRIO package in R (version 3.0.0) available at http://www.bioconductor.org [22] for all isolated OFCs, and for CL/P and CPO
trios separately. Stratified analyses were conducted for participants of European and Asian
ancestry to check for racial difference in the statistical evidence. Gene-level Bonferroni
correction was conducted for the p-values of Wald’s test and the 1 df and 2 df LRTs. This
approach is not as conservative as the traditional one correcting for the total number of
SNPs tested, which would be necessary if the SNPs are not in strong linkage disequilibrium
(LD). Because all of our candidate genes are involved in the OCM and thus are associated
with each other, the traditional Bonferroni correction might be too strict. Biomarker concentrations were categorized into 2 levels: 1) low, defined as below the median, and 2) high,
defined as above the median.

5.4

Results

5.4.1

Test of Association Considering Genotypic Effect Alone

SNP rs874232 in FUT6 and SNP rs6518702 in TCN2 showed statistically significant
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associations with CPO in the Asian sample at an adjusted value of p < 0.05 (unadjusted
p-values = 3.18× 10−4 and 3.28 × 10−4 for FUT6 and TCN2, respectively) in tests for
association considering genotypic effect alone (Figure 5.1 and ??). The odds ratio for
an Asian child with CPO carrying the minor allele at SNP rs874232 in FUT6 under an
additive model was 1.68 (95%CI: 1.27-2.24). The odds ratio for an Asian child with CPO
carrying the minor allele ay SNP rs6518702 in TCN2 under a recessive model was 3.36
(95%CI: 1.73-6.51) (Table 5.3).

5.4.2

Test of Association Jointly Considering Genotypic and Gene-Environment
Interaction in Asian and European Populations; Periconceptural maternal multivitamin (PCMV) as exposure.

Six genes showed evidence of interaction between markers and PCMV: CBS on chromosome 21 and MTHFD2L on chromosome 4 in the Asian sample; and DHFR on chromosome
5, MMAA on chromosome 4, MTR on chromosome 1 and TCN2 on chromosome 22 in the
European sample. Of these six genes, four showed evidence of GxPCMV interaction in
the 1 df LRT (CBS, MTHFD2L, MMAA and TCN2), one showed evidence of GxPCMV
interaction in the 2 df LRT (DHFR), and one showed evidence of GxPCMV interaction in
both the 1 df and 2 df LRTs (MTR) (Table 5.4).
In the Asian sample, the odds ratio for a child with CL/P carrying the minor allele at
SNP rs234783 in CBS with a mother taking PCMV was 0.57 (95% CI: 0.40-0.82) and for
a child with an OFC carrying the minor allele at rs16851150 in MTHFD2L was 1.65 (95%
CI: 1.19, 2.29). In the European sample, the odds ratio for a child with an OFC whose
mother did not take PCMV was 1.71 (95% CI: 1.28-2.30) if the child carried the minor
allele at SNP rs13182894 in DHFR and 0.61 (95% CI: 0.44-0.85) if the child carried the
minor allele at SNP rs5753268 in TCN2. The odds ratio for a child with a CL/P whose
mother used PCMV was 0.79 (95% CI: 0.63, 0.99) if the child carried the minor allele at
SNP rs13120931 in MMAA and 0.71 (95% CI: 0.55-0.93) if the child carried the minor allele
at SNP rs6428968 in MTR.
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5.4.3

Test of Association Jointly Considering Genotypic and Gene-Environment
Interaction in the Utah sample; Environmental Exposures were Maternal
Folate-Related Biomarker Levels.

Maternal exposure data were available on maternal OCM-related biomarker concentrations, namely plasma folate, plasma PLP, vitamin B12 , MMA, HoloTC and homocysteine
only in the Utah sample. The median values for maternal biomarker concentrations were
363.8 pmol/L for vitamin B12 , 81.3 pmol/L for HoloTC, 0.15 pmol/L for MMA, 46.1 nmol/L
for plasma PLP, 49.9 nmol/L for plasma folate, and 6.40 µmol/L for homocysteine. Maternal biomarker concentration was considered high if it was higher than the median level of the
corresponding biomarker and low if it was lower than the median level of the corresponding
biomarker.
After gene-level Bonferroni correction, two genes showed evidence of GxE interaction:
ALPL on chromosome 1 and GART on chromosome 21, and TCN1 on chromosome 11.
Table 5.5 shows estimated OR(OFC | G no E) and OR(OFC | G and E) and the p-values
for both the 2 df and 1 df LRTs for SNPs achieving significance for GxBiomarker interaction
in the Utah sample. For rs2275370 in ALPL, the odds ratio for an OFC child carrying the
minor allele was 0.55 (95% CI: 0.33, 0.93) if maternal plasma B12 concentration was low and
6.06 (95%CI: 2.44, 15.04) if maternal plasma B12 concentration was high. For rs12130950
in ALPL, the odds ratio for an OFC child carrying the minor allele was 0.88 (95%CI:
0.49, 1.57) if maternal plasma B12 concentration was low and 6.48 (95%CI: 2.27, 18.45) if
maternal plasma B12 concentration was high. In contrast, for SNP rs2834240 in GART,
the odds ratio for an OFC child carrying the minor allele was 1.93 (95% CI: 1.01-3.68)
if maternal plasma PLP concentration was low and 0.38 (95% CI: 0.19, 0.73) if maternal
plasma PLP concentration was high.

5.5

Discussion
Genetics has been an important focus in OFC research. Multiple GWAS conducted to

identify loci associated with clefts have identified 17 different genes significantly associated
with OFCs [1]. Because the focus of these previous GWAS was on discovery of novel loci in a
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hypothesis free manner, it is difficult to interpret the biological relevance of these significant
regions. Here we focused on genes previously confirmed to be associated with OCM or
related nutrients in a hypothesis driven approach which should also make interpretation
regarding biological pathways easier.
In our studies, we found two OCM genes associated with OFCs with marginal genotypic
effects alone (FUT6 and TCN2) in Asian populations, six OCM genes associated with
OFCs when interaction between genotype and PCMV was considered (CBS and MTHFD2L
in Asian populations, DHFR, MMAA, MTR, and TCN2 in European populations), and
two OCM genes associated with OFCs when interaction between genotype and maternal
biomarker was considered (ALPL, and GART).

5.5.1

Test of Association Considering Genotypic Effect Alone

Our study showed the presence of the minor allele at SNP rs874232 in FUT6 and
rs6518702 in TCN2 increased the CPO risk for Asian mothers by 68% under an additive
model and 236% under a recessive model, respectively. We are unaware of any publication
on CPO regarding FUT6 and TCN2. However, FUT6 was reported to be significantly
associated with plasma vitamin B12 concentrations, which was shown in a separate study
to be associated with OFCs [23], in a sequencing study which included two European
populations (i.e. Danish and Icelandic) and in a GWAS of adult Chinese men unrelated to
OFCs [24, 25]. Two studies examined the association between TCN2 and CL/P, and the
results were mixed with one reporting significant association with CL/P [26] and another
reporting no effect on CL/P risk [27].

5.5.2

Test of Association Jointly Considering Genotypic and Gene-Environment
Interaction in Asian and European Populations; Periconceptional maternal multivitamin use as exposure.

This study reported six genes associated with OFCs via possible GxE interaction where
maternal PCMV use was the exposure (CBS and MTHFD2L in the Asian sample; DHFR,
MMAA, MTR, and TCN2 in the European sample). To our knowledge, no other studies
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have been conducted to analyze the effect of these genes on OFC risk considering GxE
interactions. Dofferemt set of genes affecting the risk of OFCs in Asian and European
populations through GxE interaction with maternal PCMV use is consistent with previous
literature. Most notably, Beaty et al. [14] reported case-parent trios of European ancestry
showed strong evidence for association with CL/P for markers in 8q24 while Asian trios
showed strong evidence for association with MAFB and ABCA4.
No study has been conducted to examine association between CBS markers in Asian
population, either individually or through GxE interaction. Of the three published studies
testing for association between markers in CBS in European population, the results were
inconsistent, with two reporting positive association [28, 29] and one negative report [30].
In our study, the presence of the minor allele at SNP rs234783 in CBS and maternal PCMV
supplementation reduced the risk of OFCs in Asian trios by 43%. CBS is fundamental for
homocysteine clearance in the methionine cycle. Our hypothesis is that CBS, together with
maternal PCMV use, can influence the blood concentration of homocysteine, which was
found to associate with OFCs [31].
MTHFD2L has not been extensively studied for risk of OFCs, either in the Asian or
European samples. In our study, the presence of the minor allele at SNP rs16851150 in
MTHFD2L and maternal use of PCMV increased OFC risk by 65% among Asian trios.
MTHFD2L together with MTHFD2 encodes the bifunctional protein catalyzing the interconversion of one-carbon substituted tetrahydrofolate derivatives in the mitochondria
[32, 33]. The expression of MTHFD2L is localized to the neural tube at the time of neural
tube closure suggesting a role of MTHFD2L in neural tube development [33]. Because the
neural tube and the craniofacial regions both arise from neural crest cells, it is possible
MTHFD2L may also play a significant role in OFC development. Mutations in MTHFD2L
may interfere with conversion of tetrahydrofolate, cause tetrahydrofolate deficiency in mitochondria and affect the risk of OFCs similar to folate antagonists, which are associated
with increased risk of OFCs [34].
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The only study evaluating the possible role of DHFR in OFCs is a family based association study on 400 Italian case-parent trios and also found significant association between
DHFR and CL/P etiology [35]. In our study, the presence of the minor allele at SNP
rs13182894 without PCMV use increased OFC risk in European trios significantly by 71%.
Evidence of GxE interaction was found in the 2 df LRT ratio test, implying after taking the
GxE interaction into account, SNP rs13182894 in DHFR affects risk of OFCs. The role of
DHFR in OCM is to reduce the ingested folates to dihydrofolate then to tetrahydroflate for
use in OCM. Mutations in DHFR may cause folate deficiency and possibly lead to OFCs.
Maternal use of periconceptional supplementation could have eliminated a possible role of
SNP rs13182894 in DHFR thereby increasing risk of OFCs.
Most studies examining the association between MTR and the risk of OFCs found no
association [26, 27, 29, 36–38]. Only one study showed increased CL/P risk associated with
MTR c.2756AG and GG genotypes in a Polish sample [39]. Our study found the presence
of the minor alleles at SNP rs6428968, rs707204, and rs707210 in MTR increased the risk of
OFCs by 77%, 65%, and 56% in European children whose mothers did not use PCMV but
decreased the risk of OFCs by 29%, 31%, and 29% in European children whose mothers did
use PCMV, respectively. Both the 1 df and 2 df LRTs for these SNPs in MTR remained
significant after gene-level Bonferroni correction. MTR encodes the vitamin B12 dependent
enzyme methionine synthase, which is involved in the conversion of homocysteine to methionine and 5-methyl tetrahydrofolate to tetrahydrofolate. Mutations in the MTR gene may
cause functional methionine synthase deficiency (cbIG), which is characterized by megaloblastic anemia, cerebral atrophy, nystagmus, blindness and altered muscle tone. Patients
with cbIG disorder also display hyperhomocysteinemia and homocystinuria in the presence
of low plasma methionine and respond to biochemical therapy with hydroxocobalamin plus
betaine [32]. Maternal PCMV use may counter the effect of MTR mutations similar to
the response of patients with cbIG disorders to hydroxocobalamin and thereby reducing
maternal risk of having a child with OFCs. MTR is the only gene in our studies where
three nearby SNPs were found to be associated with OFC via GxPCMV use interaction.
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No studies had been conducted to analyze the genetic effect of markers in MMAA on
OFCs. In our study, the presence of the minor allele at SNP rs13120931 in MMAA and
maternal PCMV use during the periconceptional period reduced the risk of a European
child having OFCs by 21%. Interestingly, the presence of this minor allele and the absence
of maternal PCMV use increased risk of OFCs by 47%. These results, along with significant
1 df LRT only, suggests the presence of both the minor allele at SNP rs13120931 in MMAA
and maternal use of PCMV are required to prevent risk of OFCs. MMAA plays an important
role in the conversion of methylmalonyl CoA to syccinyl-CoA [40,41]. Mutations in MMAA
can cause methylmalonyl CoA mutase deficiency and lead to methylmalonic acidemia [42].
Methylmalonic acidemia is subdivided into two forms, one of which is vitamin B12 responsive
[43]. It is possible use of maternal periconceptional supplementation impacts the action of
MMAA on risk of OFCs via a B12 -related pathway.
The presence of the minor allele at SNP rs5753268 in TCN2 in the absence of maternal
PCMV use reduced OFC risk among European children by 39%. This protective effect
of the combination of a minor allele at SNP rs5753268 in TCN2 and maternal PCMV
use may erase the preventive effect of this allele alone. We have no explanation for this
observation; although we hypothesize vitamin B12 might be involved. The TCN2 gene was
reported to correlate with vitamin B12 levels in multiple populations including Portuguese
and Hispanic [44,45]. Low maternal plasma B12 concentration has been reported to increase
the risk of OFCs in offspring [23].

5.5.3

Test of Association Jointly Considering Genotypic and Gene-Environment
Interaction in the Utah sample; Environmental Exposures are Maternal
Folate-Related Biomarker Levels.

This study reported three genes strongly associated with OFCs via GxE interaction
where the environmental exposure is maternal blood concentration for OCM-related nutrients (ALPL, GART, and TCN1). No published studies have analyzed these OCM genes,
with the exception of TCN1, via either genotypic effect individually or considering geneenvironment interactions.
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ALPL encodes the enzyme alkaline phosphatase. Mutations in the ALPL gene can
cause accumulation of phosphor compounds including vitamin B6 and lead to hypophosphatemia, which has a significant role in skeletal mineralization in humans [46]. ALPL is
also associated with taurodontism, a tooth condition with possible link to Van der Woude
syndrome, the most common Mendelian syndrome including OFC, occurring in approximately 2% of all cases with OFCs [47, 48]. Two SNPs in ALPL, rs2275370 and rs12130950,
were found to be associated with OFC risk via GxBiomarker interaction with vitamin B12
concentration. The presence of the minor allele at SNP rs2275370 in ALPL decreased OFC
risk by 45% if the mother had low plasma B12 concentrations and increased OFC risk by
approximately six times if mother had high plasma B12 concentrations. Similarly, the presence of the minor allele at SNP rs12130950 in ALPL decreased OFC risk by 12% if the
mother had low plasma B12 concentrations and increased OFC risk by more than six times
if the mother had high plasma B12 concentrations. We are unaware of any studies analyzing
the association between ALPL and vitamin B12 , either alone or in connection with OFC
risk. However, vitamin B12 was reported to be associated with alkaline phosphatase activity
in human bone marrow [49] and could affect OFC risk through GxB12 interaction.
GART encodes the enzyme catalyzing the conversion of formyl-tetrahydrofolate to
THF in the cytoplasm [32]. The presence of the minor allele at SNP rs2834240 in GART in
mothers with low plasma PLP concentrations increased their risk of having a child with OFC
by 93%. In contrast, the presence of the minor allele at SNP rs2834240 in GART when the
mother had high plasma PLP concentrations decreased risk by 62%. Our analysis regarding
the genetic effect of GART and OFC risk yielded negative result, suggesting that GART was
associated with OFCs only when interaction with maternal plasma PLP concentrations was
considered. There are no studies analyzing the association between markers in GART and
vitamin B6 in connection with OFCs or any other disease. It is not clear how the GART
gene could be associated with the risk of OFCs via the GxE interaction with maternal
plasma PLP concentrations.
Maternal PCMV use has been reported to be inversely associated with the risk of
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OFCs [50–52]. A meta-analysis of observational studies published in 2008 also confirmed the
association between OFCs and maternal use of multivitamin supplements in early pregnancy
[51]. However, it is not possible to determine from these studies which of the nutrients in
multivitamin supplements are protective.
Findings from studies testing for association between folate-related biomarkers in OCM
have also been inconsistent. A Dutch study, published in 1999, reported higher plasma
and erythrocyte folate concentrations, but lower plasma pyridoxal-5’-phosphate (PLP) and
higher total homocysteine (tHcy) in mothers of infants with OFCs compared with mothers
of control infants [31]. The subsequent Dutch study in 2003 reported lower vitamin B6 and
B12 concentration in case mothers, but found no significant different in folate concentrations between case and control mothers [23]. In the U.K., higher plasma and erythrocyte
folate concentrations were associated with a decreased risk of CL/P but an increased risk
of CPO [53]. In the Philippines, biomarkers of vitamin B6 , zinc, and folate were associated
with OFC risk [54–56]. The association of low folate concentration and higher risk of CL/P
was modified by vitamin B6 status, which was commonly deficient in the Philippines [54].
In Utah, there was no difference in plasma zinc, PLP, and homocysteine concentrations
between case- and control-mothers, but low maternal blood folate concentrations were associated with an increased risk of OFCs, and the mean differences in case-mothers and
control-mothers widened over time, suggesting a progressive disorder of folate metabolism
among case mothers [16, 17].
GxE interactions have been suggested for several genes associated with OFCs [57, 58].
Multiple studies have focused on how GxE interactions influence the risk of OFCs using
GWAS data and the case-parent trio approach [59–62]. However, no studies to date have
focused on whether GxE interaction influences association between OCM-related genes and
risk of OFCs. Our study suggests a positive association between genes involved in the OCM
pathway and risk of OFCs, either through marginal genotypic effects individually or through
genetic and environmental interaction. We observed two patterns of GxE interactions in our
study previously mentioned in Kraft and Hunter (2005) [63]. The first notable interaction
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is “pure interaction”, where the presences of both the gene and environmental exposures
are required for any impact on disease risk such as the protective effect of the interaction
of CBS and maternal periconceptional multivitamin use on the risk of having a child with
CL/P in our Asian sample. The second interaction we observed in “qualitative interaction”,
where the genetic effect on risk is reversed by the presence of environmental exposure, such
as the interaction effect of ALPL and maternal plasma B12 concentration on the risk of
OFCs in the samller Utah sample.
The case-parent trio design used in our study gave us two important advantages: 1) it is
robust to confounding due to population stratification, and 2) it provides greater statistical
power than case-control designs for rare diseases [64]. Other key strengths of our study
include: large population size and rapid processing of maternal blood specimens and assays
of biomarkers. The collection of maternal supplement use and biomarkers information
allowed us to investigate evidence of GxE interaction for maternal PCMV supplementation
and maternal biomarker concentrations in OCM genes. A weakness of this study is the
small sample size when testing for GxE interaction in the Utah population. However, the
fact that we still detected significant GxE interaction after gene-level Bonferroni correction
further validated the association between OCM-related genes and the risk of OFCs via GxE
interaction for maternal OCM-related biomarker concentrations.
This study is the only study of case-parent trios that explicitly tested the role of
OCM-related genes and risk of OFCs, either individually or through GxE interaction with
maternal periconceptional supplemental use and OCM-related biomarkers. It illustrates the
importance of considering the role of genes involved in OCM pathway and GxE interaction
in the etiology of OFCs. Additional candidate gene studies focusing on OCM-related genes
as well as genetic studies focusing on the entire OCM pathway are required for further
understanding of the possible role of genes in the OCM pathway and risk of OFCs. Because
of the small sample in the Utah group, we must be cautious in interpreting the suggestive evidence for GxE interaction effects of OCM-related genes and maternal biomarkers
of OCM-related nutrients and the risk of mothers having a child with OFCs. Replication
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studies with an adequate number of OFC cases are still necessary. Our study also emphasized the importance of hypothesis-driven approaches using GWAS data and focusing
primarily on genes with some functional biological evidence. There is a distinct possibility
of overlooking key genes if potential GxE interactions are ignored.
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Table 5.1: Number of complete trios by recruitment sites; Johns Hopkins International
Orofacial Cleft Genetics Consortium.

Recruitment site

Ancestry

CPO Trios

CLO Trios

CLP Trios

Total

Denmark
Norway1
Iowa, US
Maryland, US1
Pittsburg,
Pensylvania, US
Utah, US1
Philippines
Singapore2
Taiwan
Weifang, PRC
Wuhan, PRC
Chendu, PRC
Korea

European
European
European
European
European

5
75
23
20
9

6
68
15
11
20

14
108
28
44
53

24
251
66
75
82

European
Asian
Asian
Asian
Asian
Asian
Asian
Asian

52
0
58
74
30
39
38
1

68
0
20
41
53
39
42
14

97
94
45
174
125
134
63
21

217
94
123
289
208
212
143
36

1
2

Abbreviations: CPO, cleft palate only; CL/P, cleft lip with or without cleft palate; OFC,
orofacial cleft; US, the United States of America; PRC, People’s Republic of China.
Also include small number of trios of Asian ancestry.
Also include small number of trios of European ancestry.

Table 5.2: Summary of genes associated with one-carbon metabolism (OCM) or related nutrients selected for analysis;
Johns Hopkins International Orofacial Cleft Genetics Consortium.
OCM or
related
nutrients

Chromosome1

GRCh37/hg19 position1

SNPs
genotyped

Reference2

1p36.12
21q22.3
19p13.3p13.2

21,835,474 - 21,904,904
43,053,191-43,076,362

83
39

[65, 66]
[29]

8,367,010 - 8,373,438

38

[25, 67]

B12

10p12.31

16,865,964 - 17,171,815

177

[25, 65,
66]

Folate

5q11.2-q13.2
11q13.3q14.1

79,922,044 - 79,950,799

44

[67]

71,900,601 - 71,907,366

25

[67]

19q13.3

49,199,227 - 49,209,190

30

B12
Folate

19p13.3
21q22.11

5,830,636 - 5,839,763
34,876,237 - 34,915,222

27
20

[25, 65,
66]
[25]
[67]

B12

9q22.1-q22.3

101,050,363 - 101,471,47834

175

[65]

B12

4q31.21

146,540,539 - 10146,581,186

34

[25]

Gene ID

Full gene name

ALPL
CBS

Alkaline phosphatase
Cystathionine-beta-synthase

CD320

CD320 antigen

B12

CUBN
DHFR

Cubilin (intrinsic factorcobalamin receptor)
Dihydrofolate reductase

FOLR1

Folate receptor 1

Folate

FUT2

Fucosyltransferase 2

B12

Fucosyltransferase 6
Phosphoribosylglycinamide
formyltransferase;
Phosphoribosylglycinamide
synthetase;
Phosphoribosylaminoimidazole
synthetase
GABBR2 Gamma-aminobutyric acid B
receptor 2
MMAA
Methylmalonic aciduria cbIA
type

FUT6
GART

B6
Homocysteine

Continued on Next Page. . .
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Table 5.2 – Continued
Gene ID

Full gene name

MMACHC Methylmalonic aciduria CbIC
type, with homocystinuria
MTHFD1 Methylenetetrahydrofolate
dehydrogenase 1;
Methenyltetrahydrofolate
cyclohydrolase;
Formultetrahydrofolate
synthetase
MTHFD2L Methylenetetrahydrofolate dehydrogenase 2-like
MTHFR

5,10-Methylenetetrahydrofolate
reductase

MTR

5-Methyltetrahydrofolatehomocysteine
methyltransferase
5-methyltetrahydrofolatehomocysteine
methyltransferase reductase

MTRR

MUT

Methylmalonyl CoA mutase

SLC19A1 Solute carrier family 19 member
1

OCM or
related
nutrients

Chromosome1

SNPs
genotyped

Reference2

B12

1p34.1

4534,965,855 - 45,976,738

10

[25]

Folate

14q24

64,854,753 - 64,926,724

34

[67]

Folate

4q13.3

74,989,018 - 75,168,815

48

[67]

Folate;
Homocysteine

1p36.3

11,845,786 - 11,866,159

40

[25, 65,
66]

B12; Folate;
Homocysteine

1q43

236,958,580 - 237,067,280

88

[67]

Folate

5p15.31

7,851,298 - 7,901,236

56

[67]

B12

6p12.3

49,398,072 - 49,431,040

33

Folate

21q22.3

46,934,628 - 46,983,044

50

GRCh37/hg19

position1

TCN1

Transcobalamin 1

B12

11q11-q12

59,620,280 - 59,634,040

11

TCN2

Transcobalamin 2

B12

22q12.2

31,003,069 - 31,023,046

43

[25, 65,
66]
[25]
170
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[25, 65,
66]
[67]

Table 5.2 – Continued
Gene ID

1
2

Full gene name

OCM or
related
nutrients

Chromosome1

GRCh37/hg19

position1

SNPs
genotyped

Reference2

Gene information was taken from http://www.ncbi.nlm.nih.gov/gene.
References listed genes as associating with one carbon metabolism or related nutrients.
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Table 5.3: Estimated odds ratio (OR) for cleft palate only (CPO) from conditional logistic regression using cases and three pseudo
controls in Asian case-parent trios for genes in one carbon metabolism (OCM) pathway that were significantly associated with CPO
via genetic effect in the Asian sample; Johns Hopkins International Orofacial Cleft Genetics Consortium.

Gene ID

Significant
SNPs

Physical
location

MAF

Model
fitted

Odds ratio (95% CI)

Raw p-value1

Corrected
p-value2

FUT6
TCN2

rs874232
rs6518702

5843609
30948752

0.32
0.24

Additive
Recessive

1.68 (1.27, 2.24)
3.36 (1.73, 6.51)

3.18 × 10−4
3.28 × 10−4

0.01
0.01

1

2

P-value denotes statistical significance of the gTDT without multiple testing correction; the model includes additive genetic
effect of FUT6 or TCN2 as predictor variable and cleft palate only as outcome variable.
P-value denotes statistical significance of the gTDT adjusted for Bonferroni correction; the model includes genetic effect of
FUT6 or TCN2 as predictor variable and cleft palate only as outcome variable. Corrected p-value was calculated as raw p-values
divided by the number of SNPs in each gene.
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Table 5.4: Estimated odds ratio of being a child with OFC with at least one copy of the risk allele in the absence of maternal
periconceptional multivitamin (PCMV) use (i.e. OR(case|G no PCMV)) and in the presence of maternal PCMV use (i.e. OR(case|G
and PCMV)) from conditional logistic regression using cases and 3 pseudo-controls in Asian and European case-parent trios for
OCM genes; Johns Hopkins International Orofacial Cleft Genetics Consortium.

Ancestry

Gene ID

CBS3
MTHFD2L3
European DHFR4
MMAA3
MTR5

Asian

TCN23
1
2

3
4
5

Significant
SNPs

Physical
location

Associated
OFC type

rs234783
rs16851150
rs13182894
rs13120931
rs6428968
rs707204
rs707210
rs5753268

44503243
75266446
79870436
146482020
236898163
236897376
236872018
31060982

CL/P
OFC
OFC
CL/P
CL/P
CL/P
CL/P
OFC

OR(case|G no
PCMV)
1.15
0.87
1.71
1.47
1.77
1.65
1.56
0.61

(0.98,
(0.75,
(1.28,
(1.10,
(1.23,
(1.16,
(1.13,
(0.44,

1.36)
1.01)
2.30)
1.97)
2.53)
2.33)
2.13)
0.85)

OR(case|G and
PCMV)
0.57
1.65
1.14
0.79
0.71
0.69
0.71
1.24

(0.40,
(1.19,
(0.92,
(0.63,
(0.55,
(0.53,
(0.56,
(0.96,

0.82)
2.29)
1.40)
0.99)
0.93)
0.89)
0.90)
1.61)

LRT 1 df
p-value1

LRT 2 df
p-values2

3.87×10−4
4.79×10−4
2.56×10−2
0.77×10−4
4.99×10−5
6.58×10−5
9.63×10−5
8.03×10−4

1.81×10−3
2.14×10−3
6.36×10−4
3.48×10−3
2.66×10−4
3.04×10−4
4.34×10−4
3.02×10−3

Abbreviations: CL/P, cleft lip with or without cleft palate; OFC, orofacial cleft
Raw p-values for the 1 degree of freedom likelihood ratio test examining the gene-environment interaction exclusive effect alone.
Raw p-values for the 2 degree of freedom likelihood ratio test examining the inherited effect of SNP considering effects of the gene-environment
interactions.
Only the 1 degree of freedom likelihood ratio test achieved significance after gene-level Bonferroni correction.
Only the 2 degree of freedom likelihood ratio test achieved significance after gene-level Bonferroni correction.
Both the 1 degree of freedom likelihood ratio test and 2 degree of freedom likelihood ratio test achieved significance after gene-level Bonferroni
correction.
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Table 5.5: Estimated odds ratio of being a child with OFC with at least one copy of the risk allele when the mother had low level of
maternal biomarker concentration (i.e. OR(case|G no E)) and when the mother had high level of maternal biomarker concentration
(i.e. OR(case|G and E)) from conditional logistic regression using cases and 3 pseudo controls in Asian and European case-parent
trios for OCM genes; Johns Hopkins International Orofacial Cleft Genetics Consortium.

Gene
ID

Significant
SNPs

ALPL

rs2275370 4
rs12130950 3
rs2834240 4

GART

1
2

3
4
5

Physical
location

Associated
OFC type

Associated
biomarker

OR(case|G no
PCMV)

OR(case|G and
PCMV)

LRT 1 df
p-value1

LRT 2 df
p-values2

21900420
21935467
34968503

OFC
OFC
OFC

B12
B12
PLP

0.55 (0.33, 0.93)
0.88 (0.49, 1.57)
1.93 (1.01, 3.68)

3.33 (1.58, 7.02)
5.67 (2.34, 13.50)
0.38 (0.19, 0.73)

1.81×10−4
1.81×10−5
1.10×10−3

3.47×10−5
1.50×10−4
3.03×10−4

Abbreviations: CL/P, cleft lip with or without cleft palate; OFC, orofacial cleft; MMA, methylmalonic acid; PLP, pyridoxal phosphate; HoloTC,
holotranscobalamin
Raw p-values for the 1 degree of freedom likelihood ratio test examining the gene-environment interaction effect only.
Raw p-values for the 2 degree of freedom likelihood ratio test examining the inherited effect of SNP considering effects of gene-environment
interactions.
Only the 1 degree of freedom likelihood ratio test achieved significance after gene-level Bonferroni correction.
Only the 2 degree of freedom likelihood ratio test achieved significance after gene-level Bonferroni correction.
Both the 1 degree of freedom likelihood ratio test and 2 degree of freedom likelihood ratio test achieved significance after gene-level Bonferroni
correction.
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Table 5.6: Summary of functions of one-carbon metabolism related genes selected for the study; Johns Hopkins International Orofacial Cleft Genetics Consortium.
Chromosome1

Gene ID

Full gene name

ALPL

Alkaline phosphatase

1p36.12

CBS

Cystathionine-beta-synthase

21q22.3

CD320

CD320 antigen

CUBN

Cubilin (intrinsic factor-cobalamin receptor)

DHFR
FOLR1
FUT2

Dihydrofolate reductase
Folate receptor 1
Fucosyltransferase 2

FUT6

Fucosyltransferase 6

19p13.3

GART

21q22.11

GABBR2

Phosphoribosylglycinamide formyltransferase;
Phosphoribosylglycinamide synthetase;
Phosphoribosylaminoimidazole synthetase
Gamma-aminobutyric acid B receptor 2

MMAA

Methylmalonic aciduria cbIA type

19p13.3-p13.2
10p12.31
5q11.2-q13.2
11q13.3-q14.1
19q13.3

9q22.1-q22.3

4q31.21

Function related to folate-related nutrients
Mutations in the ALPL gene cause the accumulation of phosphor compounds including vitamin
B6 .
Catalyze the conversion of homocysteine to cystathionine.
Mediate the cellular uptake of transcobalaminbound vitamin B12 .
Act as receptor for intrinsic factor, an important
protein that helps the body to absorb vitamin B12 .
Convert dihydrofolate into tetrahydrofolate.
Transport 5-methyltetrahydrofolate into cells
Involve in the binding of intrinsic factor to B12
which is necessary to transport B12 from intestine
to blood.
Involve in the binding of intrinsic factor to B12
which is necessary to transport B12 from intestine
to blood.
Catalyze the conversion of
10-formyltetrahydrofolate to tetrahydrofolate.
Regulate the activity of adenylylcyclase; impairment of adenylylcyclase cause vitamin B12 deficiency.
Involve in the translocation of vitamin B12 into the
mitochondrion.

Continued on Next Page. . .
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Table 5.6 – Continued
Gene ID

Full gene name

Chromosome1

Methylmalonic aciduria CbIC Type,
with Homocystinuria
MTHFD1
Methylenetetrahydrofolate dehydrogenase 1;
Methenyltetrahydrofolate cyclohydrolase;
Formyltetrahydrofolate synthetase
MTHFD2L Methylenetetrahydrofolate dehydrogenase 2-like

1p34.1

MTHFR

5,10-Methylenetetrahydrofolate reductase

1p36.3

MTR

5-Methyltetrahydrofolate-homocysteine
methyltransferase
5-methyltetrahydrofolate-homocysteine
methyltransferase reductase

MMACHC

MTRR

14q24

4q13.3

1q43
5p15.31

MUT

Methylmalonyl CoA mutase

6p12.3

SLC19A1

Solute carrier family 19 member 1

21q22.3

TCN1

Transcobalamin 1

11q11-q12

TCN2

Transcobalamin 2

22q12.2

1

Function related to folate-related nutrients
Involve in the binding and intracellular trafficking
of vitamin B12 .
Catalyzes the interconversion of one-carbon
derivatives of tetrahydrofolate.
Catalyzes the interconversion of one-carbon
derivatives of tetrahydrofolate.
Catalyze the conversion of
5,10-methylenetetrahydrofolate to
5-methyltetrahydrofolate, a co-substrate factor
involved in the conversion of homocysteine
to methionine.
Catalyze the conversion of homocysteine to
methionine.
Regenerate methionine synthase, an enzyme involved in methionine synthesis, from
5-methyltetrahydrofolate.
Encode the vitamin B12 -dependent enzyme
methylmalonyl coenzyme A mutase.
Act as a transporter of folate and is involved in the
regulation of intracellular concentrations of folate.
Encode a member of the vitamin B12 -binding
protein family.
Encode a member of the vitamin B12 -binding
protein family.

Gene information was taken from http://www.ncbi.nlm.nih.gov/gene.
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Table 5.7: Maternal multivitamin use during periconceptional period, defined as three
months before and three months after conception, in each recruitment site; Johns Hopkins
International Orofacial Cleft Genetics Consortium.
Multivitamin use (%)
Recruitment site

Denmark
Norway
Iowa, US
Maryland, US
Pittsburgh,
Pensylvania, US
Utah, US
Philippines
Singapore
Taiwan
Weifang, PRC
Wuhan, PRC
Chengdu, PRC
Korea

No

Yes

Missing

Total

11 (44.0)
132 (52.6)
17 (25.8)
9 (0.1)
16 (19.5)

14 (56.3)
118 (47.0)
49 (74.2)
66 (99.9)
66 (81.5)

0
1 (0.4)
0
0
0

25
251
66
75
82

87 (40.1)
65 (69.1)
56 (45.5)
225 (77.9)
185 (88.9)
44 (20.8)
138 (96.5)
35 (97.2)

130 (59.9)
29 (30.9)
53 (43.1)
63 (21.8)
12 (5.8)
18 (8.5)
2 (1.4)
1 (2.8)

0
0
14 (11.4)
1 (0.3)
11 (5.3)
150 (70.7)
3 (2.1)
0

217
94
123
289
208
212
143
36

Abbreviations: CPO, cleft palate only; CL/P, cleft lip with or without cleft palate; OFC,
orofacial cleft; US, the United States of America; PRC, People’s Republic of China.
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Fig. 5.1: Evidence for association from the genotypic Transmission Disequilibrium Test
(gTDT) in 1098 Asian case-parent trios for FUT6. P-value denotes the statistical significance of the gTDT before Bonferroni correction; the model includes additive genetic effect
of SNPs in FUT6 as predictor variable and cleft palate only as outcome variable; Johns
Hopkins International Orofacial Cleft Genetics Consortium.
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Fig. 5.2: Evidence for association from the genotypic Transmission Disequilibrium Test
(gTDT) in 1098 Asian case-parent trios for TCN2. P-value denotes the statistical significance of the gTDT before Bonferroni correction; the model includes additive genetic effect
of SNPs in TCN2 as predictor variable and cleft palate only as outcome variable; Johns
Hopkins International Orofacial Cleft Genetics Consortium.
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Chapter 6
Conclusion
6.1

Summary
Orofacial cleft research has experienced significant epidemiological advancement in nu-

tritional and genetic areas in recent years. One carbon metabolism (OCM) is a series of
biochemical reactions that involves the transfer of methyl groups essential for DNA synthesis, DNA methylation, detoxification, and protection against oxidation. Studies examining
the association between the risk of OFCs and OCM pathway, either through nutrients or
genes, have been inconclusive, despite the essential functions OCM plays in DNA synthesis
and methylation [1,2]. Mothers with healthy dietary patterns characterized by high intakes
of fish, garlic, nuts, and vegetables or with high adherence to the Diet Quality Index for
pregnancy at preconception were shown to have lower risks of OFCs [3, 4]. Genome-wide
association studies (GWAS) have discovered strong evidence for association with several
genes such as IRF6 and 8q24 that were not previously associated with CL/P. GWAS also
revealed differences of genetic impact on CL/P in a population-specific manner. Results
from hypothesis driven studies using GWAS data have emphasized the significant influence of gene-environment interaction on the risk of OFCs, particularly with environmental
tobacco smoke and periconceptional multivitamin use [5–8].
The results of this dissertation support the roles of nutrition and OCM through genenutrient interaction on the risk of OFCs. Our dietary pattern analysis confirmed the importance of maternal diet and supplemental usage in the etiology of oral clefts. It is different
from previous literature in that it acknowledged the significance of the joint effect of both
factors. A significant reduction in the risk of isolated OFCs was found only among periconceptional multivitamin users whose diets highly resembled the ideal Dietary Approach to
Stop Hypertension (DASH) diet suggesting that neither a healthy maternal diet nor sup-
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plement use alone is enough to prevent OFCs. High adherence to the DASH diet has been
shown to potentially prevent type 2 diabetes and obesity via lowering blood pressure and
lipid-induced oxidative stress [9, 10]. Maternal diabetes and obesity have been observed to
be in connection with OFCs [11–14]. A possible hypothesis for the combination effects of
DASH and maternal periconceptional multivitamin use is that the preventive effects may be
caused by acquired differences between case and control mothers in regards to nutritional
factors correlated in diet with vitamins and minerals obtained from multivitamins.
Plasma folate levels were significantly higher in control mothers than in case mothers
regardless of maternal multivitamin use. When comparing folate levels between mothers
who had a child with OFCs and control mothers, plasma folate levels were significantly
higher in control mothers than in case mothers with a low level of folate supplemental
intake (≤ 400 µg) but not with a high level of folate supplemental intake (> 400µg). Only
mothers with MTHFR 677CC genotypes, mothers with 677CT genotypes who did not have
a child with OFCs, and mothers with 677TT genotypes who had a child with OFCs showed
response to the increase of folate supplemental intakes through plasma folate concentrations.
Our results are consistent with the hypothesis of a disorder of folate metabolism in case
mothers suggested in a previous study using the same data [15]. The observed reduced
ability to utilize supplemental folic acid in mothers who had an OFC-affected pregnancy
compared to control mothers provides evidence that higher intake of folate and related
nutrients levels may be required for mothers with a history of an OFC-affected pregnancy.
This reduced ability in case mothers might be attributed to the manifestation of mutations
in folate-related genes.
Since folate plays an important role in OCM, the observed association between plasma
folate and OFCs motivate candidate gene association studies related to this pathway. The
candidate gene project carried out in this dissertation hypothesized that genes related to
OCM pathway influence the risk of OFCs, either individually or through gene-environment
interactions with maternal periconceptional use and OCM-related nutrients. We found two
genes significantly associated with clefts via genetic effect (FUT6 and TCN2) in Asian
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populations, six genes associated with clefts via GxE interaction in which environmental
exposure is maternal periconceptional multivitamin use (CBS and MTHFD2L in Asian
populations, DHFR, MMAA, MTR, and TCN2 in European populations), and three genes
strongly associated with clefts via interactions between gene and maternal blood concentrations for OCM-related nutrients (GART, MUT, and TCN1). Our results suggest that the
OCM pathway may influence risk for isolated, nonsyndromic orofacial clefts either through
genetic effects or gene-environment interaction effects with maternal multivitamin supplementation during the periconceptional period and maternal biomarker concentrations for
OCM-related nutrients. The etiology of nonsyndromic OFCs is considered to be complex
and heterogeneous, meaning that both genetic and environmental risk factors contribute
to the causes of OFCs [16, 17]. Because multiple risk factors contribute to OFCs etiology,
the effect of each factor may be rather small. The childrens genotype might not have a
strong effect on susceptibility with OFCs but together with environmental factors related
to the mothers, they might have a significant effect on the risk of oral clefts through geneenvironment interactions.

6.2

Future Directions
The results of this project can be augmented with future research. First, replication

studies are needed to confirm the combination effects of a DASH diet and maternal periconceptional multivitamin use on the risk of OFCs. Second, this project only addressed
the utilization of supplemental folic acid because of the lack of dietary data at the time
of blood draw. Information on dietary intake will provide a more complete comparison of
the utilization of total folic acid from both supplements and diets between control mothers
and mothers who had a history with an OFC-related pregnancy. It may also provide a
better measure of how responsive plasma folate is to food folate intake in comparison to
folic acid supplement intake as well as assess how much folate deficiency is attributed to
diet and multivitamins compared to inherited impairments caused by genetic mutations
in vitamin transport, binding and utilization. Third, our hypothesis-driven genetic study
only assessed individual SNPs and did not take into account correlation among SNPs or
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genes. Gene-gene interactions and haplotype association studies focused on OCM pathway
are necessary and may ascertain additional genes which have small effects individually in
the risk of OFCs but provide a strong impact when combined. Fourth, we only examined
the gene-environment interactions between OCM-related genes, maternal multivitamin use,
and biomarkers concentrations in the large sample of European and Asian triads in the International Consortium. Additional environmental data, such as maternal diet information
or OCM-related supplemental nutrient intakes will be helpful to understand the specific
mechanism of how these genes can affect the risk of OFCs. Fifth, genotypic imputations
should be utilized to increase the number of SNPs being tested for association with OFCs
and assess the consistency of evidence in terms of both significance and direction of effect
observed in our study.
When analyzing the association between OCM-related genes and the risk of OFCs,
we faced difficulties regarding multiple testing corrections, a common problem in GWAS
and studies using GWA data. Multiple testing corrections describe the processes used to
distinguish a true association result from spurious associations when performing many tests
of significance within one study. Several solutions have been proposed to deal with this issue,
with the simplest and most commonly used, one being the Bonferroni corrections test, where
the alpha level, often 0.05, is divided by the number of tests. The Bonferroni corrections
method depends on the assumption that the tests are independent of each other, which
is often not the case in genetic studies since SNPs can be in strong linkage disequilibrium
with each other. This method is thus too strict and provides far too few actually significant
results [18]. Other less conservative solutions have been proposed, such as the adaptive
rank truncated product or permutation-based tests [19–23]. Nonetheless, it is not clear as
to which one is superior and should be used. More research on this matter is necessary.
Observational studies have always used classical statistical methods such as general
linear models to identify the association. Nontraditional statistical tools might be helpful
to better understand the interactive effects on OFCs etiology. Data mining methods, such
as classification and regression trees and random forest, could help determine combinations
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of genetic and environmental factors and predict a womens chance of having a child with
OFCs [24].

6.3

Public Health Significance
Although more research is needed to characterize the relationship between maternal

nutrition and the risk of OFCs, a healthy maternal diet with high adherence to a DASH diet
and the use of supplementations during the periconceptional period are safe and feasible
interventions that may reduce the risk of women having a child with OFCs. Since mothers
who had a previous OFC-affected child experienced decreased efficiency of folate absorption
mechanisms, higher folic acid supplementation doses may also be required to decrease their
risk of having another child with OFCs.
The discovery of the effects of OCM-related genes on OFCs may provide clinicians to
specific target populations and more effective intervention strategies. For example, in our
study, we observed that the presence of minor allele of SNP rs13120931 in MMAA increased
the risk of OFCs by 47% through a lack of maternal use of periconceptional supplements
but decreased the risk of OFCs by 21% in the presence of multivitamins. Women with the
minor allele of this SNP can be targeted for more aggressive multivitamin supplementation
during the periconceptional period to reduce their chance of having a child with OFCs.
Mutations of MMAA can cause functional methylmalonyl CoA mutase deficiency and lead
to methylmalonic academia, in which one known type is vitamin B12-responsive. Geneenvironment interactions with maternal biomarkers are the stepping stones in understanding
how OCM-related genes can influence the risk of OFCs.
Reduction in the prevalence of OFCs could have tremendous importance. The results
of this dissertation may help identify factors important to OFCs etiology and in turn,
provide valuable targets for preventive intervention. Children born with an OFC require
medical care from birth until adulthood and encounter a higher mortality rate. The costs
incurred from caring for children born with OFCs not only includes the clinical care of many
disciplines but also involves the emotional disturbance and social and employment exclusion
for affected individuals [17, 25, 26]. Reducing the risk of OFCs would lessen considerable
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financial and emotional burdens to families and societies.
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